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This paper is the third chronological supplement to the Carcinogenic Potency Database that
first appeared in this journal in 1984 (1-4). We report here results of carcinogenesis bioassays
published in the general literature between January 1985 and December 1986, and in Technical
Reports of the National Toxicology Program between June 1986 and June 1987. This supplement
includes results of 337 long-term, chronic experiments of 121 compounds, and reports the same
information about each experiment in the same plot format as the earlier papers, e.g., the species
and strain of animal, the route and duration of compound administration, dose level, and other
aspects of experimental protocol, histopathology, and tumor incidence, TD50 (carcinogenic
potency) and its statistical significance, dose response, opinion of the author about carcinogenic-
ity, and literature citation. The reader needs to refer to the 1984 publication for a guide to the
plot ofthe database, a complete description ofthe numerical index ofcarcinogenic potency, and a
discussion of the sources of data, the rationale for the inclusion of particular experiments and
particular target sites, and the conventions adopted in summarizing the literature. The four plots
of the database are to be used together as results published earlier are not repeated. In all, the
four plots include results for approximately 4000 experiments on 1050 chemicals. Appendix 14 of
this paper is an alphabetical index to all chemicals in the database and indicates which plot(s)
each chemical appears in. A combined plot of all results from the four separate papers, that is
ordered alphabetically by chemical, is available from the first author, in printed form or on
computer tape or diskette.
Background
Development of the Carcinogenic Potency Database
(CPDB) began a decade ago, when efforts to use
animal bioassays to analyze the carcinogenic process
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in rodent experiments and to evaluate possible
hazards to humans were hampered by the lack of a
standardized method of comparing test results.
Experimental protocols as well as the type of infor-
mation reported in the literature are quite diverse,
and this large body of information was underused.
Moreover, quantitative estimates of carcinogenic
potency with a single measure had not been made for
the large number of substances that had been tested
chronically in rodents; such a measure is required to
compare rodent potency to other factors such as
mutagenicity, teratogenicity, chemical structure, andTHIRD SUPPLEMENT TO THE CARCINOGENIC POTENCY DATABASE
human exposure. The CPDB provides a standardized
resource of both qualitative and quantitative infor-
mation on the literature of chronic, long-term cancer
tests (1-3), including results published in the general
literature and in Technical Reports of the National
Cancer Institute/National Toxicolgy Program (NCI/
NTP). This is the fourth paper to present a portion of
the CPDB in plot format. The first two papers in 1984,
Gold et al. (1) and Peto et al. (4), included the pub-
lished literature through June 1981, a description of
our numerical index of carcinogenic potency (TD50),
and the statistical procedures adopted for estimating
it from experimental data. Briefly, TD50 may be
defined as follows: for a given target site(s), if there
are no tumors in control animals, then TD50 is that
chronic dose rate in mg/kg body weight/day that
would induce tumors in half the animals tested at the
end of a standard lifespan for the species. Since the
tumor(s) of interest often does occur in control ani-
mals, TD50 is more precisely defined as that chronic
dose rate that will halve the probability of remaining
tumor-free throughout the standard lifespan of the
species (4,5). The range of significant TD50 values for
carcinogens in the CPDB is more than 10 millionfold.
A detailed guide to the plot of the database was
included in the 1984 paper (1); it described the con-
tents, field by field, and discussed the sources of data,
the criteria for the inclusion of particular experi-
ments and particular target sites, and the conven-
tions adopted in summarizing the literature. The
second (2) and third (3) plots were chronological sup-
plements, and the current plot covers general litera-
ture published in 1985 and 1986 as well as NTP
Technical Reports between June 1986 and June 1987.
It is our intention that the four plots be used
together, and that readers who are not familar with
the CPDB will first read the 1984 papers when using
the plot in this paper. We have not duplicated earlier
results, and thus for complete data on each chemical
that appears in more than one plot, all four publica-
tions are necessary.
Each plot of the database provides the same set of
information about each experiment in the same for-
mat, including: the species, strain, and sex of animal
tested; features of the experimental protocol such as
route of administration, duration of dosing, dose level
in mg/kg body weight/day, and duration of experi-
ment; histopathology and tumor incidence; carcino-
genic potency and its statistical significance; shape of
the dose-response curve; opinion of the author as to
the carcinogenicity; and literature citation. A word of
caution is necessary about the limitations of the
database. We have included only long-term tests of
individual compounds that fit a set of criteria com-
patible with calculating potency; many animal cancer
tests are excluded. Moreover, we have not attempted
to evaluate whether or not a compound is a carcino-
gen; rather, we report the published opinions of the
investigators whose data we present, as well as the
statistical significance of the TD50 calculated from
their results. Furthur discussion of the criteria for
the database and the limitations can be found in (1).
In this fourth plot, the author's opinion column for
the NTP bioassays reflects a new set of interpretive
categories that NTP adopted in 1983 and redefined in
1986. Two of the categories are considered positive by
NTP. We report the NTP evaluations using the codes
"c" for clear evidence of carcinogenic activity; "p" for
"some evidence of carcinogenic activity" in an experi-
ment that is positive but where the strength of the
response is less than that required for clear evidence;
"e" for equivocal evidence of carcinogenic activity;
and "-" for no evidence of carcinogenic activity. The
full definitions of the NTP levels of evidence are given
in Appendix 11. For the general literature the
"author's opinion" column is "+" for a positive opin-
ion, "-" for a negative opinion; in other cases the
column for the literature is blank, including unclear
and borderline opinions.
The appendices to each of the four plots provide the
same types of information for the data in that publi-
cation, and are given the same appendix numbers.
Appendix 1 lists alphabetically the compounds
included in the current plot and their common syno-
nyms; Appendix 2 provides a list of those same com-
pounds ordered by Chemical Abstracts Service (CAS)
Registry number. The next several appendices provide
codes and definitions required for using the plot:
strains of test animal (Appendix 3); routes of admin-
istration (Appendix 4); sites of tumor induction
(Appendix 5); histopathology (Appendix 6); notecodes
(Appendix 7); dose-response curve symbols (Appendix
8); reference codes (Appendix 9); NCI/NTP bioassays
evaluated as inadequate (Appendix 10); and author's
opinion codes (Appendix 11). Appendices 12 and 13
give full bibliographic information for all experi-
ments reported in this plot: the bibliography for the
general literature (Appendix 12) and a list of the
NCI/NTP Technical Reports (Appendix 13). Appendix
14 lists the 1053 chemicals that appear in any of the
four plots, and indicates which plot contains results
of experiments on each chemical; it is ordered alpha-
betically by chemical name and common synonym.
We are continuing to update the Carcinogenic
Potency Database with papers published after 1986,
and are also attempting to add earlier papers that we
overlooked in our literature search. Therefore, we
would appreciate information about any tests that
the reader notices are missing.
Plot in This Supplement
The plot of the database below includes results of
337 long-term, chronic experiments on 121 chemicals.
It reports results for 20 compounds from Technical
Reports of the NTP published between June 1986 and
June 1987, and results for 102 compounds published in
the general literature between January 1985 and
December 1986. Experiments in rats, mice, and ham-
sters are reported here for compounds representing a
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variety of chemical classes, with a variety of uses.
Some are naturally occurring substances (e.g., acetal-
dehyde, hydrazine, and formaldehyde); food additives
(e.g., potassium bromate and butylated hydroxy-
anisole); industrial compounds (e.g., methylene chlo-
ride and benzene); and drugs (e.g., phenobarbital and
acetaminophen). Of the 121 chemicals, 44 were also
included in the first, second, or third plots, and we
have flagged these with a triple asterisk (***) after
the chemical name in the plot. For some substances,
only a few experiments are reported here, but several
experiments were previously reported, e.g., 2-acety-
laminofluorene and ethyl alcohol. The TD50 values for
the compounds in this supplementary plot fall within
the range of values reported earlier.
Analyses of the Database
Taken together, the four plots of the CPDB include
more than 4000 experiments on 1050 chemicals that
meet the inclusion rules of the database and are
therefore suitable for estimating TD50. Although the
inclusion rules assure some consistency in experimen-
tal protocol, there is great diversity in the database.
Most of the chemicals have been tested in rats or
mice; however, some have been tested in hamsters,
dogs, or monkeys. Experiments with 96 different
mouse strains and 72 rat strains are included. For a
given chemical, the database may contain only a sin-
gle experiment or several experiments. For example,
among the 788 chemicals tested in rats, 28% have
only one rat test and 52% have two tests; however, 13
chemicals have more than 10 tests. Overall about half
of the 1050 chemicals in the database are positive in
at least one experiment according to the opinion of
the published author. This proportion is similar for
rats and mice.
Our group has used the CPDB to address many
issues relevant to chemical carcinogenesis and inter-
species extrapolation. We summarize this work below
and refer the reader to the published papers.
With respect to the measurement of carcinogenic
potency, two methods for estimating TD50 from
animal bioassays have been compared, one based on
lifetable data and one based on summary incidence
data (6). Second, we have shown that the potency
calculated from experimental results is restricted to
an approximately 30-fold range surrounding the max-
imum dose tested in a standard bioassay (7). Third,
for chemicals that are positive in more than one test
in a species, our analysis indicates that the most
potent TD50 value from among all positive tests is
similar to other measures that average TD50 values or
functions of values (8). For the chemicals that induce
tumors in rats or mice, we have presented a concise
tabulation of the most potent TD50 values and a sum-
mary of the evaluations of carcinogenicity in each
sex-species group (8).
Correlation studies of carcinogenic potency have
been conducted. We have discussed some tautologous
aspects of the good correlation in potency between
rats and mice (7) and have reported a weak associa-
tion of mutagenic potency and carcinogenic potency
for 80 chemicals that are both mutagenic in Salmo-
nella and carcinogenic in rats or mice (9).
Reproducibility of results in animal bioassays has
been investigated in 70 "near-replicate" comparisons
consisting of two or more tests of the same chemical,
administered by the same route, and using the same
sex and strain of rodent. Overall there was good
reproducibility of positivity, target site, and TD50 in
rats, mice, and hamsters (10). We have described the
potencies of compounds that induce tumors at partic-
ular target sites in rats and mice and have examined
other indicators of a chemical's hazard including
whether or not tumors were induced at more than one
site in a single sex-species group of animal, whether
or not tumors may have caused the death of the
animal or were found at sacrifice, and whether or not
metastases of induced tumors occurred (11).
We have proposed a rough index of possible carci-
nogenic hazard to humans, HERP, that compares for
a given chemical, the chronic dose rate at which
humans are exposed (mg/kg/day) to the TD50 in
rodents. We have computed HERP values for a vari-
ety of man-made and naturally occurring substances
to which people may be exposed and have constructed
a scale to rank possible hazards. This ranking sug-
gests that carcinogenic hazards from current levels of
pesticide residues or water pollution are likely to be
of minimal concern relative to the background levels
of natural substances, though one cannot say whether
these natural exposures are likely to be of major or
minor importance in human cancer (12-17). In a sepa-
rate analysis we rank the potential carcinogenic
hazards (PERP) permitted to U.S. workers from
exposures to 41 rodent carcinogens that are regulated
with Permissible Exposure Levels (PELs) by the U.S.
Occupational, Safety, and Health Administration
(18). For some substances, exposures at the PEL
would be close to the dose rate that produces tumors
in 50% of test animals.
Approximately half of the chemicals tested in
rodent bioassays are positive in at least one experi-
ment, and among chemicals tested for mutagenicity
as well as for carcinogenicity in both rats and mice,
three-quarters are either mutagens or carcinogens.
We have discussed how representative this positive
rate might be of the proportion of all chemicals that
would be positive if tested in rodents, or the propor-
tion of all chemicals that are potentially carcinogenic
to humans (12,19).
The issue of extrapolating carcinogenesis results
from one species to another has been addressed in an
analysis of prediction between two closely related
species, rats and mice. We have examined how well
one can predict from rats to mice and from mice to
rats, and discuss three factors that affect the accu-
racy of prediction: chemical class, mutagenicity, and
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the dose level at which a chemical is toxic. Addition
ally, we have described the frequency of a carcino
genic response in each target organ and hav
determined the predictive value of individual targe
sites in one species for carcinogenicity in the secon(
species (19).
We are continuing to calculate HERP and PERP
values as we expand the CPDB and to conduct several
additional analyses, e.g., the reproducibility of bioas-
say results when chemicals are administered by dif-
ferent routes, the comparison of results in rodents
and monkeys, and the amounts of rodent carcinogens
that occur naturally in edible plants.
Errata in Earlier Plots
A few omissions and errors in the first plot of the
CPDB (1) have come to our attention. The CAS num-
ber for D & C Red No. 10 was omitted; it should be
1248-18-6. The CAS number for 2-chloro-5-(3,5-
dimethylpiperidinosulfonyl)benzoic acid was reported
incorrectly; it should be 37087-94-8. The citation for
Gass and Allaben (1977) was incorrect; the citation
should be IRCS Med. Sci.: Libr. Compend. 5: 477
(1977). For two chemicals reported earlier, aspertame
and di(2-ethyhexyl)phthalate, the dose calculation
was incorrect. Therefore, other values such as the
TD50 were also incorrect. Below we report the cor-
rected plot for these two chemicals.
Left Side of Plot
Spe Strain Site Xpo+Xpt 2Tailpvl
Sex Route Hist Notes
ASPARTAME lOOng....ug.............0......g.... 10..Io..... :.:100 .. :lIg :..o10
1 R f sLs eat bra tur 52w52 ekr .>
2 R f sis eat bramix 24m24 er P=1.
3 R m sLs eat bra tum 52w52 ekr .> P=1.
4 R m sls eat bra mix 24m24 er P<.5
DI(2-ETHYLHEXYL)PHTHALATE lOOng ....: lug : : : elmg : : 0 ... : Ig :.10
5 M fb6c eatliv MXA24m24 + *
a M f b6t eat Liv hpc 24.24 * P<.000 05 b M f b6t eat TBA MXB 24.24 350.mg c M f b6t eat Lix MXB 24.24 825.mg P<.0005 d M fb6c eat Lun MXB24m24 * P<.07 M mb6c eat Liv MXA 24.24 : *
c
M m b6t eat lix hpt 24.24 c
b M m b6t eat TBA MXB 24.24 *
P<.4
c M m b6c eat Lix MXB 24.24
M mb6c eat tun MXB 24.24
7 R f f34 eat Liv MXA 24.24 : P<.000 05 a R f f34 eat Liv hpc 24.24 *
c
b R f f34 eat lix nnd 24.24
c R f
f34 eat TBA MXB 24m24
d R f f34 eat Liv MXB 24m24
8 R m f34 eat Lix MXA 24.24 :
1.17g. c
a R m f34 eat Lix hpt 24m24 *
P<.2 . b R m f34 eat TBA MXB 24m24
-Pativ MXMB ?4mP? 1.17gm * P<.03
Right Side of Plot
RefNum LoConf UpConf
ASPARTAME 22839-47-0
1 1327m 471.mg n.s.s.
2 1327n 45.8gm n.s.s.
3 1327m 471.mg n.s.s.
4 1327n 35.2gm n.s.s.
DIT2-ETHYLHEXYL)PHTHALATE
5
c 52733 513.mg 1.67gm
a
c 52733 638.mg 1.89gm
b c 52733 175.mg 2.07gm
c c52733 513.mg 1.67gm
d
c 52733 2.20gm n.s.s.
6 t52733440.mg n.s.s.
a
c 52733 736.mg n.s.s.
b c 52733 413.mg n.s.s.
c c 52733 440.mg n.s.s.
d
c 52733 1.97gm n.s.s.
7 t52733 644.mg 2.40gm
a




c c 52733 321.mg n.s.s.
d c 52733 644.mg 2.40gm
8 c52733 526.mg n.s.s.
a c52733 1.13gm n.s.s.
b
c 52733 455.mg n.s.s.
c
c 52733 526.mg n.s.s.
Cntrt lDose lInt 2Dose
0/16 1.00gm 0/16 2.00gm 0/16 4.00gm
1/60 1.00gm 0/60 2.00gm 2/60 4.00gm
0/16 1.00gm 0/16 2.00gm 0/16
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Plot of the Carcinogenic Potency Database
Spe Strain Site Xpo+Xpt TD50 2TailpvL
Sex Route Hist Notes DR AuOp
ACETALDEHYDE lOOng..: ..ug. :10. :100.. g :1g :10. :100.:Ig. :10
1 H f syg inh ltar mix 52w81 er . 728.mg P<.04 +
a H f syg inh ltar adq 52w81 or 1.14gm P<.1 +
b H f syg inh ltar sqc 52w81 er 2.369m P<.3 +
2 H m syg inh res mix 52w81 er . 461.mg P<.02 +
a H a syg inh tar mix 52w81 er 461.mg P<.02 +
b H m syg inh lar cic 52w81 er 641..g P<.04 +
c H m syg inh nse apc 52w81 er 2.07g. P<.3 +
d H m syg inh ltar sqc 52w81 er 2.07gm P<.3 +
3 R f wis inh nse adc 26.28 erv .+ 370.mg * P<.0005+
a R f wis inh nse sqc 26.28 erv 1.039g Z P<.0005+
b R f wis inh nse cic 26.28 erv 3.00g. * P<.007 +
4 R m wis inh nse adc 26.28 erv .* 185..g * P<.0005+
a R . wis inh nse sqc 26.28 erv 627.mg Z P<.0005+
ACETANINOPHEN*** lOOng .:. .Iug.:10. :100. g : .g . :10. :100..g.10
5 N m b6c eat liv hpc 70w70 e .> no dre P-1. -
a M m b6c eat liv hpa 70w70 e no dre P-1. -
b N a b6c eat lun aLd 70w70 a no dre P-1. -
6 R f f3d eat Liv tum 24.30 e .> no dre P.1.
a R f f3d eat nas tur 24.30 a no dre P.1. -
b R f f3d eat tba mix 24.30 a no dre P-1. -
7 R m f3d eat Liv tur 24.30 a .> no dre P-1.
a R a f3d eat nas tur 24.30 a no dre P-1. -
b R a f3d eat tba mix 24.30 a no dre P-1. -
8 R f Lee eat Liv nnd 78w78 or . + . 1.34gm P<.0005+
a R f Lee eat ubL mix 78w78 ar 1.73g * P<.08 +
b R f Lee eat ubL pam 78w78 ar 2.33gm * P<.2 +
c R f Lee eat ubL car 78w78 ar 7.119m * P<.3 +
d R f Lee eat Liv hpc 78w78 ar no dre P-1.
a R f lee eat tba mix 78w78 or 565.mg * P<.0005+
9 R m Lee eat liv nnd 78w78 ar . + . 1.05gm * P<.002 +
a R m Lee eat ubl mix 78w78 ar 1.199m * P<.007 +
b R a Lee eat ubl pam 78w78 ar 1.34g * P<.02 +
c R a Lee eat ubl car 78w78 ar 11.2g * P<.3 +
d R a Lee eat Liv hpc 78w78 ar no dre P-1.
a R a Lee eat tba mix 78w78 ar 440.mg * P<.0005+
2-ACETYLANINOFLUORENE***
10 R m f3d eat liv hpc 24.24 a
a R m f3d eat liv thc 24.24 a
b R a f3d eat Liv ghc 24.24 a
c R a f3d eat Liv cLc 24.24 a
ACRYLANIDE
11 R f f34 wat mgl ban 24m24 a
a R f f34 wat mgL fib 24m24 a
b R f f34 wat orc sqp 24.24 a
c R f f34 wat mgl adc 24m24 a
d R f f34 wat tyf mix 24m24 a
a R f f34 wat pit ade 24.24 a
f R f f34 wat mgl fba 24.24 a
12 R a f34 wat tyf ada 24.24 a
a R a f34 wat tes mcm 24m24 a
b R m f34 wat spd ast 24m24 a
c R m f34 wat adr phe 24m24 a
d R a f34 wat spL Leu 24.24 a
100ng. ... :1ug.10. :100. 1g : g :10. :100.. : g :10




lOOng . . .lug.. : 10. :100.. :.leg.. : 10..:100.. : g. : 10
+ 4.2 g * P<.002 +
20.9mg * P<.0005+
16.2mg * P<.02 +
17.8mg * P<.02 +
24.4mg * P<.03
13.2mg * P<.5 +
16.5mg * P<.3 +
13.2mg * P<.003
11.4mg * P<.03 +
39.7mg * P<.05 +
16.6mg * P<.2 +
45.8mg * P<.8
ALKYLDINETHYLANINE OXIDES, COMMERCIAL GRADE.lug....: 10. : 100. g : . . :10. :100 . .. 10
13 R f cdr eat pit ada 24m24 ar .> 230.mg * P<.2
14 R m cdr eat pit ada 24m24 ar . 236.ag Z P<.03 -
3-ANINO-1,4-DINETHYL-5H-PYRIDOI4,3-blINDOLE ACETATE*** ..... ..100.:1mg.:10. :100.. : 9 :10
15 R f f3d eat liv hpc 52w52 a . + . .577mg P<.0005+
16 R a f3d eat Liv hpc 52w52 a . + . .574mg P<.0005+
2.AMINO-3,4-DINETHYLIMIDAZ0O4,5f1]QUINOLINE.1ug.... : 10. :100..:1mg. : 10. :100.. : 1: 10
17 N f cdf eat for mix 91w91 a . + . 10.7mg * P<.0005+
a N f cdf eat for sqc 91w91 a 24.5mg * P<.0005+
b N f cdf eat liv mix 91w91 a 27.1mg * P<.0005+
c N f cdf eat liv hpc 91w91 a 65.6mg / P<.0005+
d N f cdf eat lun mix 91w91 a 25.1mg \ P<.03 -
18 N a cdf eat for mix 91w91 a . + . 14.5mg * P<.0005+
a N a cdf eat for sqc 91w91 a 22.4mg / P<.0005+
b N a cdf eat Lun mix 91w91 a 148.mg * P<.2 -
c N a cdf eat Liv mix 91w91 a no dre P-1.
d N a cdf eat liv hpc 91w91 a no dre P-1.CHRONOLOGICAL SUPPLEMENT
RefNum LoConf UpConf Cntrt lDose lInc 2Dose 2Inc
ACETALDEHYDE 75-07-0
1 1766 219.mg n.s.s.
a 1766 279.mg n.s.s.
b 1766 383.mg n.s.s.
2 1766 158.mg n.s.s.
a 1766 158.mg n.s.s.
b 1766 193.mg n.s.s.
c 1766 337.mg n.s.s.
d 1766 337.mg n.s.s.
3 1757 263.mg 540.mg
a 1757 624.mg 1.92gm
b 1757 1.36gm 33.3gm
4 1757 137.mg 259.mg








































ACETAMINOPHEN*** (TylenoL, paracetamoL) 103-90-2
5 1779 867.mg n.s.s. 0/30 600.mg 0/32 1.20gm
a 1779 1.64gm n.s.s. 3/30 600.mg 2/32 1.20gm
b 1779 2.58gm n.s.s. 2/30 600.mg 1/32 1.20gm
6 1712 2.79gm n.s.s. 0/50 260.mg 0/50 520.mg
a 1712 2.79gm n.s.s. 0/50 260.mg 0/50 520.mg
b 1712 885.mg n.s.s. 40/50 260.mg 42/50 520.mg
7 1712 1.55gm n.s.s. 0/50 144.mg 0/50 288.mg
a 1712 1.55gm n.s.s. 0/50 144.mg 0/50 288.mg
b 1712 90.8mg n.s.s. 50/50 144.mg 49/50 288.mg
8 1753 651.mg 3.83gm 0/40 250.mg 0/49 500.mg
a 1753 782.mg n.s.s. 0/40 250.mg 5/49 500.mg
b 1753 950.mg n.s.s. 0/40 250.mg 4/49 500.mg
c 1753 1.75gm n.s.s. 0/40 250.mg 1/49 500.mg
d 1753 953.mg n.s.s. 0/40 250.mg 0/49 500.mg
1753 341.mg 1.08gm 0/40 250.mg 6/49 500.mg
9 1753 512.mg 3.35gm 0/40 200.mg 1/48 400.mg
a 1753 558.mg 14.3gm 0/40 200.mg 3/48 400.mg
b 1753 608.mg n.s.s. 0/40 200.mg 3/48 400.mg
c 1753 1.82gm n.s.s. 0/40 200.mg 0/48 400.mg
d 1753 747.mg n.s.s. 0/40 200.mg 0/48 400.mg
e 1753 265.mg 820.mg 0/40 200.mg 5/48 400.mg
Citation or PathoLogy
Brkly Code

































10 1756 .385mg 1.11mg 0/30 .320mg 3/29 1.60mg 26/28
a 1756 .421mg 1.21mg 0/30 .320mg 3/29 1.60mg 25/28
b 1756 28.2mg n.s.s. 0/30 .320mg 0/29 1.60mg 1/28
c 1756 1.52mg n.s.s. 0/30 .320mg 0/29 1.60mg 0/28
ACRYLAMIDE (2-propenamide) 79-06-1
11 1787 2.08mg 22.0mg 10/60
a 1787 7.94mg 87.1mg 0/60
b 1787 6.10mg n.s.a. 0/60
c 1787 6.46mg n.s.s. 2/60
d 1787 7.94mg n.s.s. 1/58
1787 2.50mg n.s.s. 25/59
f 1787 4.19mg n.s.s. 9/60
12 1787 5.50mg 89.4mg 1/60
a 1787 4.29mg n.s.s. 2/60
b 1787 11.0mg n.s.s. 1/60
c 1787 5.04mg n.s.s. 3/60

































































ALKYLDIMETHYLAMINE OXIDES, COMMERCIAL GRADE mixture
13 1697 73.8mg n.s.s. 32/49 5.00mg 26/50 50.0mg 28/50 100.mg 36/50
14 1697 103.mg n.s.s. 16/50 4.00mg 4/50 40.0mg 11/50 80.0mg 20/49
3-AMINO-1,4-DINETHYL-5H-PYRIDO[4,3-blINDOLE ACETATE*** (trp-P-1 acetate) 75104-43-7
15 1683 .310mg 1.04mg 0/50 10.0mg 37/39
16 1683 .342mg 1.01mg 0/50 6.00mg 30/36
2-AMINO-3,4-DIMETHYLIMIDAZOI4,5-fIQUINOLINE (MeIQ) 77094-11-2
17 1798 7.18mg 16.5mg 0/40 13.0mg 19/36 52.0mg 34/38
a 1798 16.0mg 39.7mg 0/40 13.0mg 11/36 52.0mg 24/38
b 1798 17.2mg 45.4mg 0/40 13.0mg 4/36 52.0mg 27/38
c 1798 36.4mg 135.mg 0/40 13.0mg 0/36 52.0mg 16/38
d 1798 10.1mg n.s.s. 5/40 13.0mg 12/36 (52.0mg 7/38)
18 1798 9.53mg 23.1mg 0/29 12.0mg 7/38 48.0mg 35/38
a 1798 14.4mg 37.1mg 0/29 12.0mg 3/38 48.0mg 30/38
b 1798 46.8mg n.s.s. 6/29 12.0mg 6/38 48.0mg 12/38
c 1798 70.6mg n.s.s. 4/29 12.0mg 11/38 48.0mg 7/38






















Spa Strain Site XPO+Xpt
Sex Route Hust Notes
TD50 2TaiLpvL
DR AuOp
2-ANIN0-3-NETHYLINIDAZ014,5.f]QUINOLINE***..1ug... .10 ...:.100...1:.mg... .10 ...:.100... .Ig ...:.10
19 R f f3d eat zym sqc 24.24 .+ .9.14mg
a R f f3d eat cti sqc 24.24 14.8mg
b R f f3d eat Liv hpc 24.24 17.2mg
c R f f3d eat Lgi adc 24.24 40.3mg
d R f f3d eat ski sqc 24.24 132.mg
R f f3d eat smi adc 24.24 406.mg
f R f f3d eat orc sqc 24.24 406.mg
20 R m f3d eat zym sqc 24.24 .+.3.57mg
a R m f3d eat tiv hpc 24.24 7.45mg
b R m f3d eat Lgi adc 24.24 8.38mg
c R m 3d eat ski sqc 24.24 14. 9mg
d R f3d eat smi adc 24m24 23.1mg
R m f3d eat orc sqc 24m24 160 .mg
2-ANINO-3-NETHYLINIDAZOI4,5.fjQUINOLINE.HCL.Iug... .10 .... 100..1m:.lg... .10 ....100...I:.g ....10
21 R f ada gay mgL car 31w52 myv + .3.29mg
a R f ada gay main mix 31w52 ev 3.80mg
b R f ada gay zym epc 31w52 ev 4.50mg
c R f sda gay tiv mix 31w52 ev 9.12mg
d R f sda gay Liv nnd 31w52 ev 19.2mg
R f ada gay Liv hpc 31w52 ev 29.3mg
f R f sadsgay Liv ham 31w52 29.3mg
g R f ada gay pan ana 31w52 ev 59.7mg
h R f Ida gay mix tpp 31w52 ev 59.7mg
























4-AMIMODIPHENYL.HCI lOOng..:. .lug...:.10 .... 100 .. :mg...:.10... ..100...I:g ...:.10
22 N f bcn wet Liv hpc 96w96 ekr + 36.8mg * P<.0005+
a N f bcn mat mix ang 96w96 ekr
b N f bcn wat ubL car 96w96 ekr
23 N m bcn wat ubL car 96w96 ekr
323.mg * P<.2 +
325.mg * P<.4 +
32.6mg * P<.0005+
a N m bcn mat Liv hpc 96w96 ekr
24 R f ada gay mgL car 31w52 ev
a R f ada gay main mix 31w52 ev
b R f ada gay Liv tum 31w52 ev
c R f ada gay tba mix 31w52 ev





ANOBARBITAL lOOng. .: ..lug...:.10 ...:.100..1m:.lg...:.10... ..100...:.Ig ...:.10
25 R m 134 wat Liv hct 72w72 a .> no dre P-1.
AMPICILLIN TRIHYDRATE
26 f b6c gay TBA NXB 24m24
a f b6c gay Liv NXB 24m24
b f b6c gay Lun NXB 24m24
27 m b6c gay TBA NXB 24m24
a m b6c gay Liv NXB 24m24
b m b6c gay Lun NXB 24m24
28 R f 34 gay pta can 24m24
a R f 134 gay TBA NXB 24m24
b R f 134 gay Liv NXB 24m24
29 R m f 34 gay amd NXA 24m24
a R m f34 gay muL NXA 24m24
b R m f34 gay muL mnL 24m24
c R m 134 gay muL MXA 24m24
d R m 34 gay TBA NXB 24m24
R m 134 gay Liv NXB 24m24
lOOng.. :. .lug... .10 ...:. 100.:.lg... .10 ....100... .Ig ...:. 10
:> 24.9gm * P<.9
no dre P-1.
17.7gm * P<.3












ANYLOPECTIN SULFATE lbOng. .: lug...:.10 ....100 1.: mg...:.10 ...:.100...:.Ig ...:.10
30 R .1f34 eat cLr adc 26w52 r + 287.mg P<.0005+
31 R 134 eat cLr a/2 39w52 r + 280.mg P<.0005+
ASPIRIN*** lOOng..:. .Iug...:.10 ...:.100 1.: mg...:.10 ...:.100...:.Ig ...:.10
32 R m 134 eat ubL pam 68w68 .> 1.67gm P<.3
a R m 134 eat Liv tum 68w68 a no dre P-1.
BARBITURIC ACID bOOng..:. .lug...:.10 ...:.100 1. : mg...:.10... ..100...:.Ig ...:.10
33 R m 134 wat Liv hct 72w72 .> no dre P-1.
BE NZEN E***
34 R f ada inh mgL meL 24m35 egv
a R f ada inh orc car 24m35 egv
b R f ada inh zym car 24m35 egv







RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc
2-AMINO-3-METHYLIMIDAZOj4,5-f JQUINOLINE***
19 1767 5.60mg 16.1mg 0/50 15.0mg
a 1767 8.64mg 28.3mg 0/50 15.0mg
b 1767 9.79mg 34.1mg 0/50 15.0mg
c 1767 18.9mg 112.mg 0/50 15.0mg
d 1767 39.9mg n.s.s. 0/50 15.0mg
* 1767 66.1mg n.s.s. 0/50 15.0mg
f 1767 66.1mg n.s.s. 0/50 15.0mg
20 1767 2.11mg 6.16mg 0/50 12.0mg
a 1767 4.53mg 13.4mg 1/50 12.0mg
b 1767 5.08mg 15.0mg 0/50 12.0mg
c 1767 8.35mg 30.1mg 0/50 12.0mg
d 1767 11.8mg 54.1mg 0/50 12.0mg
















2-AMINO-3-METHYLIMIDAZO14,5-fIQUINOLINE.HCl (IQ, hydrochloride salt)
21 1721 1.75mg 7.23mg 0/27 11.1mg 14/32
a 1721 1.86mg 16.6mg 2/27 11.1mg 14/32
b 1721 2.24mg 11.5mg 0/27 11.1mg 11/32
c 1721 3.71mg 81.0mg 0/27 11.1mg 6/32
d 1721 5.82mg n.s.s. 0/27 11.1mg 3/32
1721 7.22mg n.s.s. 0/27 11.1mg 2/32
f 1721 7.22mg n.s.s. 0/27 11.1mg 2/32
9 1721 9.71mg n.s.s. 0/27 11.1mg 1/32
h 1721 9.71mg n.s.s. 0/27 11.1mg 1/32





22 1711m 16.6mg 113.mg 0/34 1.40mg
a 1711m 52.6mg n.s.s.
b 1711m 52.9mg n.s.s.
23 1711n 18.2mg 68.6mg
a 1711n 61.0mg n.s.s.
24 1721 .553mg 1.95mg
a 1721 .535mg 2.41mg
b 1721 7.80mg n.s.s.











0/20 3.80mg 1/29 7.60mg 2/24 15.0mg
0/20 3.80mg 0/29 7.60mg 0/24 15.0mg
0/20 3.80mg 0/29 7.60mg 1/24 15.0mg
0/23 2.33mg 1/32 4.67mg 0/29 9.17mg














25 1690 29.6mg n.s.s. 0/13 25.0mg 0/12 Diwan; jnci ,74,509-516;1985
AMPICILLIN TRIHYDRATE 7177-48-2
26 c56086 1.659m n.s.s. 32/50
a c56086 n.s.s. n.s.s. 0/50
b c56086 4.60gm n.s.s. 2/50
27 c56086 1.489m n.s.s. 23/50
a c56086 3.47gm n.s.s. 9/50
b c56086 3.939m n.s.s. 6/50
28 c56086 2.39gm n.s.s. 0/50
a c56086 660.mg n.s.a. 44/50
b c56086 n.s.s. n.s.s. 0/50
29 c56086 560.mg n.s.s. 13/50
a c56086 830.mg n.s.s. 5/50
b c56086 859.mg n.s.s. 5/50
c c56086 851.mg n.s.s. 6/50
d c56086 468.mg n.s.s. 39/50
































30 1716m 133.mg 830.mg 0/18 1.009m 9/20
31 1716n 140.mg 669.ag 0/18 1.509m 12/20
ASPIRIN*** 50-78-2
32 1786 272.mg n.s.s. 0/36 200.mg 1/29














33 1690 32.1mg n.s.s. 0/13 25.0mg 0/13
BENZENE*** 71-43-2
34 bt4004 291.mg n.s.s. 2/60 53.4mg 6/54
a bt4004 496.mg n.s.s. 0/60 53.4mg 2/54
b bt4004 433.mg n.s.s. 1/60 53.4mg 3/54
Maltoni ;aj im,7,415-446;1985
225226
Spa Strain Site Xpo+Xpt
Sex Route Hist Notes
c R f sda inh Liv hpt 24.35 egv
d R f sda inh nas car 24a35 egv
a R f sda inh tba car 24.35 egv
f R f sda inh tba mai 24a35 egv
35 R f sda gav zym car 12.33 ej
a R f ada gav orc car 12.33 ej
b R f sda gav mgL mal 12.33 ej
c R f sda gav Liv hpt 12.33 ej
d R f ada gav ski car 12.33 ej
a R f sda gav -- Leu 12m33 ej
f R f sda gav tba mal 12.33 ej
36 R f sda gav orc car 24.33 a
a R f sda gav zym car 24.33 a
b R f sda gav for cic 24a33 o
c R f sda gav Liv hpt 24.33 e
d R f sda gav Liv ang 24.33 a
a R f sda gav nas car 24.33 a
f R f sda gav ski car 24.33 a
g R f sda gav tba a.l 24.33 a
h R f sda gav tba car 24.33
37 R a sda gav - -- Leu 12.33 ej
a R m sda gav liv hpt 12.33 eJ
b R m ada gav sub ang 12.33 ej
c R m sda gav mgL maL 12.33 *j
d R m sda gav ski car 12a33 e*
e R f sda gav orc car 12.33 ej
f R a sda gav zy. car 12.33 ej
g Rf sda gav tba maL 12.33 oj
38 R m ada gav orc car 24a33 a
a R m ada gav zym car 24a33 e
b R a sda gav ski car 24a33 a
c R m sda gav nas car 24a33 a
d R . sda gav Liv ang 24a33 o
a R f sda gav for ivc 24.33 e
f R a sda gav Liv hpt 24.33 a
g R f sda gav tba mal 24a33 a










































39 N f b6c gav MXB MXB 24,24 s
a N f b6c gav liv MXA 24a24 s
b M f b6c gav for sqp 24.24 s
c N f b6c gav Liv hpa 24m24 s
d N f b6c gav TBA MXB 24.24 s
a N f b6c gav Liv MXB 24,24 s
f N f b6c gav lun MXB 24.24 s
40 M m b6c gav MXB MXB 24.24
a N a b6c gav Liv NXA 24.24
b N a b6c gav Liv hpa 24.24
c M a b6c gav for MXA 24.24
d M a b6c gav for sqp 24m24
a M a b6c gav TBA MXB 24.24
f a m b6c gav liv MXB 24.24
g M a b6c gav Lun MXB 24.24
41 R f f34 gav TBA MXB 24.24
a R f f34 gav Liv MXB 24.24
42 R mI f34 gav pan ana 24.24
a R a f34 gav pre MXA 24.24
b R a f34 gav pro MXA 24.24
c R a f34 gav pre ccn 24.24
d R a f34 gav TBA MXB 24.24
e R f34 gav Liv MXB 24m24
lOOng. . .. :1ug . 10. :100. g :. . :10 .:100...
1.759m / P<.003
2.03gm / P<.02
2.94gm * P<.04 p







1.91gm * P<.03 p




285.mg * P<.06 -
6.48gm * P<.6







43 N f b6c gav for mix 24m25 e
a M f b6c gav lun mix 24m25 o
b M f b6c gav for car 24m25 o
c N f b6c gav liv mix 24m25 a
44 M b6c gav for mix 24m25 o
a N b6c gav for car 24m25 o
b M m b6c gav --- h/2 24a25 o
c M m b6c gav liv mix 24m25 a
d M m b6c gav lun aix 24m25 a
45 R f f34 gav thy mix 24m25
a R f f34 gav liv nnd 24.25 o
46 R f34 gav liv nnd 24m25
lOOng.. : .ug.:10. :100. g :.1g :10..:100.:Ig. :10
+ . 81.0mg * P<.0005+
337.mg * P<.04
445.mg * P<.04 +
no dre P-1.
49.6ag / P<.0005+






no dre P-1.CHRONOLOGICAL SUPPLEMENT














































































































































































































39 c06508 795.mg 7.34gm
a c06508 874.mg n.s.s.
b c06508 1.029m n.s.s.
c c06508 1.279m n.s.s.
d c06508 383.mg n.e.s.
e c06508 874.mg n.e.s.
f c06508 2.30gm n.s.s.
40 c06508 399.mg 1.87gm
a c06508 387.mg 5.38gm
b c06508 540.mg 1.96gm
c c06508 808.mg n.s.s.
d c06508 877.mg n.s.s.
c06508 309.mg n.s.s.
f c06508 387.mg 5.38gm
g c06508 1.44gm n.s.s.
41 c06508 116.mg n.s.s.
a c06508 950.mg n.s.s.
42 c06508 146.mg 1.86gm
a c06508 814.mg n.s.s.
b c06508 916.mg n.s.s.
c c06508 1.26gm n.s.s.
d c06508 134.mg n.s.s.






































































BENZYL CHLORIDE (aLpha-chloro toLuene) 100-44-7
43 1827 49.8mg 144.mg 0/52 20.7mg 5/50 41.5mg 19/51
a 1827 132.mg n.s.s. 1/52 20.7mg 2/51 41.5mg 6/51
b 1827 169.mg n.e.s. 0/52 20.7mg 2/50 41.5mg 3/51
c 1827 272.mg n.s.s. 7/52 20.7mg 5/51 41.5mg 3/51
44 1827 33.0mg 79.2mg 0/51 20.7mg 4/52 41.5mg 32/52
a 1827 108.mg 736.mg 0/51 20.7mg 2/52 41.5mg 8/52
b 1827 172.mg 10.5gm 0/52 20.7mg 0/52 41.5mg 5/52
c 1827 49.7mg n.s.s. 17/52 20.7mg 28/52 41.5mg 20/51
d 1827 99.1mg n.s.s. 11/52 20.7mg 15/52 41.5mg 11/52
45 1827 19.8mg 1.52gm 4/52 6.22mg 8/51 12.4mg 14/52
a 1827 49.2mg n.s.s. 2/52 6.22mg 5/52 12.4mg 3/52















Lij insky; jnci ,76,1231-1236;1986
227228 GOLD ETAL.
Spe Strain Site Xpo+Xpt
Sex Route HiSt No
FD S C BLUE NO. 2***
47 M f cdr eat tba mal 23m23 o
a M f cdr eat tba mix 23m23 a
48 N m cdr eat tba mix 95w95 e
a M m cdr eat tba mat 95w95 a
BROMATE, POTASSIUM***
49 N f b6c wat Liv ade 18.24 a
a N f b6c wat Lun mix 18m24 o
b M f b6c wat Liv mix 18m24 a
c N f b6c wat Lun ado 18m24 a
d M f b6c wat tba mix 18m24 a
BROMOACETALDEHYDE
50 M f b6c wat Liv hem 80w80 e
a M f b6c wat for sqp 80w80 a
b M f b6c wat Lun tum 80w80 a
c M f b6c wat tba mix 80w80 a
51 M m b6c wat for sqp 78w78 o
a M m b6c wat liv tum 78w78 e
b M m b6c wat Lun ptm 78w78 o
c M m b6c wat tba mix 78w78 e
BROMODICHLOROMETHANE
52 R f wis wat liv nnd 43.43 ev
53 R m wis wat pit tum 42.42 ev
a R m wis wat Liv nnd 42m42 ev
BROMOETHANOL
54 M f b6c wat for sqp 79w79 e
a M f b6c wat Liv hem 79w79 e
b M f b6c wat lun ptm 79w79 e
c M f b6c wat tba mix 79w79 e
55 M m b6c wat for sqp 78w78 e
a M m b6c wat Liv tum 78w78 e
b M m b6c wat lun ptm 78w78 e
c M m b6c wat tba mix 78w78 o
BUTYL p-HYDROXYBENZOATE
56 M f icr eat lun tum 24.25
a M f icr eat Liv tue 24m25
b M f icr eat tba mix 24.25
57 M m icr eat Liv tum 24m25
a M m icr eat Lun tue 24m25






ng. .: ..lug.. : 10. :100.. :le«g.. : 10. :100.. :I1g. :10
.33.9gm * P<.3 -
no dre P-1. -
.>23.4gm * P<.2 -
57. 1gm * P<.5 -
ng. .: ..lug.. : 10. :100.. :lemg.. : 10. :100.. : Ig. :10














































bO0ng. ... :1ug. 10. :100. le : 1g . : 10. :100.:1g..:10
A 5.10gm * P<.06 -
no dre P-1.
2.729m * P<.08 -
.> 27.4gm * P<.5 -
119.gm * P<1. -
5.24gm * P<.4 _
N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE*** .: .1ug. :10. 1 :. 100. g : ....:10. 1 :..100.. : . :10
58 R m f34 wat ubl tcc 78w78 or . + . .175mg P<.0005+
a R m f34 wat tes ldc 78w78 er .386mg P<.002 +
BUTYLATED HYDROXYANISOLE*** 1 O0ng ..: . .lug. 1 :..10 :..100. g : ..1. :. 10 : .100. : .. 10. : 10
59 R m f3d eat for pam 24.24 e .+ . 598.mg Z P<.0005+
a R m f3d eat for sqc 24m24 e
b R m f3d eat liv hpc 24m24 e
4.55gm Z P<.0005+
no dre P-1.
CALCIUM ACETATE O0ng..:. .lug. : 10. :100.. e :1g. : 10. :100. : 9 . :.10
60 R m sda eat kid tue 79w79 o .> no dre P-1.
a R m sda eat Liv tue 79w79 e no dre P-1.
CATECHOL lO0ng. . .. . :ug.10. :100. le : 1g .:10..:100..:Ig. :10
61 R m f34 wat pro cic 78w78 or .> 236.mg P<.8
a R m f34 wat ubt tum 78w78 or no dre P-1.
CHLORAMBUC IL***
62 R f sda gav mgt mix 18.24
a R f sda gav auc sqc 18.24
b R f ada gav nor mix 18.24
c R f sda gav tba mat 18.24
d R f sda gav tba ben 18.24
CHLORENDIC ACID
63 N f b6c eat Lun MXA 24m24
a M f b6c eat Lun a/a 24.24
b M f b6c eat MXA MXA 24.24
1O0ng .:. .lug.:10. :100. e : 1mg ..:10. :100.. : 1:.10
+ . .657mg \ P<.0005+
6.41mg * P<.005 +
3.86mg * P<.02 +
.588mg * P<.0005
1.47mg * P<.09
bO0ng. ... :1ug. 10. :100 . :eg . :10. 100..:Ig. :10
+ #343.mg * P<.003 -
412.mg * P<.002
1.17gm * P<.03CHRONOLOGICAL SUPPLEMENT
RefNum LoConf UpConf CntrL IDose lInc 2Dose 2Inc Citation or Pathology
FD & C BLUE NO. 2*** (indigo carmine) 860-22-0
47 1698 9.55gm n.a.s. 30/120 650.mg 15/57 1.95gm 15/48 6.50gm 20/60
a 1698 14.1gm n.s.s. 50/120 650.mg 20/57 1.95gm 20/48 6.509m 22/60
48 1698 7.549m n.s.s. 26/119 600.mg 13/55 1.80gm 19/58 6.00gm 19/60
a 1698 11.0gm n.s.s. 22/119 600.mg 8/55 1.80gm 16/58 6.00gm 13/60
BrkLy Code
BROMATE, POTASSIUM*** 7758-01-2
49 1789 480.mg n.s.s. 0/46
a 1789 369.mg n.s.a. 3/46
b 1789 449.mg n.s.s. 3/46
c 1789 549.mg n.s.s. 2/46
d 1789 163.mg n.s.s. 15/46
BROMOACETALDEHYDE 17157-48-1
50 1761 166.mg n.s.s. 0/50
a 1761 180.mg n.s.s. 1/50
b 1761 311.mg n.s.s. 0/50
c 1761 150.mg n.s.s. 7/50
51 1761 121.mg n.s.s. 1/45
a 1761 208.mg n.s.s. 0/45
b 1761 155.mg n.s.s. 5/45
c 1761 134.mg n.s.s. 8/45
75.0mg 3/48 150.mg 3/47
75.0mg 3/48 150.mg 8/47
75.0mg 3/48 150.mg 6/47
75.0mg 1/48 150.mg 5/47












52 1681 307.mg 1.51gm 0/18 94.9mg 17/53
53 1681 382.mg n.s.s. 1/22 83.7mg 10/47
a 1681 920.mg n.s.s. 5/22 83.7mg 6/47
BROMOETHANOL *--
54 1761 32.8mg 215.mg
a 1761 130.mg n.s.s.
b 1761 141.mg n.s.s.
c 1761 30.8mg 1.68gm
55 1761 37.9mg 315.mg
a 1761 255.mg n.s.s.
b 1761 190.mg n.s.s.



















56 1688 2.00gm n.s.s. 2/50
a 1688 1.159m n.s.s. 0/50
b 1688 1.04gm n.s.s. 12/50
57 1688 5.299m n.s.s. 0/50
a 1688 3.879m n.s.s. 3/50
b 1688 1.41gm n.s.s. 8/50
188.mg 4/50 375.mg 2/50 751.mg 8/50
188.mg 0/50 375.mg 0/50 751.mg 0/50
188.mg 14/50 375.mg 8/50 751.mg 21/50
173.mg 1/50 346.mg 0/50 693.mg 1/50
173.mg 2/50 346.mg 2/50 693.mg 3/50
173.mg 7/50 346.mg 11/50 693.mg 11/50
Inai;fctx,23,575-578;1985
N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE*** (butyL-butanol-nitrosamine) 3817-11-6
58 1718 .100mg .340mg 0/30 .500mg 20/30
a 1718 .187mg 1.55mg 2/30 .500mg 13/30
LaVoie;gann,76,266-271; 1985/pers. comm.
BUTYLATED HYDROXYANISOLE*** (BHA, 2(3)-tort-butyL-4-hydroxyanisote) 25013-16-5
59 1784 431.mg 858.mg 0/50 50.0mg 0/50 100.mg 0/50 200.mg 0/50 400.mg 10/50 800.mg 50/50 Ito;
jnci ,77,1261 *1265;1986
a 1784 2.28gm 11.1gm 0/50 50.0mg 0/50 100.mg 0/50 200.mg 0/50 400.mg 0/50 800.mg 11/50
b 1784 6.039m n.s.s. 0/50 50.0mg 0/50 100.mg 0/50 200.mg 3/50 400.mg 0/50 800.mg 0/50
CALCIUM ACETATE 62-54-4
60 1709 4.28gm n.s.s. 0/30 1.209m 0/30
a 1709 4.289m n.s.s. 0/30 1.209m 0/30
CATECHOL 120-80-9
61 1718 23.9mg n.s.s. 5/30 25.0mg 6/30




62 1770 .286mg 2.96mg 8/120 .323mg 10/30 (.645mg 5/30)
a 1770 1.94mg 65.5mg 0/120 .323mg 0/30 .645mg 3/30
b 1770 1.37mg n.s.s. 2/120 .323mg 3/30 .645mg 3/30
c 1770 .343mg 1.26mg 13/120 .323mg 15/30 .645mg 15/30
d 1770 .517mg n.s.s. 43/120 .323mg 15/30 .645mg 15/30
Berger;smon, 13,8-13; 1986
CHLORENDIC ACID 115-28-6
63 c55072 153.mg 1.94gm 1/50 79. 1lg 5/50 160.mg 6/50
a c55072 177.mg 1.68gm 0/50 79.1mg 4/50 160.mg 4/50





BorzolLeca;fctx,23,719-722; 1985230 GOLD ETAL.
Spa Strain Site Xpo+Xpt
Sex Route Hist Notes
c M f b6c eat TBA MXB 24.24
d M f b6c eat liv MXB 24.24
a M f b6c eat Lun MXB 24.24
64 M m b6c eat Liv MXA 24.24
a M m b6c eat liv hpc 24.24
b M m b6c eat liv hpa 24.24
c M m b6c eat thy fca 24a24
d M m b6c eat TBA MXB 24.24
a M m b6c eat liv MXB 24.24
f M m b6c eat lun MXB 24.24
65 R f f34 eat Liv MXA 24m24
a R f f34 eat Liv nnd 24.24
b R f f34 eat Liv hpc 24.24
c R f f34 eat TBA MXB 24m24
d R f f34 eat Liv MXB 24.24
66 R m f34 eat MXB MXB 24.24
a R m f34 eat Liv nnd 24m24
b R m f34 eat liv MXA 24m24
c R m f34 eat pan ana 24.24
d R m f34 eat Lun MXA 24.24
e R m f34 eat Lun a/a 24.24
f R m f34 eat pre MXA 24,24
g R m f34 eat sub fbs 24.24
h R m f34 eat pre can 24m24
i R m f34 eat TBA MXB 24.24
j R m f34 eat Liv MXB 24m24
CHLORINATED TRISODIUM PHOSPHATE
67 M f b6c gav sub srn 24m24 s
a M f b6c gav TBA MXB 24m24 s
b M f b6c gav liv MXB 24.24 s
c M f b6c gav lun MXB 24.24 s
68 M m b6c gav adr coa 24.24
a M m b6c gav mul aLp 24.24
b M m b6c gav TBA MXB 24m24
c M a b6c gav Liv MXB 24m24






141.mg * P<.004 c
206.mg * P<.009 c






162.mg * P<.004 c






131.mg * P<.005 c
148.mg * P<.01
168.mg * P<.01 a
59.4mg \ P<.02
380.mg * P<.05
189.mg * P<.2 e
no dre P-1.
32.2mg * P<.002
lOOng.. : .ug.. : 10. :100.. :lamg.. : 10. :100.. g.10









3-CHLORO-2-METHYLPROPENE, TECHNICAL GRADE (CONTAINING 5% DINETHYLVINYL CHLORIDE).:. .10... :100..:Ig..:10
69 M f b6c gav for MXA 24.24 : +: 82.3mg / P<.0005c
a M f b6c gav for sqp 24m24 87.7mg I P<.0005c
b M f b6c gav TBA MXB 24m24 149.mg I P<.03
c M f b6c gav liv MXB 24m24 no dre P-1.
d M f b6c gav lun MXB 24,24 5.18gm * P<.8
70 N m b6c gav for MXA 24m24 : + : 73.5mg * P<.0005c
a M a b6c gav for sqp 24,24 96.2mg * P<.0005c
b M m b6c gav for sqc 24,24 432.mg * P<.005 c
c M a b6c gav TBA MXB 24.24 402.mg * P<.6
d M m b6c gav liv MXB 24m24 no dre P-1.
e M a b6c gav Lun NXB 24.24 no dre P-1.
71 R f f34 gav for ppn 24.24 : + : 320.mg I P<.003 c
a R f f34 gav sub fib 24.24 524.mg * P<.02
b R f f34 gav TBA MXB 24.24 323.mg * P<.7
c R f f34 gav Liv MXB 24m24 no dre P-I.
72 R m f34 gav for ppn 24m24 : + : 68.7mg I P<.0005c
a R m f34 gav tes ict 24m24 54.0mg * P<.02
b R m f34 gav TBA MXB 24m24 109.mg * P<.2
c R m f34 gav Liv MXB 24m24 714.mg / P<.2
CHLOROFORM***
73 M f b6c wat Liv hpc 24.24 a
a M f b6c wat liv hpa 24m24 e
b M f b6c wat Liv mix 24.24 e
c M f b6c wat tba mix 24m24 e
74 R osm wat kid mix 24m24 e
a R m osm wat kid mix 24.24
b R m osm wat kid tla 24.24 e
c R m osm wat --- nf 24m24 e
d R osm wat --- mix 24m24 e
e R m osm wat tba mix 24m24 a
75 R f wis wat Liv nnd 43m43 ev
a R f wis wat Liv hpc 43m43 ev
b R f wis wat kid tum 43m43 ev
76 R m wis wat kid adc 40m40 ev
a R m wis wat kid ade 40m40 ev
b R m wis wat Liv hpc 40m40 ev
c R m wis wat Liv nnd 40m40 ev
lOOng.. :. .ug.. : 10. :100.. :.1mg.:10. :100.. :. g..:10
















no dre P-1.CHRONOLOGICAL SUPPLEMENT
RefNum LoConf UpConf Cntrl IDose lInc 2Dosa 2Inc
c c55072 46.6mg 350.mg
d c55072 150.mg 52.5gm
* c55072 153.mg 1.94gm
64 c55072 72.2mg 1.17gm
a c55072 101.mg 8.479m
b c55072 150.mg n.s.s.
c c55072 474.mg n.s.s.
d c55072 74.7mg n.s.s.
* c55072 72.2mg 1.17gm
f c55072 379.mg n.s.s.
65 c55072 56.0mg 283.mg
a c55072 80.3mg 1.11gm
b c55072 122.mg n.s.s.
c c55072 41.7mg n.s.s.
d c55072 56.0mg 283.mg
66 c55072 16.2mg 57.9mg
a c55072 16.3mg 58.7mg
b c55072 18.2mg 127.mg
c c55072 63.4mg 1.04gm
d c55072 69.7mg 10.19m
* c55072 75.9mg 8.53gm
f c55072 26.2mg n.s.s.
9 c55072 130.mg n.s.s.
h c55072 68.2mg n.sa.s.
i c55072 25.7mg n.s.s.

























































































































CHLORINATED TRISODIUM PHOSPHATE 56802-99-4
67 c55754 488.mg 48.39m 0/50 350.mg 4/50 (701.mg 0/50)
a c55754 305.mg n.s.s. 29/50 350.mg 32/50 701.mg 29/50
b c55754 774.mg n.s.s. 6/50 350.mg 8/50 701.mg 6/50
c c55754 2.31gm n.s.s. 6/50 350.mg 2/50 701.mg 3/50
68 c55754 2.02gm n.s.s. 0/50 352.mg 1/50 707.mg 3/50
a c55754 2.54gm n.s.s. 0/50 352.mg 0/50 707.mg 3/50
b c55754 577.mg n.s.s. 35/50 352.mg 37/50 707.mg 30/50
c c55754 812.mg n.s.s. 14/50 352.mg 14/50 707.mg 17/50
d c55754 1.229m n.s.s. 8/50 352.mg 12/50 707.mg 7/50
3-CHLORO-2-METHYLPROPENE, TECHNICAL GRADE (CONTAINING 5X DINETHYLVINYL CHLORIDE) 563-47-3
69 c54820 57.4mg 124.mg 0/50 70.1mg 16/50 140.mg 31/50
a c54820 60.5mg 134.mg 0/50 70.1mg 15/50 140.mg 29/50
b c54820 66.0mg n.s.s. 28/50 70.1mg 32/50 140.mg 37/50
c c54820 707.mg n.s.s. 4/50 70.1mg 3/50 140.mg 1/50
d c54820 469.mg n.s.s. 3/50 70.1mg 2/50 140.mg 3/50
70 c54820 49.2mg 141.mg 3/50 70.1mg 24/50 140.mg 36/50
a c54820 61.5mg 212.mg 3/50 70.1mg 19/50 140.mg 30/50
b c54820 221.mg 2.76gm 0/50 70.1mg 5/50 140.mg 7/50
c c54820 74.5mg n.s.s. 33/50 70.1mg 42/50 140.mg 45/50
d c54820 177.mg n.s.s. 22/50 70.1mg 16/50 (140.mg 13/50)
* c54820 472.mg n.s.s. 7/50 70.1mg 10/50 140.mg 3/50
71 c54820 149.mg 1.82gm 1/50 52.6mg 1/50 105.mg 10/50
a c54820 213.mg n.s.s. 0/50 52.6mg 2/50 105.mg 4/50
b c54820 49.7mg n.s.s. 43/50 52.6mg 42/50 105.mg 41/50
c c54820 714.mg n.s.s. 2/50 52.6mg 1/50 105.mg 0/50
72 c54820 43.8mg 119.mg 1/50 52.6mg 5/50 105.mg 30/50
a c54820 25.0mg n.s.s. 36/50 52.6mg 43/50 105.mg 43/50
b c54820 37.1mg n.s.s. 40/50 52.6mg 32/50 105.mg 40/50



















73 1671 2.69gm n.s.s. 2/415
a 1671 5.189m n.s.s. 19/415
b 1671 3.739m n.s.s. 21/415
c 1671 664.mg n.s.s. 225/423
74 1671 265.mg 1.799m 5/301
a 1671 305.mg 1.97gm 4/301
b 1671 420.mg 6.25gm 4/301
c 1671 676.mg n.s.s. 2/303
d 1671 343.mg n.s.s. 5/303
1671 90.2mg n.s.s. 212/303
75 1681 429.mg 5.429m 0/18
a 1681 1.639m n.s.s. 0/18
b 1681 3.06gm n.s.s. 0/18
76 1681 862.mg n.s.s. 0/22
a 1681 862.mg n.s.s. 0/22
b 1681 862.mg n.s.s. 0/22
c 1681 574.mg n.s.s. 5/22
40.0mg 7/410 80.0mg 1/142 180.mg
40.0mg 8/410 80.0mg 8/142 180.mg
40.0mg 15/410 80.0mg 9/142 180.mg
40.0mg 217/415 80.0mg 90/142 180.mg
10.0mg 6/313 20.0mg 7/148 45.0mg
10.0mg 4/313 20.0mg 4/148 45.0mg
10.0mg 2/313 20.0mg 3/148 45.0mg
10.0mg 2/316 20.0mg 1/148 45.0mg
10.0mg 19/316 20.0mg 5/148 45.0mg































Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
CHLORPHENIRANINE NALEATE***
77 N f b6c gav TBA NXB 24.24
a N f b6c gav Liv NXB 24.24
b N f b6c gav lun NXB 24.24
78 N m b6c gav arp adn 24.24 s
a N m b6c gav sub NXA 24.24 s
b N a b6c gav sub NXA 24.24 s
c N m b6c gav sub fbs 24.24 s
d N m b6c gav TBA MXB 24.24 s
e N m b6c gav Liv NXB 24.24 s
f N m b6c gav lun NXB 24.24 s
79 R f f34 gav TBA NXB 24.24 s
a R f f34 gav Liv NXB 24.24 s
80 R m f34 gav TBA NXB 24.24
a R m f34 gav liv NXB 24.24
TD50 2Tailpvl
DR AuOp
lOOng.. :. .ug.:10. :100. lg :. . :10. :100..:19 :10
:> no dre P-1.
no dre P.1.
no dre P-1.







:> no dre P.1.
3.18gm * P<.9
:> no dre P-1.
208.mg * P<.6
CHOLINE CHLORIDE lOOng. . .. :1ug . 10. :100. g :. . :10. : 100.. : . :10
81 R m f34 eat Liv nnd 17m24 a .> no dre P-1.
CHRYSAZIN
82 N m can eat liv hpc 77w77 a
a N m can eat liv hpa 77w77 a
b N m can mat Liv mix 77w77 a
83 R m aci eat Lgi a/2 69w69 r
a R m aci eat Liv tum 69w69 r
CROTONALDEHYDE
84 R m chi wat Liv mix 26.26
a R m chi wat Liv nnd 26.26
b R m chm wat Liv hpc 26.26
100ng. .:. ..ug :10. :100.l. : g.:10. :100. g.10
A 336.mg P<.02 +
201.mg P<.2 +
201.mg P<.2 +
+ . 245.mg P<.003 +
no dre P-1.
1O0ng..: ..lug.:10. :100. lu :g.:10. :100. g.10
+ . 4.20mg \ P<.0005+
4.20mg \ P<.0005
no dre P-1.
DDT*** lOOng..:. .1ug.:10. 1 :100. g :. . :10..:100..1:0 . :10
85 R . f34 eat Liv nnd 17m24 er .> 56.2mg P<.2
DIALLYLNITROSANINE
86 H b syg gav trh ppp 53w59 am
a H b syg gav ncp adc 53w59 ae
b H b syg gav Lar ppp 53w59 ae
c H b syg gav phr pa. 53w59 ae
d H b syg gav Liv cho 53w59 ae
a H b syg gav Lun ada 53w59 ae
f H b syg gav tba mix 53w59 am
87 R f bd9 wat npc mix 24m24 r
a R f bd9 wat npc adc 24m24 r
88 R m bd9 wat npc mix 24m24 r
a R m bd9 wat npc adc 24m24 r
O,S-DIBENZOYL THIANINE.HCL
89 R f sda mat Liv hga 24m24 a
a R f ada mat tba mix 24m24 a
b R f ada mat tba maL 24m24 a
90 R m sda mat liv Lcm 24m24 a
a R sda mat liv Lcb 24m24 a
b R sda mat tba maL 24m24 a
c R i sda mat tba mix 24m24 a
1,2-DIBRONOETHANE***
91 N f b6c wat for mix 73w73 a
a N f b6c wat for sqc 73w73 a
b N f b6c wat mso sqp 73w73 a
c N f b6c wat Lun ptm 73w73 a
d N f b6c wat Liv tum 73w73 a
a N f b6c wat tba mix 73w73 a
92 N f b6c wat for pam 78w78 a
a N f b6c wat for sqc 78w78 a
b N f b6c wat mso pam 78w78 a
c N f b6c wat Liv hpt 78w78 a
d N f b6c wat lun pt. 78w78 a
a N f b6c wat tba mix 78w78 a
93 N b6c wat for sqc 65w65 a
a N b6c wat for mix 65w65 a
b N b6c wat Liv tum 65w65 a
c N m b6c wat Lun pt. 65w65 a
d N m b6c wat tba mix 65w65 a
94 N b6c wat for sqc 78w78 a
a N m b6c wat eso sqc 78w78 a
lOOng.. :. .ug.:10. :100. g : . 1g :10. :100..g.10







+ . 32.1mg * P<.0005+
33.6mg * P<.0005+
+ . 36.0mg Z P<.0005+
46.9mg Z P<.0005+
bO0ng.. : . .ug.:10. :.100. 1mg : . 1g :10. :..100.:Ig..:10
.> no dre P-I. -
no dre Pal. -
14.39m * P<.9 -
.> 6.77gm * P<.2 -
6.98gm * P<.2 -
2.34gm / P<.4 -
no dre P-1. -







































RefNum LoConf UpConf CntrL IDose lInc 2Dose 2Inc
CHLORPHENIRANINE NALEATE*** 113-92-8
77 c55265 66.8mg n.s.s. 37/50 70.7mg
a c55265 498.mg n.s.s. 6/50 70.7mg
b c55265 480.mg n.s.s. 6/50 70.7mg
78 c55265 34.7mg n.s.s. 2/50 17.7mg
a c55265 39.7mg n.s.s. 4/50 17.7mg
b c55265 41.2mg 13.1gm 3/50 17.7mg
c c55265 51.1mg n.s.s. 3/50 17.7mg
d c55265 14.3mg n.s.a. 39/50 17.7mg
* c55265 25.8mg n.s.s. 16/50 17.7mg
f c55265 105.mg n.s.s. 16/50 17.7mg
79 c55265 21.5mg n.s.s. 42/50 21.2mg
a c55265 96.6mg n.s.s. 2/50 21.2mg
80 c55265 14.2mg n.s.s. 44/50 10.6mg































81 1803 764.mg n.s.s. 2/28 280.mg 2/28
CHRYSAZIN (danthron) 117-10-2
82 1796 115.mg n.s.s. 0/19
a 1796 65.2mg n.s.s. 5/19
b 1796 65.2mg n.s.s. 5/19
83 1725 104.mg 1.06gm 0/15






















Nor i ;gann,77,871-876; 1986
Mori ;bjca,52,781-783;1985
CROTONALDEHYDE (trans-2-butenal) 123-73-9
84 1774 1.96mg 12.8mg 0/23 2.10mg
a 1774 1.96mg 12.8mg 0/23 2.10mg






85 1803 17.6mg n.s.s. 2/28 14.0mg 6/28
DIALLYLNITROSAMINE 16338-97-9
86 1826 1.86mg 5.49mg 0/30
a 1826 1.85mg 4.74mg 0/30
b 1826 2.33mg 11.8mg 0/30
c 1826 9.60mg n.s.s. 0/30
d 1826 n.s.s. n.s.s. 1/30
1826 23.6mg n.s.s. 0/30
f 1826 .933mg 3.37mg 7/30
87 1714 20.9mg 53.2mg 0/20
a 1714 21.8mg 56.3mg 0/20
88 1714 19.7mg 75.0mg 0/20





































89 1728 4.65gm n.s.s.
a 1728 212.mg n.s.s.
b 1728 998.mg n.s.s.
90 1728 1.75gm n.s.s.
a 1728 1.14gm n.s.s.
b 1728 544.mg n.s.s.























1,2-DIBROMOETHANE*** (ethylene dibromide, EDB) 106-93-4
91 1761 6.68mg 25.7mg 1/50 103.mg 27/29
a 1761 13.9mg 46.5mg 0/50 103.mg 22/29
b 1761 96.3mg n.s.s. 0/50 103.mg 3/29
c 1761 175.mg n.s.s. 1/50 103.mg 1/29
d 1761 303.mg n.s.s. 0/50 103.mg 0/29
e 1761 6.84mg 28.6mg 7/50 103.mg 27/29
92 1806 13.9mg 44.8mg 9/96 48.0mg 29/49
a 1806 20.7mg 67.1mg 0/96 48.0mg 20/49
b 1806 75.0mg 1.58gm 0/96 48.0mg 4/49
c 1806 273.mg n.s.s. 2/96 48.0mg 0/49
d 1806 192.mg n.s.s. 13/96 48.0mg 2/49
1806 n.s.s. n.s.s. 84/96 48.0mg 49/49
93 1761 5.98mg 23.1mg 0/45 116.mg 26/28
a 1761 6.01mg 23.5mg 1/45 116.mg 26/28
b 1761 261.mg n.s.s. 0/45 116.mg 0/28
c 1761 146.mg n.s.s. 5/45 116.mg 2/28
d 1761 6.21mg 27.4mg 8/45 116.mg 26/28
94 1806 5.97mg 15.5mg 2/99 46.7mg 41/48







Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
b N . b6c wat eso pae 78w78 e
c N m b6c wat liv hpt 78w78 e
d N m b6c wat tba mix 78w78 e
1,4-DICHLOROBENZENE
95 N f b6c gav liv NXA 24.24
a N f b6c gav Liv hpc 24.24
b N f b6c gav liv hpa 24.24
c N f b6c gav thy fca 24.24
d N f b6c gav TBA NXB 24.24
e N f b6c gav Liv NXB 24.24
f N f b6c gav lun NXB 24.24
96 N m b6c gav Liv NXA 24.24
a N m b6c gav Liv hpc 24.24
b N m b6c gav Liv hpa 24.24
c N m b6c gav acd NXA 24.24
d N m b6c gav Liv hpb 24.24
e N m b6c gav TBA NXB 24.24
f m m b6c gav Liv NXB 24.24
g N m b6c gav Lun NXB 24.24
97 R f f34 gav TBA NXB 24.24
a R f f34 gav Liv NXB 24.24
98 R m f34 gav kid NXA 24.24
a R m f34 gav kid uac 24.24
b R m f34 gav muL mnl 24.24
c R m f34 gav TBA NXB 24.24
d R m f34 gav liv MXB 24.24
1,2-DICHLOROPROPANE
99 N f b6c gav liv NXA 24.24 s
a N f b6c gav liv hpa 24.24 s
b N f b6c gav for MXA 24.24 s
c N f b6c gav TBA NXB 24.24 s
d N f b6c gav Liv MXB 24.24 s
e N f b6c gav lun NXB 24.24 s
100 N m b6c gav Liv NXA 24.24
a N m b6c gav liv hpa 24.24
b N m b6c gav for sqp 24.24
c N m b6c gav TBA NXB 24.24
d N m b6c gav Liv NXB 24.24
e N m b6c gav Lun NXB 24.24
101 R f f34 gav mgl acn 24.24
a R f f34 gav TBA NXB 24.24
b R f f34 gav Liv NXB 24.24
102 R o f34 gav TBA MXB 24.25






lOOng .: ..ug.:10. :100. g : ..g :10. :100.:Ig. :10
+ 483.mg / P<.005 c
852..g / P<.005 c





339.mg / P<.005 c
559.mg / P<.02 c








+ 586.mg * P<.005




lOOng .. :. .ug.:10. :100. g : . 1g :10. :100..g.10
+ 346.mg * P<.008 p





229.mg * P<.05 p





767.mg * P<.03 e
240.mg * P<.3
no dre P-1.
69.7mg I P<.04 -
2.579g * P<.8
DIGLYCIDYL RESORCINOL ETHER, TECHNICAL GRADE .... .:10. :100. 1g :. . :10. :100.. : . :10
103 N f b6c gav sto MXA 24.24 s : + 17.9mg * P<.0005c
a N f b6c gav sto sqc 24m24 s 36.3mg * P<.0005c
b N f b6c gav sto NXA 24m24 s 48.2mg * P<.0005c
c N f b6c gav Liv hpc 24m24 a 221 .mg * P<.02
d M f b6c gav TBA NXB 24m24 s 32.3mg * P<.007
e N f b6c gav Liv NXB 24m24 s 169.mg * P<.06
f N f b6c gav Lun MXB 24m24 s 4.799m * P<I.
104 M m b6c gav sto MXA 24m24 s :+ 37.8mg * P<.0005c
a M m b6c gav sto sqc 24m24 s 55.5mg * P<.0005c
b N m b6c gav sto NXA 24m24 s 145.mg * P<.0005c
c N m b6c gav TBA MXB 24m24 s 36.6mg \ P<.2
d M m b6c gav Liv MXB 24.24 s 84.7mg \ P<.3
e M m b6c gav Lun MXB 24m24 s 1.35gm * P<.8
105 R f f34 gav sto MXB 24m24 s + 4.47mg * P<.0005
a R f f34 gav sto sqc 24m24 a 5.10mg * P<.0005c
b R f f34 gav sto sqp 24m24 s 45.5mg * P<.0005c
c R f f34 gav TBA NXB 24m24 s 8.53mg * P<.004
d R f f34 gav liv NXB 24m24 s no dre P-1.
106 R f f34 gav for MXB 24m24 + 3.53mg P<.0005
a R f f34 gav for sqc 24m24 5.93mg P<.0005c
b R f f34 gav for sqp 24m24 8.95mg P<.0005c
c R f f34 gav TBA MXB 24m24 16.0mg P<.4
d R f f34 gav Liv MXB 24m24 174.mg P<.6
107 R m f34 gav tes ict 23m24 a + 2.35mg I P<.0005
a R f134 gav sto MXB 23m24 a 2.89mg * P<.0005
b R m f34 gav sto sqc 23m24 a 3.06mg * P<.0005c
c R m f34 gav pit adn 23m24 a 12.2mg * P<.008CHRONOLOGICAL SUPPLEMENT
RefNum LoConf UpConf Cntrt lDose lInc 2Dose 2Inc Citation or Pathology
b 1806 71.4mg 1.40gm 0/99 46.7mg 4/48
c 1806 215.mg n.s.s. 12/99 46.7mg 1/48
d 1806 n.s.s. n.s.s. 76/99 46.7mg 48/48
1,4-DICHLOROBENZENE 106-46-7
95 c54955 244.mg 4.20gm 15/50
a c54955 427.mg 7.32gm 5/50
b c54955 422.mg n.s.s. 10/50
c c54955 1.54gm n.s.s. 0/50
d c54955 220.mg n.s.s. 37/50
* c54955 244.mg 4.20gm 15/50
f c54955 2.279m n.s.s. 5/50
96 c54955 172.mg 3.15gm 17/50
a c54955 267.mg n.s.s. 14/50
b c54955 324.mg n.s.s. 5/50
c c54955 916.mg n.s.s. 0/50
d c54955 1.21gm n.s.s. 0/50
* c54955 230.mg n.s.s. 35/50
f c54955 172.mg 3.15gm 17/50
g c54955 213.mg n.s.s. 6/50
97 c54955 289.mg n.s.s. 43/50
a c54955 1.62gm n.s.s. 1/50
98 c54955 270.mg 5.06gm 1/50
a c54955 285.mg 20.0gm 1/50
b c54955 250.mg n.s.a. 5/50
c c54955 78.2mg n.s.s. 38/50













































1,2-DICHLOROPROPANE (propylene dichloride) 78-87-5
99 c55141 168.mg 6.759m 2/50 86.8mg 8/50 175.mg
a c55141 235.mg n.s.s. 1/50 86.8mg 5/50 175.mg
b c55141 387.mg n.s.s. 0/50 86.8mg 2/50 175.mg
c c55141 92.1mg n.s.s. 35/50 86.8mg 29/50 175.mg
d c55141 168.mg 6.75gm 2/50 86.8mg 8/50 175.mg
* c55141 1.079m n.s.s. 6/50 86.8mg 1/50 175.mg
100 c55141 98.6mg n.s.s. 18/50 86.8mg 26/50 175.mg
a c55141 165.mg n.s.s. 7/50 86.8mg 10/50 175.mg
b c55141 524.mg n.s.s. 0/50 86.8mg 1/50 175.mg
c c55141 102.mg n.s.s. 33/50 86.8mg 36/50 175.mg
d c55141 98.6mg n.s.s. 18/50 86.8mg 26/50 175.mg
* c55141 312.mg n.s.s. 11/50 86.8mg 8/50 175.mg
101 c55141 294.mg n.s.s. 1/50 86.8mg 2/50 175.mg
a c55141 72.5mg n.s.s. 42/50 86.8mg 46/50 175.mg
b c55141 2.18gm n.s.s. 1/50 86.8mg 0/50 175.mg
102 c55141 29.8mg n.s.s. 45/50 42.8mg 37/50 86.4mg
a c55141 208.mg n.s.s. 3/50 42.8mg 3/50 86.4mg
DIGLYCIDYL RESORCINOL ETHER, TECHNICAL GRADE 101-90-6
103 c54966 11.9mg 27.9mg
a c54966 23.1mg 59.8mg
b c54966 25.4mg 113.mg
c c54966 74.9mg n.s.s.
d c54966 15.5mg 484.mg
* c54966 58.0mg n.s.s.
f c54966 112.mg n.s.s.
104 c54966 26.5mg 56.5mg
a c54966 37.4mg 88.8mg
b c54966 78.0mg 423.mg
c c54966 12.6mg n.s.s.
d c54966 24.7mg n.s.s.
* c54966 156.mg n.s.s.
105 c54966 2.88mg 7.26mg
a c54966 3.23mg 8.51mg
b c54966 19.4mg 141.mg
c c54966 4.09mg 64.0mg
d c54966 66.5mg n.s.s.
106 c54967 2.36mg 5.59mg
a c54967 3.72mg 10.3mg
b c54967 5.20mg 17.3mg
c c54967 3.84mg n.s.s.
d c54967 24.5mg n.s.s.
107 c54966 1.33mg 4.84mg
a c54966 1.61mg 5.01mg
b c54966 1.67mg 5.54mg
























































































35.0mg 17/50 70.1mg 33/50
35.0mg 12/50 70.1mg 23/50
35.0mg 5/50 70.1mg 10/50
35.0mg 1/50 70.1mg 3/50
35.0mg 27/50 70.1mg 38/50
35.0mg 1/50 70.1mg 7/50
35.0mg 3/50 70.1mg 2/50
35.0mg 17/50 70.4mg 33/50
35.0mg 14/50 70.4mg 25/50
35.0mg 4/50 70.4mg 10/50
35.0mg 40/50 (70.4mg 41/50)
35.0mg 18/50 (70.4mg 11/50)
35.0mg 2/50 70.4mg 8/50
17.7mg 38/50 35.4mg 4/50
17.7mg 34/50 35.4mg 3/50
17.7mg 7/50 35.4mg 1/50
17.7mg 41/50 35.4mg 6/50






17.7mg 39/50 35.7mg 11/50
17.7mg 45/50 35.7mg 10/50
17.7mg 38/50 35.7mg 4/50

















Brkty Code236 GOLD ETAL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
d R m f34 gav sto sqp 23.24 a
e R m f34 gav TBA MXB 23.24 a
f R m f34 gav liv MXB 23.24 a
108 R m f34 gav for MXB 24.24
a R m f34 gav for sqc 24.24
b R m f34 gav for sqp 24m24
c R m f34 gav TBA MXB 24.24
d R m f34 gav Liv MXB 24.24
DINETHYLVINYL CHLORIDE
109 M f b6c gav for MXA 24m24
a M f b6c gav for MXA 24m24
b M f b6c gav for sqc 24m24
c M f b6c gav for MXA 24m24
d N f b6c gav MXA NXA 24.24
e M f b6c gav hag ppa 24.24
f M f b6c gav Liv hpa 24.24
g M f b6c gav Lun MXA 24.24
h M f b6c gav Lun a/a 24.24
i M f b6c gav for sqp 24m24
j M f b6c gav MXA MXA 24m24
k M f b6c gav TBA MXB 24m24
l M f b6c gav Liv NXB 24m24
* M f b6c gav Lun MXB 24.24
110 M m b6c gav MXB MXB 24m24
a M m b6c gav for MXA 24m24
b M m b6c gav for sqc 24m24
c M m b6c gav Liv MXA 24m24
d M m b6c gav Liv hpa 24m24
a M m b6c gav Lun MXA 24m24
f M m b6c gav pre sqc 24m24
g M m b6c gav Liv hpc 24.24
h M m b6c gav Lun a/a 24m24
i M m b6c gav MXA MXA 24m24
j M mb6c gav hag ppa 24m24
k M m b6c gav MXA MXA 24m24
L M m b6c gav for sqp 24m24
* M mb6c gav Lun a/c 24m24
n M m b6c gav NXA MXA 24,24
o M m b6c gav MXA MXA 24,24
p M m b6c gav TBA MXB 24m24
q M m b6c gav Liv MXB 24m24
r M m b6c gav Lun MXB 24m24
111 R f f34 gav MXB MXB 23m24 a
a R f f34 gav nas MXA 23m24 a
b R f f34 gav nas MXA 23m24 a
c R f f34 gav mgL MXA 23m24 a
d R f f34 gav mgL fba 23m24 a
e R f f34 gav nas MXA 23.24 a
f R f f34 gav nas can 23.24 a
g R f f34 gav pta MXA 23.24 a
h R f f34 gav pta MXA 23m24 a
i R f f34 gav ut. MXA 23m24 a
j R f f34 gav ute esp 23m24 a
k R f f34 gav for MXA 23m24 a
l R f f34 gav thy MXA 23m24 a
m R f f34 gav thy fcc 23m24 a
n R f f34 gav nas NXA 23m24 a
o R f f34 gav nas adc 23.24 a
p R f f34 gav for sqc 23m24 a
q R f f34 gav for sqp 23m24 a
r R f f34 gav Lun MXA 23.24 a
s R f f34 gav eso sqc 23m24 a
t R f f34 gav MXA MXA 23m24 a
u R f f34 gav MXA MXA 23m24 a
v R f f34 gav pta MXA 23.24 a
w R f f34 gav pta cra 23.24 a
x R f f34 gav muL MXA 23.24 a
y R f f34 gav muL mnL 23m24 a
z R f f34 gav pta crc 23m24 a
A R f f34 gav thy cca 23.24 a
B R f f34 gav or. sqp 23.24 a
C R f f34 gav TBA MXB 23,24 a
D R f f34 gav Liv MXB 23m24 a











lOOng .. :. .ug.. : 10. :100.. :l1ug.. : 10. :100.. :I1g. :10


















































209.mg * P<.008 c
218.mg * P<.002
250.mg * P<.003 c
318.mg / P<.0005c












RefNum LoConf UpConf CntrL IDose lInc 2Dose 2Inc Citation or Pathology
d c54966 14.5mg 45.0mg
e c54966 1.41mg 4.70mg
f c54966 14.0mg n.s.s.
108 c54967 1.55mg 3.66mg
a c54967 1.79mg 4.38mg
b c54967 4.42mg 17.1mg
c c54967 2.19mg 61.9mg










109 c54819 8.29mg 24.3mg 0/50
a c54819 8.29mg 24.3mg 0/50
b c54819 8.34mg 24.8mg 0/50
c c54819 8.34mg 24.8mg 0/50
d c54819 45.7mg 1.329m 10/50
c54819 52.9mg 489.mg 0/50
f c54819 50.0mg 3.68gm 4/50
g c54819 58.7mg 1.62gm 3/50
h c54819 68.5mg 2.729m 2/50
i c54819 83.4mg 5.109m 0/50
j c54819 64.1mg n.s.s. 6/50
k c54819 9.20mg 25.3mg 32/50
L c54819 50.0mg 3.68gm 4/50
m c54819 58.7mg 1.62gm 3/50
110 c54819 9.93mg 23.6mg 2/50
a c54819 10.1mg 23.7mg 1/50
b c54819 11.2mg 26.2mg 0/50
c c54819 24.0mg 133.mg 11/50
d c54819 36.4mg 407.mg 8/50
a c54819 37.2mg 355.mg 6/50
f c54819 41.8mg 213.mg 1/50
g c54819 44.3mg 375.mg 3/50
h c54819 43.2mg 778.mg 3/50
i c54819 51.1mg 4.329m 6/50
j c54819 50.4mg 1.51gm 2/50
k c54819 52.0mg 7.57gm 6/50
l c54819 66.8mg 827.mg 1/50
m c54819 65.5mg 3.88gm 3/50
n c54819 68.2mg 5.79gm 2/50
o c54819 83.9mg n.s.s. 1/50
p c54819 8.92mg 23.2mg 26/50
q c54819 24.0mg 133.mg 11/50
r c54819 37.2mg 355.mg 6/50
111 c54819 15.9mg 40.5mg 1/50
a c54819 20.8mg 55.6mg 0/50
b c54819 21.1mg 57.5mg 0/50
c c54819 19.1mg 89.9mg 11/50
d c54819 19.5mg 98.1mg 10/50
c54819 26.9mg 77.7mg 0/50
f c54819 29.2mg 89.1mg 0/50
g c54819 29.5mg 616.mg 17/50
h c54819 30.3mg 940.mg 17/50
i c54819 35.3mg 543.mg 8/50
j c54819 36.6mg 801.mg 8/50
k c54819 40.2mg 313.mg 1/50
L c54819 44.3mg 994.mg 1/50
c54819 44.9mg 1.53gm 1/50
n c54819 54.6mg 412.mg 0/50
o c54819 56.8mg 504.mg 0/50
p c54819 65.9mg 832.mg 0/50
q c54819 62.0mg 7.92gm 1/50
r c54819 70.5mg 1.119m 0/50
s c54819 72.5mg 1.89gm 0/50
t c54819 117.mg 1.13gm 0/50
u c54819 343.mg 10.5gm 0/50
v c54819 37.4mg n.s.s. 16/50
w c54819 38.9mg n.s.s. 16/50
x c54819 59.6mg n.s.s. 5/50
y c54819 64.5mg n.s.s. 5/50
z c54819 64.6mg n.s.s. 1/50
A c54819 64.4mg n.s.s. 3/50
B c54819 369.mg n.s.s. 0/50
C c54819 7.69mg 19.4mg 33/50
D c54819 n.s.s. n.s.s. 0/50









































































































































































































































duo:mLm; lyd:mno; mul:grl,mlh,mlm,mLp,mLu; spL:mLm. S
S
duo:mlm; Lyd:mno; muL:mLh,mlm,mLp,mLu; spl:mLm. S
S




























BrkLy Code238 GOLD ETAL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
a R m f34 gav MXB MXB 22,24 a
b R m f34 gav nas MXA 22m24 a
c R m f34 gav for MXA 22.24 a
d R m f34 gav nas MXA 22m24 a
e R m f34 gav nas can 22m24 a
f R m f34 gav for sqp 22m24 a
g R m f34 gav nas acn 22m24 a
h R m f34 gav eso MXA 22m24 a
i R m f34 gav mul mnl 22m24 a
j R m f34 gav for sqc 22m24 a
k R m f34 gav eso sqc 22m24 a
l R m f34 gav MXA MXA 22m24 a
m R m f34 gav MXA MXA 22m24 a
n R m f34 gav eso sqp 22m24 a
o R m f34 gav nas sqc 22.24 a
p R m f34 gav ton MXA 22m24 a
q R m f34 gav ton sqc 22m24 a
r R m f34 gav MXA MXA 22m24 a
a R m f34 gav TBA MXB 22m24 a
t R m f34 gav Liv MXB 22m24 a
DIPYRONE***
113 R f wis eat mgl ada 24m30 e
a R f wis eat Liv Lcc 24m30 a
b R f wis eat Liv ade 24m30 a
c R f wis eat Liv ang 24m30 a
114 R m wis eat Liv ada 24m30 e
a R m wis eat Liv apc 24m30 e
EPICHLOROHYDRIN***
115 R f wis gav for sqc 24m24 a
a R f wis gav Liv nnd 24m24 e
b R f wis gav tba mix 24m24 e
116 R m wis gav for sqc 24m24 e
a R m wis gav liv tum 24m24 e
b R m wis gav liv hpc 24m24 e
c R m wis gav liv nnd 24m24 e
















218.mg * P<.002 c
297.mg * P<.009 c
415.mg * P<.002 c




lOOng .. :. .ug.:10. :100. 1m : g.:10. :100. : g..:10
+ . 328.mg \ P<.004 -
8.33gm * P<.3 _
33.1gm * P<1. -
41.4gm * P<.9 _
.> 3.34gm * P<.4 -
no dre P-.
lOOng. . .. :1ug . 10. :100. g :.. :10. :100.. : . :10
+ . 2.55mg / P<.0005+
no dre P-1. -
no dre P-1.
. + . 3.53mg * P<.0005+
218.mg P<.3 -
no dre P-1. -
no dre P-1. -
4.83mg P<.4
DL-ETHIONINE*** lOOng .:. .lug. :10. :100. g :. 1g :10. :100.:Ig. :10
117 N f bal eat liv mix 24m24 e . + . 59.7mg * P<.0005+
a M f baL eat liv hpc 24m24 e 112.mg * P<.0005+
b M f bal eat Lun adc 24m24 e no dre P-1.
c M f baL eat Lun ade 24m24 a no dre P-I.
118 M m bal eat Lun adc 24m24 e . 222.mg \ P<.04
a M m baL eat Liv mix 24m24 e 791.mg P<.02 +
b M m baL eat Liv hpc 24m24 e 1.54gm * P<.02 +
c M m baL eat Lun ade 24m24 e no dre P-1.
119 M f can gav Liv mix 7m24 . 33.8mg \ P<.05 +
120 M f can eat Liv mix 68w68 esv . + . 62.5mg * P<.0005+
a M f can eat Liv hpc 68w68 *sv 128.mg * P<.0005+
b M f cen eat Lun ada 68w68 esv 1.13gm * P<.06
121 M m can eat Liv hpc 68w68 e . + . 182.mg P<.003 +
a M m can eat Liv mix 68w68 e 181.mg * P<.08 +
b M m cen eat Lun ada 68w68 a no dre P-I.
122 M f scd eat Liv mix 24m24 *sv . + . 67.3mg \ P<.0005+
a M f scd eat Liv hpc 24m24 esv 151.mg * P<.0005+
b M f scd eat Lun adc 24m24 esv no dre P-1.
c M f scd eat Lun ada 24m24 esv no dre P-1.
123 R m f3d eat Liv hpc 24m24 a . + . 46.0mg Z P<.0005+
a R m f3d eat Liv thc 24m24 a 46.0mg Z P<.0005+
b R m f3d eat Liv ghc 24m24 a no dre P-1.
c R m f3d eat Liv cLc 24m24 a no dre P-1.
o-ETHOXYBENZAMIDE lOOng ..:.lug.:10. 1 :100. g :. . :10. 1 :100... : . :10
124 M f b6c eat liv mix 22m23 ar .> 3.31gm * P<.4
125 M m b6c eat liv mix 22m23 or . + . 513.mg * P<.005 +
ETHYL ACRYLATE
126 N f b6c gav for MXA 24m24
a M f b6c gav TBA MXB 24m24
b M f b6c gav Liv MXB 24m24
c M f b6c gav Lun MXB 24m24
127 M f b6c inh nac tum 24m24 r
bO0ng .:. .lug. :10. :100. 1m : g.:10. :100.. :g. :10




.> no dre P-.CHRONOLOGICAL SUPPLEMENT
RefNum LoConf UpConf CntrL IDose lInc 2Dose 2Inc
a c54819 10.8mg 28.5mg 0/50
b c54819 18.2mg 47.1mg 0/50
c c54819 19.8mg 98.0mg 0/50
d c54819 32.0mg 84.8mg 0/50
e c54819 38.2mg 101.mg 0/50
f c54819 26.7mg 230.mg 0/50
g c54819 29.7mg 185.mg 0/50
h c54819 32.0mg 249.mg 0/50
i c54819 44.2mg 2.22gm 3/50
j c54819 50.3mg 463.mg 0/50
k c54819 44.3mg 770.mg 0/50
l c54819 56.5mg 511.mg 0/50
m c54819 58.0mg 708.mg 0/50
n c54819 59.8mg 1.31gm 0/50
o c54819 87.7mg 13.1gm 0/50
p c54819 157.mg 2.06gm 0/50
q c54819 165.mg 4.25gm 0/50
r c54819 29.2mg n.s.s. 13/50
s c54819 6.56mg 17.2mg 40/50



























































































113 1673 134.mg 2.04gm 0/49
a 1673 1.369m n.s.s. 0/49
b 1673 1.07gm n.s.s. 2/49
c 1673 1.51gm n.s.s. 1/49
114 1673 822.mg n.s.s. 0/47





















115 1727 1.46mg 4.71mg 0/38
a 1727 72.1mg n.s.s. 1/50
b 1727 10.3mg n.s.s. 33/50
116 1727 2.34mg 5.56mg 0/49
a 1727 35.5mg n.s.s. 0/49
b 1727 66.2mg n.s.s. 1/49
c 1727 66.2mg n.s.s. 1/49



















117 1782n 36.2mg 106.mg
a 1782n 62.6mg 227.mg
b 1782n 342.mg n.s.s.
c 1782n 318.mg n.s.s.
118 1782n 88.4mg n.s.s.
a 1782n 306.mg n.s.s.
b 1782n 584.mg n.s.s.
c 1782n 1.20gm n.e.s.
119 1782 13.5mg n.s.s.
120 1782m 36.4mg 127.mg
a 1782m 66.5mg 377.mg
b 1782m 278.mg n.e.s.
121 1782m 79.6mg 1.38gm
a 1782m 69.7mg n.s.s.
b 1782m 573.mg n.s.s.
122 1782n 37.6mg 132.mg
a 1782n 97.3mg 251.mg
b 1782n 328.mg n.s.s.
c 1782n 1.87gm n.s.s.
123 1756 27.2mg 83.0mg
a 1756 27.2mg 83.0mg
b 1756 19.0mg n.s.s.
















































124 1797 787.mg n.s.s. 5/19 499.mg




















































126 c50384 193.mg n.s.s. 1/50
a c50384 134.mg n.s.s. 32/50
b c50384 392.mg n.s.s. 3/50
c c50384 420.mg n.s.s. 2/50
















Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
128 M f b6c inh lab a/2 6.27 ar
a N f b6c inh liv a/2 6.27 er
b N f b6c inh tba ben 6.27 er
c N f b6c inh tba mal 6.27 ar
d M f b6c inh tba mix 6.27 ar
129 N f b6c inh Lab h/2 27.27 e
a M f b6c inh Liv a/2 27.27 e
b M f b6c inh liv h/2 27.27 e
c M f b6c inh tba mix 27.27 e
d N f b6c inh tba maL 27.27 e
e N f b6c inh tba ben 27.27 e
130 M m b6c gav for MXA 24.24
a M m b6c gav for sqp 24.24
b N m b6c gav for sqc 24.24
c N m b6c gav TBA NXB 24.24
d N m b6c gav Liv NXB 24.24
e M m b6c gav Lun MXB 24.24
131 N m b6c inh nac tum 24.24 r
132 N m b6c inh thy ade 6W27 or
a M m b6c inh liv a/2 6.27 or
b N m b6c inh Lab a/2 6.27 or
c N m b6c inh tba ben 6.27 or
d N m b6c inh tba mal 6.27 er
e M m b6c inh tba mix 6.27 er
133 M m b6c inh Lab a/2 27.27 e
a N m b6c inh liv a/2 27.27 e
b N m b6c inh liv h/2 27.27 e
c N m b6c inh tba ,ix 27.27 e
d M m b6c inh tba mal 27m27 e
e N m b6c inh tba ben 27m27 a
134 R f f34 gav for MXA 24.24
a R f f34 gav for sqp 24.24
b R f f34 gav TBA MXB 24.24
c R f f34 gav liv MXB 24,24
135 R f f34 inh nac tum 24.24 r
136 R f f34 inh liv bht 6.27 or
a R f f34 inh Liv sar 6.27 er
b R f f34 inh tyf a/2 6.27 or
c R f f34 inh tba mix 6.27 er
d R f f34 inh tba ben 6.27 or
* R f f34 inh tba mal 6.27 or
137 R f f34 inh tyf a/2 27.27 e
a R f f34 inh Liv sar 27.27 e
b R f f34 inh Liv bht 27.27 e
c R f f34 inh tba ben 27.27 e
d R f f34 inh tba mal 27m27 e
* R f f34 inh tba mix 27m27 e
138 R m f34 gav for MXA 24m24
a R m f34 gav for sqp 24m24
b R m f34 gav for sqc 24m24
c R m f34 gav mul mLe 24m24
d R m f34 gav pan MXA 24,24
* R m f34 gav TBA MXB 24m24
f R m f34 gav Liv MXB 24m24
139 R m f34 inh nac tum 24m24 r
140 R m f34 inh tyf a/2 6m27 or
a R m f34 inh Liv hpc 6W27 er
b R m f34 inh liv bht 6m27 or
c R m f34 inh tba ben 6m27 or
d R m f34 inh tba mal 6m27 or
* R m f34 inh tba mix 6m27 er
141 R m f34 inh tyf a/2 27m27 e
a R m f34 inh liv bht 27m27 e
b R m f34 inh liv hpc 27m27 e
c R m f34 inh tba mix 27,27 e
d R m f34 inh tba ben 27,27 e




no dre P-1. -
no dre P-1. -
no dre P-1. -
no dre P-1. -
1.269m * P<.2 -
no dre P-I. -
no dre Pal. -
11.7gm * P<1. -
no dre P-1.
no dre P-I.
+ 260.mg * P<.0005c
339mg * P<.002 c




no dre P-1. -
+ 515.mg P<.01 -
no dre P-I. -
no dre P-I. -
no dre P-1. -
no dre P-1. -
no dre P-I. -
no dre P-I. -
no dre P-I. -
no dre P-I. -
2.17gm * P<.9 -
300.mg * P<.2 -
no dre P-I. -
+ 362.mg * P<.004 c
420.mg * P<.01 c
534.mg * P<.7
4.669m * P<.3
no dre P-I. -
no dre P-I. -
no dre P-I. -
no dre P-I. -
no dre P-I. -
no dre P-I. -
no dre P-I. -
1.03gm * P<.2 -
no dre P-I. -
no dre P-I. -
no dre P-I. -
no dre P-I. -








no dre P-I. -
267.mg P<.2 -
no dre P-1. -
no dre P-1. -
12.8mg P<.4 -
no dre P-1. -
noTD50 P<.4 -
77.9mg \ P<.03 -
599.mg * P<.6 -
1.67gm * P<.6 -
5.76mg * P<.08 -
6.27mg * P<.03 -
39.0mg * P<.04 -
ETHYL ALCOHOL*** lOOng. ....lug 10. 100. 1 10. 100. Ig.. 10
142 R m wis wat for sqc 91w91 r .> no dre P-I.
Z-ETHYL-0,N,N.AZOXYETHANE
143 R m f34 wat Liv mix 30w55
a R m f34 wat nas mix 30w55
b R m f34 wat eso mix 30w55


































































































































































































































































































143 1723 n.s.s. 23.8ug 2/20 .218mg 20/20
a 1723 11.0ug 47.7ug 0/20 .218mg 17/20
b 1723 15.4ug 66.5ug 0/20 .218mg 15/20
Salmon;carc,7, 1447-1450; 1986
Lij insky;canr,45,76-79;1985242
Spe Strain Site Xpo+Xpt
Sex Route Hist No
c R m f34 wat Liv hes 30w55
d R m f34 wat liv hpc 30w55
e R m f34 wat Liv nsc 30w55
f R m f34 wat Liv nnd 30w55
Z-ETHYL-0,N,N-AZOXYMETHANE
144 R m f34 wat Liv mix 30w55
a R m f34 wat Liv hpc 30w55
b R m f34 wat Liv hes 30w55
c R a f34 wat liv nsc 30w55
d R m f34 wat coL a/2 30w55
e R m f34 wat iLm tum 30w55



























ETHYL BENZENE lOOng.. :. .lug.:10. :100.l. : g.:10. :100. g.10
145 R f sda gav tba maL 24m33 e . 1.21gm
146 R m sda gav tba mal 24.33 o .> 1.98gm
FORMALDEHYDE***
147 R m sda inh nac sqc 28m28 e
a R m sda inh nac car 28m28 e
b R m sda inh nac fbs 28m28 e
c R m sda inh Liv hpc 28m28 e





GEMCADIOL lOOng..: ..ug. :10. :100.1. : g1g :10 : .100.. :. . :10
148 R f cdr eat Liv hpa 52w52 k .> no dre








150 M f b6c eat liv tum 52w52
151 M f b6c eat liv hpa 78w78 e
a M f b6c eat Liv hpc 78w78 e
152 M f b6c eat liv hpc 25m25 e
a M f b6c eat liv hpa 25m25 e
b N f b6c eat hag ade 25m25 e
c N f b6c eat ute rta 25m25
d M f b6c eat vag rta 25m25 e
e N f b6c sat ubl rta 25.25 e
f M f b6c cat ova rta 25m25 e
153 N m b6c eat Liv hpa 52w52
154 M m b6c eat liv hpa 78w78 e
a N m b6c eat Liv hpc 78w78 e
155 M m b6c eat Liv hpa 25m25 e
a N m b6c eat liv hpc 25m25
b M m b6c eat hag ade 25m25 e
GLYCYRRHIZINATE, DISODIUM
156 M f b6c wat Lun ade 22.26 o
a M f b6c wat Liv hpa 22m26 o
b N f b6c wat Liv hpc 22.26 e
c N f b6c wat Lun adc 22.26 o
d M f b6c wat Liv hem 22.26
a M f b6c wat tba mix 22m26 e
157 M m b6c wat Liv hem 22m26 e
a M m b6c wat Liv hpc 22m26 e
b M m b6c wat Liv hpa 22.26 e
c N m b6c wat Lun ade 22m26 e
d M m b6c wat Lun adc 22m26 e
M m b6c wat tba mix 22m26 o
HEXACHLOROBENZENE***
158 R f f34 eat Liv mix 90w90 r
a R f f34 eat Liv hpc 90w90 r
b R f f34 eat Liv nnd 90w90 r
159 R m f34 cat Liv mix 90w90 r
HUMIC ACIDS, COMMERCIAL GRADE
160 M f b6c wat Liv hem 24m24 e
a M f b6c wat Liv hnd 24m24 e
b M f b6c wat Lun pt. 24.24 a
c M f b6c wat tba mix 24.24 e
161 M m b6c wat lun ptm 24,24 e
a N m b6c wat Liv hpt 24m24 e
b N m b6c wat tba mix 24m24 e
lOOng. ..lug. :10. :100.:.g. :10. :100.. :Ig :10
no dre P-I1.
+ . 115.mg * P<.003 +






834.mg * P<.002 +
912.mg * P<.0005+
no dre P-1.
636.mg * P<.5 -
no dre P-1.
+ . 139.mg * P<.0005+
222.mg * P<.0005+
615.mg * P<.03 +
bO0ng..: ..lug. :10. :100.:1g. :10. :100. :Ig :10
.> 14.4gm * P<.2 -
28.9gm * P<.2 -









3.17gm * P<.8 -


























RefNum LoConf UpConf Cntrl IDose Ilnc 2Dose 2Inc Citation or Pathology
c 1723 17.7ug 78.lug 0/20 .218mg 14/20
d 1723 17.7ug 78.lug 0/20 .218mg 14/20
1723 41.5ug .368mg 0/20 .218mg 7/20
f 1723 .252mg n.s.s. 2/20 .218mg 0/20
Z-ETHYL-0,N,N-AZOXYMETHANE 57497-29-7
144 1723 n.s.s. 20.4ug 2/20 .187mg 20/20
a 1723 9.44ug 40.9ug 0/20 .187mg 17/20
b 1723 19.5ug 93.3ug 0/20 .187mg 12/20
c 1723 35.6ug .315mg 0/20 .187mg 7/20
d 1723 47.Oug 1.44mg 0/20 .187mg 5/20
1723 66.6ug n.s.s. 0/20 .187mg 3/20
f 1723 .216mg n.s.s. 2/20 .187mg 0/20
Lij insky;canr,45,76-79;1985
ETHYL BENZENE 100-41-4
145 bt905 433.mg n.s.s. 10/49 237.mg 14/37
146 bt905 528.mg n.s.s. 11/45 237.mg 14/40
FORMALDEHYDE*** 50-00-0
147 1674 1.22mg 2.86mg 0/99 .952mg 38/100
a 1674 14.1mg n.s.s. 0/99 .952mg 1/100
b 1674 14.1mg n.s.s. 0/99 .952mg 1/100
c 1674 16.0mg n.s.s. 1/99 .952mg 1/100
GENCADIOL (2,2,9,9-tetramethyL-1,10-decanediol) 35449-36-6
148 1768 186.mg n.s.s. 0/10 30.0mg 1/10 150.mg 0/10 300.mg 0/10
149 1768 185.mg n.s.s. 0/10 30.0mg 2/10 150.mg 0/10 300.mg 0/10
GENTIAN VIOLET 548-62-9
150 1680m 10.7mg n.s.s.
151 1680n 51.5mg 734.mg
a 1680n 103.mg n.s.s.
152 1680o 44.7mg 77.0mg
a 1680o 49.8mg 128.mg
b 1680o 166.mg 1.13gm
c 16800 244.mg 786.mg
d 16800 335.mg 2.14gm
1680o 407.mg 3.57gm
f 1680o 430.mg 3.27gm
153 1680m 79.4mg n.s.s.
154 1680n 106.mg n.s.s.
a 1680n 119..g n.s.s.
155 1680o 90.3mg 260.mg
a 16800 123.mg 742.mg
b 1680o 255.mg n.s.s.
GLYCYRRHIZINATE, DISODIUM
156 1685 3.54gm n.s.s.
a 1685 4.71gm n.s.s.
b 1685 4.73gm n.s.s.
c 1685 3.72gm n.s.s.
d 1685 5.96gm n.s.s.
1685 1.33gm n.s.s.
157 1685 1.22gm n.s.s.
a 1685 1.23gm n.s.s.
b 1685 1.41gm n.s.s.
c 1685 1.53gm n.s.s.
d 1685 1.88gm n.s.s.






















































































HaLtoni ;aj i.,7,415-446; 1985
SeL Lakumar;txap,81,401-406; 1985
FitzgeraLd;faat,6,520-531;1986





























158 1708 2.16mg 12.4mg 0/15 10.0mg 10/15
a 1708 4.75mg 120.mg 0/15 10.0mg 5/15
b 1708 4.75mg 120.mg 0/15 10.0mg 5/15
159 1708 7.04mg n.s.s. 0/15 8.00mg 2/15
HUNIC ACIDS, COMMERCIAL GRADE 1415-93-6
160 1806 305.mg n.s.s. 3/96 100.mg
a 1806 442.mg n.s.s. 2/96 100.mg
b 1806 289.mg n.s.s. 13/96 100.mg
c 1806 32.4mg n.s.s. 84/96 100.mg
161 1806 113.mg n.s.s. 22/99 83.3mg
a 1806 242.mg n.s.s. 12/99 83.3mg













RefNum LoConf UpConf CntrL IDose lInc 2Dose
HYDRAZINE*** 302-01-2
162 1679n 2.32mg 8.95mg
a 1679n 6.05mg 115.mg
b 1679n 5.33mg n.a.s.
c 1679n 7.19mg n.s.s.
d 1679n 11.5mg n.s.s.
a 1679n 11.5mg n.s.s.
163 1679n 3.12mg n.s.s.
164 1679m .485mg 1.29mg
a 1679m 2.64mg 79.3mg
b 1679m 2.27mg n.s.s.
c 1679m 2.72mg n.s.s.
d 1679m 3.23mg n.s.s.
e 1679m 4.30mg n.s.s.
165 1679. .144mg .271mg
a 1679m .715mg 3.05mg
b 1679m 1.85mg 55.5mg
c 1679m 1.85mg 55.5mg
d 1679m .658mg n.s.s.
1679m 1.85mg n.s.s.

















































































HYDROCHLORIC ACID (hydrogen chLoride) 7647-01-0
166 1674 14.8mg n.s.s. 1/99 .781mg 1/99


















167 1792 21.6ug .105mg 1/20 .540mg 18/20
a 1792 80.3ug .489mg 0/20 .540mg 9/20
b 1792 .623mg n.s.s. 2/20 .540mg 0/20
IODOACETANIDE 144-48-9
168 1759 21.1mg n.s.s. 0/20 9.87mg 0/20
ISOBUTYL p-HYDROXYBENZOATE 4247-02-3
169 1688 3.62gm n.s.s. 2/50 188.mg 3/50 375.mg 2/50 751.mg
a 1688 1.15gm n.s.s. 0/50 188.mg 0/50 375.mg 0/50 751.mg
b 1688 1.61gm n.s.s. 12/50 188.mg 10/50 375.mg 12/50 751.mg
170 1688 3.08gm n.s.s. 0/50 177.mg 4/50 353.mg 0/50 706.mg
a 1688 2.84gm n.s.s. 3/50 177.mg 6/50 353.mg 3/50 706.mg
b 1688 1.38gm n.s.s. 8/50 177.mg 12/50 353.mg 9/50 706.mg
KANECHLOR 400 (PCBs, polychlorinated biphenyls) 12737-87-0
171 1762 20.8mg n.s.s. 0/10 6.19mg 0/25
LEAD ACETATE*** 301-04-2
172 1755 13.4mg 68.2mg 0/10 130.mg 13/16
a 1755 229.mg n.s.s. 0/10 130.ag 0/16







LEAD ACETATE, BASIC*** 1335-32-6
173 1709 138.mg 604.mg 0/30 400.mg 13/29
a 1709 1.38gm n.s.s. 0/30 400.mg 0/29
METHAFURYLENE 531-06-6
174 1790 80.6mg n.s.s. 1/21 29.5mg 2/20
a 1790 77.7mg n.s.s. 6/21 29.5mg 4/20
175 1790 88.0mg n.s.s. 4/19 23.4mg 1/20
METHAPHENILENE 493-78-7
176 1790 70.3mg n.s.s. 1/21 25.7mg 2/20
a 1790 83.9mg n.s.s. 6/21 25.7mg 3/20
177 1790 66.5mg n.s.s. 4/19 18.0mg 2/20
a 1790 77.5mg n.s.s. 2/19 18.0mg 1/20
DL-METHIONINE 59-51-8
178 1803 1.15gm n.s.s. 2/28 419.mg 2/28
Z-METHYL-O,N,N-AZOXYETHANE 57497-34-4
179 1723 5.32mg 46.7mg 2/20 16.2mg
a 1723 8.13mg 57.5mg 0/20 16.2mg
b 1723 52.9mg 405.mg 0/20 16.2mg
c 1723 83.6mg n.s.s. 0/20 16.2mg

















Spe Strain Site Xpo+Xpt
Sex Route Nist No,
HYDRAZINE***
162 H m syg inh nlas mdp 12m24 era
a N m syg inh thy pfa 12m24 era
b N m syg inh coL adc 12m24 era
c N m syg inh sto bcc 12m24 era
d N m syg inh cot Ley 12m24 era
e N m syg inh coL pam 12m24 ers
163 N f cb6 inh Lun ado 12m27 er
164 R f 134 inh nec edp 12m30 er
a R f 134 inh nes sqp 12m30 er
b R f f34 inh nas vtp 12m30 er
c R f f34 inh nas adc 12m30 er
d R f f34 inh nas sqc IWmO er
e R f f34 inh Lun b/a 12m30 er
165 R m 134 inh nes edp 12m30 er
a R m 134 inh nas vLp 12m30 er
b R m f34 inh Lun b/a 12m30 er
c R m f34 inh nes sqp 12m30 er
d R m f34 inh thy car 12m30 er
a R m 134 inh nes sqc 12m30 er
f R m 134 inh nas adc IWO3 or
TD50 2TeiLpvL
DR AuOp ~tes
loong. .:. .lug... .10 ...:.100... .lug... -10... 100... I-g.. ..-10
+ .4.16mg * P<.0005+
17.5mg * P<.003 +
14.0mg * P<.03 +
37.6mg * P<.4 +
70.5mg * P<.2 +
70.5mg * P<.2 +
7.78mg P<.04
+ . ~~~~~~~~~.758mg Z P<.0005+
8.72mg * P.'.004 +
6.56mg * P<.03 +
9.20mg * P<.03 +
13. 1mg * P<.02 +
26.4mg * P<.09 +
.194mg * P<.0005+
1.36mg * P<.0005+
6.10mg * P<.004 +
6. 10mg * P<.004 +
1.60mg * P<.02
6.12mg * P<.02 +
no dre P-1. +
HYDROCHLORIC ACID bOOng..: ..lug...:.10 ...:.100... m.lg...:.10 ....100...i:g ...:.10
166 R m sde inh Liv hpc 30m30 e .> no dre P-1. -
a R m sda inh nec tum 30m30 e no dre P-1. -
1. (2-HYDROXYETHYL)-.1-NITROSOUREA***
167 R m 134 gav tun a/t 55w55 e
a R m 134 gav for mix 55w55 e
b R m 134 gav Liv nnd 55w55 e




IODOACETANIDE bOOng. .:..lug...:.10...:.100.1m:.lg.....10... ..100...:.Ig...:.10
168 R m wis wet sto car 74w75 r .> no dre P-I.-
ISOBUTYL p.HYDROXYBENZOATE
169 N f icr eat Lun tum 24m25
a N f icr eat Liv tum 24m25
b M f icr eat tba mix 24m25
170 N m icr eat Liv tum 24m24
a N m icr eat Lun tum 24m24
b N m icr eat tba mix 24m24
bOOng. .:. .ug...:.10.....100.1m:.lg...:.10....100...I:g...:.10
.> 37.2gm * P<.8-
no dre P-I.-
12.3gm * P<.7-
.> 26.3gm Z P<.7-
no dre P-I.-
6.57gm * P<.5-
KANECHLOR 400 lOOng. .:. .ug...:.10...:.100...1:mg ....10... ..100... Ig1...:.10
171 R f don eat Liv tum 26w84 a .> no dre P-I.-
LEAD ACETATE***
172 R m ide wet kid tcc 76w76 e
a R m ida wet Liv tum 76w76 a
b R m sda wet tba mix 76w76 e




LEAD ACETATE, BASIC*** bOOng..:. .lug...:.10 ....100.. 1 : mg ....10 ....100...:. lg ...:.10
173 R m ide eat kid mix 79w79 a . + . 266.mg P<.0005+
a R m sda eat Liv tum 79w79 a no dre P-I. -
NETHNAFURYLENE
174 R f 134 wet tyf mix 22m30 a
a R f 134 wet Liv mix 22m30 a
175 R m 134 wet Liv mix 22m27 e
NETHAPHENILENE
176 R f 134 wet tyf mix IWmO e
a R 1 134 wet Liv mix IWmO e
177 R m 134 wet Liv mix 19c30 a
a R m 134 wet tyf mix IWmO e









DL-NETNIONINE .1OOng..:. .lug...:.10 ...:.100 1. :mg...:.10 ...:.100...j:g... .10
178 R m 134 eat Liv nnd 17m24 .> no dre P-I.
Z-NETHYL .O,N,N -AZOXYETHANE
179 R m 134 wet Liv mix 30w95
a R m 134 wet Liv hpc 30w95
b R m 134 wet kid mix 30w95
c R m 134 wet Liv hes 30w95
d R m 134 wet Liv nnd 30w95
.1OOng. .: .lug...:. 10 ...:. 100 .. .1mg ... .10 ...:. 100...I: g .... 10
















Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2TailpvL
DR AuOp
3 -METHYL-4-DIMETHYLAMINOAZOBENZENE : .lug. :.g 10. :100.. :Ig :10
180 R m aap gav liv hpc 52w52 bekr .> 3.64mg P<.4 +
181 R m f3d eat liv hpc 24.24 e . + . 3.28mg * P<.0005+
a R m f3d eat liv thc 24.24 4.94mg * P<.0005
b R m f3d eat liv ghc 24.24 a 10.1lg Z P<.0005
c R m f3d eat liv cLc 24.24 a 46.7mg * P<.0005
METHYL METHACRYLATE
182 M f b6c inh TBA
a M f b6c inh liv
b M f b6c inh lun
183 M m b6c inh TBA
a N m b6c inh Liv
b M m b6c inh Lun
184 R f f34 inh TBA
a R f f34 inh Liv
185 R m f34 inh TBA






















N-NETHYL-N'-NITRO-N-NITROSOGUANIDINE***..:..ug.............0......g.... 10....... :.100 10.
186 R m aLb wat gam adc 34w52 er . + . .4
187 R f wis wat duo adc 32w57 r .> 6.
a R f wis wat stg adc 32w57 r 6.





















189 M m b6c wat Liv mix
a M b6c wat Liv hpc
b M m b6c wat Liv hpa
c M m b6c wat thy tum
190 R f f34 wat Liv nnd
191 R f f34 wat Liv mix
a R f f34 wat Liv nnd
b R f f34 wat liv hpc
192 R f f34 wat Liv mix
a R f f34 wat Liv nnd
b R f f34 wat Liv hpc
193 R m f34 wat Liv nnd
194 R m f34 wat liv nnd
a R m f34 wat liv mix
b R m f34 wat Liv hpc
195 R m f34 wat Liv mix
a R m f34 wat Liv nnd
b R m f34 wat Liv hpc
oong..:. .lug. : :100. :. g. :10. : 00.. : g :10
24m24 ae 1.31gm * P<.07 -
24m24 e 2.35gm * P<.2 -
24m24 2.90gm * P<.2 -
24m24 a no dre P-I.
78w78 ek no dre P-I.
18.24 e A 1.54gm P<.02 -
18m24 1.54gm P<.02 -
18m24 e no dre P-I.
24m24 * + 1.43gm * P<.003 -
24.24 e 2.34gm * P<.02 -
24m24 e 3.63gm * P<.06 -
78w78 ek no dre P-I.
18m24 .> 1.61gm P<.4
18m24 e 3.66gm P<.8 _
18m24 e no dre P-I. -
24m24 no dre P-1.
24m24 no dre P-I.
24m24 e no dre P- 1
N-14.(5-NITRO-2-FURYL)-2-THIAZOLYLIFORMAMIDE***- ............. 100. 1g. : .. :10. :100.. g. : . :10
196 M f nmr gav for sqc 68w75 esv . + . 139.mg * P<.0005+
a M f nmr gav for pam 68w75 esv 164.mg * P<.0005+
b M f nur gav stg mal 68w75 ecv 944.mg * P<.02
c N f nur gav liv maL 68w75 esv 2.39gm * P<.2
d M f nmr gav Lun adc 68w75 esv no dre P-1.
e M f nmr gav tba mal 68w75 esv 59.5mg * P<.0005
f M f nur gav tba ben 68w75 esv 69.4mg * P<.0005
1-NITROSO-1-HYDROXYETHYL-3-CHLOROETHYLUREA.. ......... .........g...........1:..100.. : . :10
197 R f f34 gav liv mix 9m27 e . + . .488mg P<.0005+
a R f f34 gav liv nnd 9m27 e .564mg P<.0005+
b R f f34 gav Liv hpc 9.27 e .653mg P<.0005+
c R f f34 gav --- mnL 9m27 e .760mg P<.02
d R f f34 gav Liv clc 9m27 e 4.38mg P<.09 +
R f f34 gav ktu mix 9m27 e 4.38mg P<.09 +
198 R m f34 gav Liv mix 8m28 o . + . .150mg * P<.0005+
a R m f34 gav liv hpc 8.28 o .233mg * P<.0005+
b R m f34 gav ktu mix 8m28 .663mg * P<.0005+
c R m f34 gav liv cLc 8m28 e .926mg * P<.0005+
d R m f34 gav Liv nnd 8m28 1.19mg * P<.02 +
1-NITROSO-1-(2-HYDROXYPROPYL)-3-CHLOROETHYLUREA............. ...... ............. ......lg ::100.1
199 R f f34 gav Liv mix 40w95 . + . .885mg P<.0005+
a R f f34 gav Liv nnd 40w95 o .885mg P<.0005+
b R f f34 gav --- mnL 40w95 .962mg P<.05
c R f f34 gav Liv hpc 40w95 8.81mg P<.3 +
200 R m f34 gav Liv mix 8m28 e . + . .861mg * P<.0005+
a R m f34 gav Liv nnd 8.28 e 1.17mg * P<.002 +
b R m f34 gav Liv hpc 8m28 2.71mg * P<.004 +
c R m f34 gav Lun a/t 8m28 e 2.39mg * P<.02
246CHRONOLOGICAL SUPPLEMENT
RefNum LoConf UpConf CntrL IDose lInc 2Dose 2Inc Citation or Pathology
3 -METHYL-4-DIMETHYLAMINOAZOBENZENE 55-80-1
180 1710 .590mg n.s.s. 0/5 2.50mg 1/9
181 1756 2.04mg 5.42mg 0/30 .960mg 4/27 4.80mg
a 1756 3.06mg 8.18mg 0/30 .960mg 3/27 4.80mg
b 1756 4.56mg 32.2mg 0/30 .960mg 1/27 4.80mg








182 c50680 1.08g. n.s.s. 34/50
a c50680 1.82gm n.s.a. 7/50
b c50680 1.04gm n.s.s. 2/50
183 c50680 1.32gm n.s.s. 30/50
a c50680 2.07gm n.s.s. 16/50
b c50680 7.86gm n.s.s. 11/50
184 c50680 78.2mg n.s.s. 40/50
a c50680 526.mg n.s.s. 0/50
185 c50680 139.mg n.s.s. 44/50




























186 1778 .160mg 1.90mg 0/6 2.83mg 7/10
187 1726 1.04mg n.s.s. 0/5 1.59mg 1/20
a 1726 1.04mg n.s.s. 0/5 1.59mg 1/20
188 1726 .668mg n.s.s. 0/5 1.39mg 2/20
METHYLENE CHLORIDE*** (dichloromethane, Freon 30) 75-09-2
189 1802 540.mg n.s.s. 24/125 60.0mg 51/200 125.mg 30/100 185.mg
a 1802 815.mg n.s.s. 14/125 60.0mg 33/200 125.mg 18/100 185.mg
b 1802 1.01gm n.s.s. 10/125 60.0mg 20/200 125.mg 14/100 185.mg
c 1802 825.mg n.s.s. 0/125 60.0mg 0/200 125.mg 0/100 185.mg
190 1801m 9.99mg n.s.s. 0/20 5.00mg 0/20 50.0mg 0/20 125.mg
191 1801n 379.mg n.s.s. 0/100 188.mg 2/25
a 1801n 379.mg n.s.s. 0/100 188.mg 2/25
b 1801n 966.mg n.s.s. 0/100 188.mg 0/25
192 1801o 638.mg 10.1g. 0/100 5.00mg 1/50 50.0mg 4/50 125.mg
a 18010 880.mg n.s.s. 0/100 5.00mg 1/50 50.0mg 2/50 125.mg
b 1801o 1.25gm n.s.s. 0/100 5.00mg 0/50 50.0mg 2/50 125.mg
193 1801m 489.mg n.s.s. 0/20 5.00mg 1/20 50.0mg 2/20 125.mg
194 1801n 307.mg n.s.s. 9/100 188.mg 4/25
a 1801n 341.mg n.s.s. 13/100 188.mg 4/25
b 1801n 966.mg n.s.s. 4/100 188.mg 0/25
195 1801o 2.41gm n.s.s. 13/100 5.00mg 1/50 50.0mg 1/50 125.mg
a 1801o 2.58gm n.s.s. 9/100 5.00mg 1/50 50.0mg 1/50 125.mg
b 1801o 3.01gm n.s.s. 4/100 5.00mg 0/50 50.0mg 0/50 125..g
N-14-(5-NITRO-2-FURYL)-2-THIAZOLYLIFORMAMIDE*** (FANFT) 24554-26-5
196 1771 89.7mg 232.mg 0/100 114.mg 14/60 115.mg 4/13 118.mg
a 1771 103.mg 285.mg 0/100 114.mg 18/60 115.mg 1/13 118.mg
b 1771 358.mg n.s.s. 0/100 114.mg 5/60 115.mg 0/13 118.mg
c 1771 588.mg n.s.s. 0/100 114.mg 0/60 115.mg 0/13 118.mg
d 1771 106.mg n.s.s. 1/100 114.mg 0/60 115.mg 0/13 118.mg
1771 40.0mg 103.mg 18/100 114.mg 35/60 115.mg 7/13 118.mg




























1 -NITROSO- 1-HYDROXYETHYL-3-CHLOROETHYLUREA - - -
197 1792 .242mg 1.17mg 0/20 .582mg 12/19
a 1792 .274mg 1.40mg 0/20 .582mg 11/19
b 1792 .310mg 1.70mg 0/20 .582mg 10/19
c 1792 .308mg n.s.s. 4/20 .582mg 11/19
d 1792 1.08mg n.s.s. 0/20 .582mg 2/19
1792 1.08mg n.s.s. 0/20 .582mg 2/19
198 1792 73.4ug .298mg 2/20 .390mg 18/20 .758mg 20/20
a 1792 .135mg .412mg 0/20 .390mg 14/20 .758mg 20/20
b 1792 .387mg 1.25mg 0/20 .390mg 7/20 .758mg 14/20
c 1792 .519mg 2.01mg 0/20 .390mg 7/20 .758mg 10/20
d 1792 .564mg n.s.s. 2/20 .390mg 10/20 .758mg 8/20
1-NITROSO-1-(2-HYDROXYPROPYL)-3-CHLOROETHYLUREA ---
199 1792 .396mg 2.80mg 0/20 .791mg 8/20
a 1792 .396mg 2.80mg 0/20 .791mg 8/20
b 1792 .358mg n.s.s. 4/20 .791mg 10/20
c 1792 1.43mg n.s.s. 0/20 .791mg 1/20
200 1792 .462mg 2.43mg 2/20 .438mg 4/19 .751mg 15/20
a 1792 .587mg 5.55mg 2/20 .438mg 4/19 .751mg 12/20
b 1792 1.17mg 16.8mg 0/20 .438mg 1/19 .751mg 6/20






Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2TaiLpvL
DR AuOp
NITROSO-5-METHYLOXAZOLIDONE lOOng .:. .:ug.:10. 1 :100. g :.. :10. 1 :100... : . :10
201 H f syg gav for mix 28w6O e . + . .172mg P<.0005+
N-NITROSO-1,3-OXAZOLIDINE lOOng . . .lug.:10. :100. g :.. :10. :100.. : . :10
202 H f syg gav for mix 7.24 e . 2.61mg P<.07 +
a H f syg gav liv tur 7.24 e no dre P-1.
N -NITROSOPYRROLIDINE***
203 M m swi gav tba mix 76w76 e
204 R m chi wat liv hpc 84w84
a R m chm wat liv nnd 84w84
b R m chm wat liv ctc 84w84
205 R f f34 wat Liv hpc 7m26 e
a R f f34 wat Liv nnd 7m26 e
b R f f34 wat Liv hes 7m26 e
c R f f34 wat Liv cLc 7m26 e
d R f f34 wat tba mix 7.26 .
206 R m sda wat Liv hpc 20.30
a R m sda wat tba maL 20.30
207 R m sda wat Liv hpc 10m30
a R m sda wat tba mal 10I30
NITROUS OXIDE
208 M f sww inh lun
a M f sww inh liv
b M f sww inh mix
209 M m sww inh Lun
a M m sww inh mix
b M m sww inh liv
OCHRATOXIN A***
210 M f b6c eat liv hpc
a N f b6c eat liv hpa
b M f b6c eat kid mix
211 M m b6c eat kid mix
a M m b6c eat kid ade
b M m b6c eat kid car
c M m b6c eat liv hpa
d M m b6c eat liv hpc
OCTACHLOROSTYRENE
212 R f sda eat liv tur 52w52
213 R m sda eat liv tur 52w52
OLEATE, SODIUM
214 R f f3d wat liv hnd
a R f f3d wat tba mix
215 R i f3d wat pan mix
a R m f3d wat pan is.
b R f3d wat liv hnd
c R m f3d wat liv mix
d R i f3d wat tba mix
OMEPRAZOLE
216 M f cdl gay gam cnd
217 M n cdl gay gam cnd
218 R f sda gay gam cnd
219 R m sda gav gam cnd
OXAMYL















































bO0ng . . .lug. : 10. :100. : g..:10. :100.:Ig. :10
24.24 er . 34.8mg * P<.02 +
24.24 or 109.mg * P<.3
24.24 or no dre P-1.
24.24 er . + . 3.53mg * P<.0005+
24m24 er 4.64mg * P<.0005
24.24 er 10.3mg * P<.0005
24.24 er 48.1mg * P<.3
24.24 er 58.7mg * P<.2
lOOng.. :. .lug. :10. :100. g :.. :10. :100.. : . :10
no dre P-1.
no dre P-1.
Ong.. :. .lug. :10. :100. g :. 1g :10. : 100.. : . :10
no dre P-1.
no dre P-1.
10.1gm * P<.003 -
12.6gm * P<.005 -
29.1gm * P<.03 -
39.3gm * P<.2 -
no dre P-1.
bO0ng . . .:ug. :10. :100. g :.1g :10. :100..:g. :10
.> no dre P-1.
no dre P.1.
63.0mg Z P<.0005












eat tbaemix 24m24 v
221 N m cdl eat tba mix 24m24 v
222 R f cdr eat liv hph 24m24 eg
223 R cdr eat liv tur 24.24 eg







D dre PI. 1
D dre Pl. 1
N-OXYDIETHYLENE THIOCARBAMYL-N-OXYDIETHYLENE SULFENAMIDE.......100.. 1 : g.:10. :100.:Ig. :10
224 R f sda eat unt tum 52w52 sk .> no dre P-1.
*at unt mix 26.26
eat ubl mix 26m26
eat kid mix 26m26 a
eat kid sqc 26.26
eat kid utc 26.26 e
eat ubl utp 26.26





571 .mg * P<.007
571.mg * P<.007 +
862.mg * P<.03 +
248
225 R f ada
a R f sda
b R f sda
c R f sda
d R f sda
e R f sda
f R f sda
.+ .CHRONOLOGICAL SUPPLEMENT
RefNum LoConf UpConf CntrL lDose lInc 2Dose 2Inc Citation or Pathology
NITROSO-5-METHYLOXAZOLIDONE 79624-33-2
201 1672 80.7ug .391mg 1/20 1.70mg 18/20
N-NITROSO-1,3-OXAZOLIDINE (nitrosooxazolidone) 39884-52-1
202 1672 .855mg n.s.s. 1/20 .899mg 5/20
a 1672 3.71mg n.s.s. 0/20 .899mg 0/20
N NNITROSOPYRROLIDINE*** 930-55-2
203 1713 .309mg 2.84mg 1/20
204 1774 .340mg 1.35mg 0/23
a 1774 .601mg 2.40mg 0/23
b 1774 3.63mg n.s.s. 0/23
205 1795 n.s.s. .409mg 0/20
a 1795 .915mg n.s.s. 1/20
b 1795 2.44mg n.S.s. 0/20
c 1795 2.44mg n.s.s. 0/20
d 1795 n.s.s. n.s.s. 19/20
206 1717m .454mg .958mg 0/80
a 1717m .412mg 1.10mg 19/80
207 1717n .346mg .712mg 0/80














NITROUS OXIDE (nitrogen oxide) 10024-97-2
208 1769 118.9m n.s.s.
a 1769 841.9g n.s.s.
b 1769 465.9m n.s.s.
209 1769 39.79m n.s.s.
a 1769 320.9m n.s.s.









































210 1691 12.3mg n.s.s.
a 1691 21.7mg n.s.s.
b 1691 1.18mg n.s.s.
211 1691 2.25mg 5.92mg
a 1691 2.87mg 8.13mg
b 1691 5.52mg 22.5mg
c 1691 12.2mg n.s.s.



























212 1773 n.s.s. n.s.s. 0/20
213 1773 n.s.s. n.s.s. 0/20
OLEATE, SODIUM 143-19-1
214 1687 22.29m n.s.s. 0/43
a 1687 2.999m n.s.s. 24/43
215 1687 5.099g 45.39m 0/41
a 1687 5.919m 94.5gm 0/41
b 1687 10.09m n.s.s. 0/41
c 1687 10.89m n.s.s. 1/41
d 1687 625.mg n.s.s. 40/41
ONEPRAZOLE 73590-58-6
216 1781m 63.3mg n.s.s. 0/109
217 1781m 63.3mg n.s.s. 0/109
218 1781n 41.1mg 103.mg 0/120
219 1781n 486.mg 3.65gm 0/119
OXANYL 23135-22*0
220 1788 35.8mg n.s.s. 32/80
221 1788 30.7mg n.s.s. 35/80
222 1788 46.4mg n.s.s. 1/60
223 1788 37.1mg n.s.s. 0/60
250.ng 0/20 2.50ug 0/20 25.Oug 0/20 .250mg 0/20 2.50mg 0/20 Chu;faat,6,69-77;1986



















0/55 44.0mg 0/55 141.mg 0/55
0/55 44.0mg 0/55 141.mg 0/55
13/60 44.0mg 19/60 (141.mg 24/60)
0/60 44.0mg 1/60 141.mg 6/60
3.25mg 42/79 6.50mg 28/79 9.94mg 27/80






N-OXYDIETHYLENE THIOCARBAMYL-N-OXYDIETHYLENE SULFENANIDE (OTOS) 13752-51-7
224 1765m .351mg n.s.s. 0/10 1.00mg 0/10 3.00mg 0/10 10.0mg 0/10 30.0mg
225 1765n 54.0mg 200.mg 0/50
a 1765n 93.4mg 604.mg 0/50
b 1765n 128.mg 1.449m 0/50
c 1765n 173.mg 10.6gm 0/50
d 1765n 173.mg 10.6gm 0/50
1765n 173.mg 10.6gm 0/50








0/50 3.00mg 0/50 10.0mg 0/50 30.0mg
0/50 3.00mg 0/50 10.0mg 0/50 30.0mg
0/50 3.00mg 0/50 10.0mg 0/50 30.0mg
0/50 3.00mg 0/50 10.0mg 0/50 30.0mg
0/50 3.00mg 0/50 10.0mg 0/50 30.0mg
0/50 3.00mg 0/50 10.0mg 0/50 30.0mg












Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
9 R f sda eat ubL utc 26e26 e
h R f sda eat kid utp 26e26 e
i R f sda eat ubl sqc 26e26 a
226 R m ada eat unt tue 52w52 ek
227 R e sda eat unt mix 26e26 e
a R e sda eat ubL mix 26e26 a
b R m sda eat ubt utc 26e26 a
c R e sda eat ubl utp 26e26 a
d R m ada eat kid mix 26e26 a
a R f sda eat kid utc 26e26 a
f Rt sda eat ubl sqc 26e26 a
9 R a sda eat ubL sqp 26.26 a
h R m ada eat kid sqc 26e26 a
i R a sda eat kid utp 26.26 a
OXYTETRACYCLINE .HCl
228 N f b6c eat TBA MXB 24e24
a N f b6c eat Liv MXB 24e24
b N f b6c eat lun MXB 24.24
229 M e b6c eat TBA MXB 24e24
a N e b6c eat liv NXB 24e24
b N e b6c eat lun NXB 24e24
230 R f f34 eat ute ess 24e24
a R f f34 eat pta adn 24e24
b R f f34 eat TBA MXB 24.24
c R f f34 eat liv MXB 24.24
231 R m f34 eat aed MXA 24e24
a R e f34 eat TBA MXB 24e24
b R m f34 eat liv MXB 24e24
PENTACHLORONITROBENZENE***
232 M f b6c eat lun a/a 24m24 s
a N f b6c eat NXA NXA 24m24 s
b N f b6c eat TBA NXB 24e24 s
c M f b6c eat liv NXB 24e24 s
d M f b6c eat Lun NXB 24e24 s
233 N e b6c eat TBA MXB 24e24
a N e b6c eat liv MXB 24.24
b M e b6c eat lun MXB 24e24
PHENOBARBITAL***
234 H m syg eat Liv mix 52w52 er
235 N m chh eat liv esn 55w55 ek
a N m chh eat liv bsn 55w55 ek
236 M m chh eat liv esn 65w65 ek
a M e chh eat liv bsn 65w65 ek
237 R f f34 wat liv hpa 76w76 ar
238 R m f34 wat liv hpa 76w76 er
239 R m f34 wat liv hpa 72w72 e
240 R m f34 eat liv nnd 17.24 a
PHENOBARfBITAL, SODIUM***
241 M f bal wat lun ada 27e28
a M f bal wat Liv hpc 27.28
b N f bal wat tba mix 27e28
242 M m bal wat lun ada 27e27
a N m baL wat liv hpc 27e27
b N m baL wat tba mix 27e27
243 R m f34 eat liv nnd 95w95
a R m f34 eat thy cca 95w95
PHENYLEPHRINE .HCL
244 N f b6c eat TBA MXB 24e24
a M f b6c eat liv MXB 24.24
b M f b6c eat lun MXB 24.24
245 M m b6c eat sub fbs 24.24
a M m b6c eat MXA MXA 24.24
b N e b6c eat TBA MXB 24.24
c M m b6c eat liv MXB 24.24
d M m b6c eat lun MXB 24.24
246 R f f34 eat TBA MXB 24.24
a R f f34 eat liv MXB 24.24
247 R m f34 eat TBA MXB 24.24




862.mg * P<.03 +
1.74ge * P<.2




340.mg * P<.003 +
457mg * P<.007 +
528.mg * P<.06 +
690..g * P<.03
690.mg * P<.03 +
1.39gm * P<.2 +
1.39gm * P<.2
no dre P-1.
1O0ng . . .:ug.:10. :100. 1g :.. :10. :100.. : . :10
:> no dre P-1.
no dre P-1.
no dre P-1.
















lOOng. .:. .lug.:10. :100.. m : g. :10. :100.:Ig. :10





13.0gm * P<I. -
23.1g. * P<I.
no dre P-1.


























+ 120.mg * P<.004
31.7mg \ P<.03












no dre P-1.CHRONOLOGICAL SUPPLEMENT
RefNum LoConf UpConf CntrL lDose lInc 2Dose 2Inc
9 1765n 212.mg n.s.s.
h 1765n 283.mg n.s.s.
i 1765n 283.mg n.s.s.
226 1765. .281mg n.s.s.
227 1765n 46.3mg 189.mg
a 1765n 63.4mg 334.ag
b 1765n 117.mg 2.03ga
c 1765n 138.mg 8.46gm
d 1765n 143.mg n.s.s.
1765n 170.mg n.s.s.
f 1765n 170.mg n.s.s.
9 1765n 226.mg n.s.s.
h 1765n 226.mg n.s.s.
















228 c56473 2.12gm n.s.s. 43/50
a c56473 12.49m n.s.s. 6/50
b c56473 6.109m n.s.s. 3/50
229 c56473 1.589m n.s.s. 36/50
a c56473 2.379m n.s.a. 18/50
b c56473 4.329m n.s.s. 10/50
230 c56473 8.10gm n.s.s. 0/50
a c56473 1.79gm n.s.s. 19/50
b c56473 1.60gm n.s.s. 49/50
c c56473 6.17gm n.s.s. 5/50
231 c56473 1.91gm n.s.s. 12/50
a c56473 723.mg n.s.s. 48/50






































































































































232 c00419 770.mg n.s.s.
a c00419 881.mg n.s.s.
b c00419 284.mg n.s.s.
c c00419 720.mg n.s.s.
d c00419 896.mg n.s.s.
233 c00419 527.mg n.s.s.
a c00419 804.mg n.s.s.











234 1804 23.7mg n.s.s. 0/5 46.0mg
235 1776m n.s.s. 22.6mg 0/5 85.0mg
a 1776m 8.26mg n.s.s. 1/5 85.0mg
236 1776n 24.8mg 123.mg 0/30 85.0mg
a 1776n 68.8mg n.s.s. 12/30 85.0mg
237 1689 16.1mg n.s.s. 0/10 28.6mg
238 1689 14.1mg n.s.s. 0/10 25.0mg
239 1690 11.0mg n.s.s. 0/13 25.0mg


























PHENOBARBITAL, SODIUM*** (phenobarbitone, sodium) 57-30-7
241 1772 209.mg n.s.s. 7/50 95.8mg 6/30
a 1772 789.mg n.s.s. 0/50 95.8mg 0/30
b 1772 274.mg n.s.s. 12/50 95.8mg 6/30
242 1772 219.ag n.s.s. 19/50 83.3mg 8/30
a 1772 630.mg n.s.s. 0/50 83.3mg 0/30
b 1772 246.mg n.s.s. 22/50 83.3mg 8/30
243 1783 60.5mg 908.mg 1/42 20.0mg 7/42 60.0mg 10/42
a 1783 13.7mg n.s.s. 9/42 20.0mg 19/42 (60.0mg 11/42)
PHENYLEPHRINE.HCL 61-76-7
244 c55641 236.mg n.s.s. 22/50
a c55641 1.01gm n.s.s. 3/50
b c55641 579.mg n.s.s. 2/50
245 c55641 744.mg n.s.s. 0/50
a c55641 742.mg n.s.s. 0/50
b c55641 274.mg n.s.s. 27/50
c c55641 409.mg n.s.s. 15/50
d c55641 485.mg n.s.s. 6/50
246 c55641 37.9mg n.s.s. 44/50
a c55641 714.mg n.s.s. 2/50
247 c55641 20.1mg n.s.s. 45/50


























































251252 GOLD ET AL.
Spe Strain Site Xpo+Xpt
Sex Route Hist No'
o-PHENYLPHENATE, SODIUM***
248 R f f3d eat ubL mix 65w65 er
a R f f3d eat ubL tcc 65w65 er
b R f f3d eat ubL tpp 65w65 or
249 R . f3d eat ubL can 24.24 or
a R m f3d eat ubL pam 24.24 er
250 R m f3d eat ubl mix 65w65 er
a R m f3d eat ubl tcc 65w65 er
b R m f3d eat ubt tpp 65w65 er
TD50 2TailpvL
DR AuOp tes
lOOng.. : .ug. : 10. :100. le : g.:10. :100.:Ig. :10
A 2.88gm * P<.l +
5.89gm * P<.3 +
5.89gm * P<.3 +
* 3.18gm * P<.04 +
3.189m * P<.04 +
. + . 195.mg / P<.0005+
364.mg / P<.0005+
852.mg * P<.008 +
PHOSPHINE bO0ng ..u. : ug.. :.10 .:100.l. : g.:10. :100.:Ig. :10
251 R f sda eat tba tur 52w52 ek .> no dre P-1.
252 R f sda eat tba mix 24.24 e no dre P-1.
253 R m sda eat tba tur 52w52 ek .> no dre P-1.
254 R m sda eat tba mix 24m24 e .> no dre P-1.
PIPERONYL BUTOXIDE***
255 R f f3d eat liv nnd 24m26 e
a R f f3d eat tba mix 24m26 e
256 R m f3d eat liv nnd 24m26 e
a R m f3d eat liv hpc 24m26 e
b R m f3d eat tba mix 24.26 e
POTASSIUM CHLORIDE
257 R m f34 eat amd phe 24.24
a R m f34 eat mgl fba 24m24
PREDNIMUSTINE
258 R f sda gav auc sqc 18.24
a R f sda gav tba ben 18m24
b R f sda gav tba maL 18m24
PREDNISOLONE
259 R f sda gav tba ben 18.24
a R f sda gav tba maL 18m24
RETINOL ACETATE
260 R f f3d wat amd phe 24m25 e
a R f f3d wat cli ade 24.25 e
b R f f3d wat liv nnd 24m25 e
c R f f3d wat tba mix 24.25 e
261 R m f3d wat amd phe 24m25 e
a R m f3d wat spl mnL 24.25 e
b R m f3d wat amd ph. 24m25 e
c R m f3d wat liv nnd 24m25 e
d R m f3d wat Liv mix 24m25 e
e R m f3d wat Liv cho 24m25 e
f R m f3d wat Liv hpc 24.25 e
g R m f3d wat tba mix 24.25 e
SACCHARIN, SODIUM***
262 R m f34 eat ubL pam 24m24
263 R m f34 eat Liv nnd 95w95
264 R m f34 eat Liv tum 61w68 e
SODIUM CHLORIDE
265 M f b6c wat Lun pt, 24m24 e
a M f b6c wat Liv hnd 24,24 e
b M f b6c wat tba mix 24.24 e
266 M m b6c wat Lun pt. 24m24 o
a M m b6c wat Liv hnd 24m24 e
b M m b6c wat liv hem 24,24 e
c M m b6c wat Liv hpt 24.24 a
d M m b6c wat tba mix 24.24 e
267 R m f34 eat amd phe 24.24
SODIUM CHLORITE
268 M f b6c wat Liv mix 85w85 a
a M f b6c wat Liv hnd 85w85 e
b M f b6c wat lun mix 85w85 e
c M f b6c wat tba mix 85w85 e
269 M m b6c wat lun mix 85w85 a
a M m b6c wat Liv mix 85w85 e
b M m b6c wat Liv hnd 85w85 e
c M m b6c wat Lun ado 85w85 o
d M m b6c wat tba mix 85w85 e
loong.. :. .ug.. : 10. :100.. : l1g.. : 10. :100.. :Ig..:10
.> no dre P-I1.
no dre P-1.
.> 7.699m * P<.3 -
20.19m * P<.3 -
no dre P-I1.
lOOng..:. .lug.:10. :100.l. : g.:10. :100.:Ig. :10
.> 6.21gm * P<.2 -
33.5gm Z P<.5 _
bO0ng .. : ..ug.:10. :100. 1m : g.:10. :100..:g. :10
+ . 19.2mg * P<.005 +
14.0mg * P<.5 _
21.6mg * P<.3 -
lOOng..: ..lug.:10. :100. 1m : g.:10. :100.:Ig. :10
1.96mg * P<.2 -
no dre P-1.
lO0ng..: ..lug.:10. :100. m : g.:10. :100..:Ig. :10












bO0ng . . .lug.. : 10. :100. g :. 1g :10. :100.:Ig..:10
.54.19m P<.3 +
no dre P-1.
.> no dre P-1.




























169.mg * P<.4CHRONOLOGICAL SUPPLEMENT
RefNum LoConf UpConf CntrL IDose lInc 2Dose 2Inc Citation or Pathology
o-PHENYLPHENATE, SODIUM***
248 1777 707.mg n.s.s.
a 1777 958.mg n.s.s.
b 1777 958.mg n.s.s.
249 1752 779.mg n.s.s.
a 1752 779.mg n.s.s.
250 1777 103.mg 423.mg
a 1777 175.mg 959.mg











251 1692. 245.ng n.s.s. 0/20
252 1692n 43.lng n.s.s. 10/10
253 1692. 206.ng n.s.s. 0/19
254 1692n 264.ng n.s.s. 2/11
PIPERONYL BUTOXIDE*** 51-03-6
255 1686 4.33gm n.s.s. 0/47
a 1686 726.mg n.s.s. 35/47
256 1686 1.88gm n.s.s. 1/48
a 1686 3.28gm n.s.s. 0/48
b 1686 267.mg n.s.s. 48/48
POTASSIUM CHLORIDE 7447-40-7
257 1807 1.84gm n.s.s. 11/50
a 1807 5.609m n.s.s. 0/50
PREDNIMUSTINE 29069-24-7
258 1770 6.64mg 167.mg 0/120
a 1770 2.92mg n.s.s. 43/120




















0/8 400..g 0/9 800.mg 2/5























100.mg 16/50 400.mg 20/50 1.60gm 19/50
100.mg 6/50 400.mg 1/50 1.60gm 4/50
1.29mg 2/30 2.58mg 2/30
1.29mg 12/30 2.58mg 13/30









259 1770 .599mg n.s.s. 43/120
a 1770 2.37mg n.s.s. 13/120
.323mg 12/30 .645mg 15/30
.323mg 4/30 .645mg 2/30
Berger;smon, 13,8-13; 1986
RETINOL ACETATE 127-47-9
260 1693 135.mg 539.mg
a 1693 416.mg n.s.s.
b 1693 1.209m n.s.s.
c 1693 115.mg n.s.s.
261 1693 51.8mg 212.mg
a 1693 251.mg n.s.s.
b 1693 246.mg n.s.s.
c 1693 533.mg n.s.s.
d 1693 537.mg n.s.s.
a 1693 1.05gm n.s.s.
f 1693 440.mg n.s.s.














262 1722 8.81gm n.s.s. 0/40
263 1783 14.49m n.s.s. 1/42
264 1786 4.58gm n.s.s. 0/36
SODIUM CHLORIDE 7647-14-5
265 1806 1.50gm n.s.s.
a 1806 5.279m n.s.s.
b 1806 547.mg n.s.s.
266 1806 1.08gm n.s.s.
a 1806 1.449m n.s.s.
b 1806 2.349m n.s.s.
c 1806 2.51gm n.s.s.
d 1806 297.mg n.s.s.











268 1789 225.mg n.s.s. 5/47
a 1789 292.mg n.s.s. 5/47
b 1789 442.mg n.s.s. 3/47
c 1789 151.mg n.s.s. 14/47
269 1789 115.mg 1.26gm 0/35
a 1789 46.8mg n.s.s. 7/35
b 1789 65.1mg n.s.s. 3/35
c 1789 149.mg n.s.s. 0/35







































































































Brkly Code254 GOLD ETAL.
Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
270 R f f34 wat tba mix 85w85 es
271 R m f34 wat tba mix 85w85 es
SODIUM HYPOCHLORITE
272 N f b6c wat Lun a/2 24.25 e
a N f b6c wat Liv mix 24.25 a
b N f b6c wat Liv hpc 24m25 e
c N f b6c wat tba mix 24.25 e
273 N m b6c wat Liv mix 24.25 e
a N m b6c wat Lun a/2 24.25 e
b N m b6c wat Liv hpc 24.25 e
c N a b6c wat tba mix 24.25 e
274 R f f3d wat Liv mix 24.26 e
275 R m f3d wat Liv cho 24.26 e
a R m f3d wat Liv fih 24.26 e
b R m f3d wat Liv mix 24m26 e
STYRENE OXIDE***
276 N f b6c gav for mix 24m25 e
a M f b6c gav for sqp 24m25 e
b M f b6c gav for sqc 24,25 e
c M f b6c gav Liv mix 24m25 e
277 N m b6c gav for mix 24m25 e
a M m b6c gav for sqp 24m25 e
b M m b6c gav Liv mix 24m25 e
c M m b6c gav for sqc 24m25 e
278 R f f34 gav for mix 24m25 e
a R f f34 gav for sqc 24m25 a
b R f f34 gav for sqp 24m25 e
c R f f34 gav Liv nnd 24m25 e
279 R m f34 gav for mix 24m25 e
a R m f34 gav for sqc 24m25 e
b R m f34 gav for sqp 24m25 a
c R m f34 gav Liv nnd 24m25 e
TETRACHLORVINPHOS***
280 M f b6c eat Liv mix 24m24 er
a M f b6c eat Liv hpc 24m24 er
b N f b6c eat kid mix 24m24 er
c N f b6c eat Liv hpa 24.24 er
281 M f b6c eat Liv mix 24m24 er
TD50 2TailpvL
DR AuOp
no dre P-1. -
no dre P-1. -
lOOng .:. .:ug.. : 10. :100.. :1"mg.. : 10. :100.. :Ig. :10




876.mg * P<.5 -
2.04gm * P<.5 -
no dre P-1.
350.mg * P<.4 _




lOOng . . .:ug.. : 10. :100.. :1nmg.. : 10. :100.. : g. :10






















a N f b6c eat Liv hpc 24m24 er
b N f b6c eat liv hpa 24m24 er









282 N m b6c eat Liv mix 24m24 er
a N m b6c eat Liv hpc 24m24 er
b N m b6c eat kid mix 24m24 er
c N m b6c eat kid tuc 24m24 er
d N m b6c eat Liv hpa 24m24 or







TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM CHLORIDE.1ug.... : 10. :100.:1.. :10. :100.. : . :10
283 M f b6c gav TBA MXB 24.24 :> 908.mg * P<1.
a N f b6c gav liv MXB 24m24 200.mg * P<.4
b N f b6c gav lun MXB 24m24 no dre P-1.
284 M m b6c gav TBA MXB 24m24 :> no dre P-I.
a N m b6c gav Liv MXB 24m24 no dre P-1.
b N m b6c gav Lun MXB 24m24 103.mg * P<.6
285 R f f34 gav TBA MXB 24m24 : 4.78mg * P<.09
a R f f34 gav Liv MXB 24m24 no dre P-1.
286 R m f34 gav sub fib 24m24 #24.9mg * P<.03
a R m f34 gav TBA MXB 24m24 14.7mg * P<.7
b R m f34 gav liv MXB 24m24 24.5mg * P<.3
TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM SULFATE.. lug. :10 :..100. :1 .. :10. : 100..: . :10
287 M f b6c gav muL mLm 24m24 #15.7mg * P<.02 -
a N f b6c gav TBA MXB 24m24 no dre P-1.
b M f b6c gav liv MXB 24m24 no dre P-1.
c N f b6c gav lun MXB 24m24 234..g * P<.8
288 M m b6c gav mul MXA 24m24 A #11.4mg \ P<.04







RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc Citation or Pathology
270 1789 69.9mg n.s.s. 21/47 17.1mg 14/44 34.3mg 15/50
271 1789 155.mg n.s.a. 28/34 15.0mg 3/30 30.0mg 6/43
SODIUM HYPOCHLORITE (Clorox; hypochtorous acid, sodium saLt) 7681-52-9
272 1789 734.mg n.s.s. 7/72
a 1789 965.mg n.s.s. 9/72
b 1789 1.96gm n.s.s. 4/72
c 1789 285.mg n.s.s. 42/72
273 1789 187.mg n.s.s. 31/73
a 1789 402.mg n.s.s. 10/73
b 1789 377.mg n.s.s. 24/73
c 1789 92.1mg n.s.s. 53/73
274 1780 1.03gm n.s.s. 0/50
275 1780 450.mg n.s.s. 0/49
a 1780 450.mg n.s.s. 0/49




























276 1791 105.mg 309.mg
a 1791 298.mg 775.mg
b 1791 246.mg 1.35gm
c 1791 969.mg n.s.s.
277 1791 57.8mg 150.mg
a 1791 124.mg 458.mg
b 1791 113.mg 1.17gm
c 1791 308.mg 828.mg
278 1791 29.8mg 61.7mg
a 1791 83.0mg 161.mg
b 1791 150.mg 328.mg
c 1791 472.mg n.s.s.
279 1791 19.4mg 47.0mg
a 1791 59.6mg 114.mg
b 1791 87.2mg 283.mg


















































280 1696m 4.17gm 36.99m 0/99 2.08gm 6/47
a 1696m 4.72gm 54.79m 0/99 2.08gm 5/47
b 1696m 7.91gm n.s.s. 0/99 2.08gm 2/47
c 1696m 10.6gm n.s.a. 0/99 2.08gm 1/47
281 1696n 4.04gm 15.4gm 0/99 2.28mg 1/48 8.32mg 0/49 41.6mg 0/50 208.mg 4/49 1.04gm
2.089m 7/50
a 1696n 4.63gm 25.8gm 0/99 2.28mg 0/48 8.32mg 0/49 41.6mg 0/50 208.mg 3/49 1.04gm
2.08gm 4/50
b 1696n 12.2gm 428.gm 0/99 2.28mg 1/48 8.32mg 0/49 41.6mg 0/50 208.mg 1/49 1.04gm
2.08gm 3/50
c 1696n 16.5mg n.s.s. 0/99 2.28mg 0/48 8.32mg 0/49 41.6mg 0/50 208.mg 0/49 1.04gm
2.08gm 0/50
282 1696m 660.mg 2.429m 26/99 1.929m 35/46
a 1696m 855.mg 3.63gm 24/99 1.92gm 31/46
b 1696a 2.239m 11.3gm 1/99 1.92gm 12/46
c 1696m 2.56gm 13.5gm 0/99 1.92gm 10/46
d 1696m 5.26gm n.s.s. 2/99 1.92gm 4/46
1696m 7.509m n.s.s. 1/99 1.92gm 2/46
TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM CHLORIDE (THPC) 124-64-1
283 c55061 19.2mg n.s.s. 35/50 10.5mg 32/50 21.2mg 36/50
a c55061 47.9mg n.s.s. 4/50 10.5mg 4/50 21.2mg 7/50
b c55061 101.mg n.s.s. 3/50 10.5mg 3/50 21.2mg 2/50
284 c55061 12.9mg n.s.s. 33/50 5.31mg 31/50 10.6mg 33/50
a c55061 25.8mg n.s.s. 17/50 5.31mg 15/50 10.6mg 13/50
b c55061 19.1mg n.s.s. 4/50 5.31mg 6/50 10.6mg 8/50
285 c55061 1.84mg n.s.s. 40/50 2.65mg 45/50 5.31mg 36/50
a c55061 n.s.s. n.s.s. 0/50 2.65mg 1/50 5.31mg 0/50
286 c55061 9.06mg n.s.s. 0/50 2.65mg 2/50 5.31mg 3/50
a c55061 2.34mg n.s.s. 42/50 2.65mg 42/50 5.31mg 36/50
b c55061 6.80mg n.s.s. 1/50 2.65mg 4/50 5.31mg 2/50
TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM SULFATE (THPS) 55566-30-8
287 c55050 7.73mg n.s.s. 1/50 3.54mg 8/50 7.07mg 9/50
a c55050 5.58mg n.s.s. 32/50 3.54mg 35/50 7.07mg 35/50
b c55050 33.4mg n.s.s. 7/50 3.54mg 3/50 7.07mg 3/50
c c55050 21.4mg n.s.s. 2/50 3.54mg 3/50 7.07mg 3/50
288 c55050 4.59mg n.s.s. 2/50 3.54mg 10/50 (7.07mg 1/50)



















RefNum LoConf UpConf Cntrl lDose lInc 2Dose 2Inc
b c55050 10.9mg n.e.s. 18/50
c c55050 9.59mg n.s.s. 7/50
289 c55050 3.69mg n.s.s. 45/50
a c55050 30.1mg n.s.s. 3/50
290 c55050 1.03mg n.s.s. 30/50
a c55050 1.38mg n.s.s. 21/50
b c55050 1.44mg n.s.s. 21/50
c c55050 .766mg n.s.s. 46/50
d c55050 3.19mg n.s.s. 3/50
3.54mg 12/50 7.07mg 17/50
3.54mg 10/50 7.07mg 9/50
3.50mg 46/50 7.01mg 41/50
3.50mg 2/50 7.01mg 2/50
3.50mg 36/50 (7.01mg 20/50)
3.50mg 27/50 (7.01mg 14/50)
3.50mg 26/50 (7.01mg 14/50)
3.50mg 49/50 (7.01mg 37/50)











291 1790 96.3mg n.s.s. 1/21 25.1mg 1/20
a 1790 53.7mg n.s.s. 6/21 25.1mg 5/20
292 1790 23.0mg n.s.s. 4/19 17.6mg 7/20
a 1790 75.6mg n.s.s. 2/19 17.6mg 1/20
Lij insky;zkko, 112,57-60;1986
THIABENDAZOLE (2-(4-thiazolyl)-benzimazole) 148-79-8
293 1777 113.mg n.s.s. 0/15 100.mg 0/14
294 1777 96.6mg n.s.s. 1/14 80.0mg 0/15
a 1777 96.6mg n.s.s. 1/14 80.0mg 0/15
TILIDINE FUMARATE (VaLoron) 55567-81-2
295 1794 88.4mg n.s.s. 10/100 16.0mg
a 1794 62.5mg n.s.s. 2/100 16.0mg
b 1794 79.7mg n.s.s. 38/100 16.0mg
c 1794 96.3mg n.s.s. 32/100 16.0mg
d 1794 172.mg n.s.s. 14/100 16.0mg
296 1794 148.mg n.s.s. 15/100 16.0mg
a 1794 334.mg n.s.s. 0/100 16.0mg
b 1794 401.mg n.s.s. 9/100 16.0mg
c 1794 73.9mg n.s.s. 25/100 16.0mg
d 1794 90.9mg n.s.s. 21/100 16.0mg
e 1794 243.mg n.s.s. 9/100 16.0mg
297 1794 222.mg 2.88gm 2/100 16.0mg
a 1794 169.mg n.s.s. 17/100 16.0mg
b 1794 136.mg n.s.s. 74/100 16.0mg
c 1794 83.8mg n.s.s. 81/100 16.0mg
298 1794 413.mg n.s.s. 4/100 16.0mg
a 1794 54.3mg n.s.s. 55/100 16.0mg
b 1794 97.6mg n.s.s. 45/100 16.0mg





















299 bt903 281.mg 3.199m 10/49 237.mg 21/40
300 bt903 371.mg n.e.s. 11/45 237.mg 18/40
TOLUENE DIISOCYANATE, CONMERCIAL GRADE (2,4 (80%)- AND 2,6
301 c50533 97.9mg 612.mg 2/50 42.5mg 4/50 84.1mg
a c50533 103.mg 5.59gm 4/50 42.5mg 5/50 84.1mg
b c50533 121.mg 2.38gm 2/50 42.5mg 3/50 84.1mg
c c50533 236.mg 10.7gm 0/50 42.5mg 1/50 84.1mg
d c50533 362.mg n.s.s. 0/50 42.5mg 0/50 84.1mg
c50533 66.0mg n.s.s. 26/50 42.5mg 31/50 84.1mg
f c50533 103.mg 5.59gm 4/50 42.5mg 5/50 84.1mg
g c50533 282.mg n.s.s. 0/50 42.5mg 3/50 84.1mg
302 c50533 75.0mg n.s.s. 22/50 84.9mg 27/50 (168.mg
a c50533 371.mg n.s.s. 11/50 84.9mg 12/50 168.mg
b c50533 416.mg n.s.s. 2/50 84.9mg 5/50 168.mg
303 c50533 14.7mg 57.3mg 19/50 42.1mg 26/50 83.3mg
a c50533 18.5mg 87.1mg 15/50 42.1mg 21/50 83.3mg
b c50533 44.4mg 344.mg 3/50 42.1mg 8/50 83.3mg
c c50533 51.9mg 383.mg 0/50 42.1mg 7/50 83.3mg
d c50533 58.3mg 523.mg 0/50 42.1mg 6/50 83.3mg
c50533 58.4mg 2.25gm 2/50 42.1mg 5/50 83.3mg
f c50533 67.1mg 3.51gm 2/50 42.1mg 3/50 83.3mg
g c50533 87.6mg 1.88gm 0/50 42.1mg 1/50 83.3mg
h c50533 32.1mg n.s.s. 25/50 42.1mg 15/50 83.3mg
i c50533 33.7mg n.s.s. 27/50 42.1mg 15/50 83.3mg
j c50533 73.7mg 43.3gm 2/50 42.1mg 1/50 83.3mg
k c50533 87.3mg n.s.s. 0/50 42.1mg 4/50 83.3mg
l c50533 13.6mg 82.8mg 45/50 42.1mg 36/50 83.3mg
m c50533 44.4mg 344.mg 3/50 42.1mg 8/50 83.3mg
304 c50533 6.93mg 71.9mg 48/50 21.0mg 35/50 41.7mg
a c50533 14.9mg 65.4mg 4/50 21.0mg 8/50 41.7mg
b c50533 18.0mg 88.4mg 3/50 21.0mg 6/50 41.7mg




























































































abc:hes; liv:hes,hpa; ova:hes; spl:hem; sub:hem. C
liv:hpa,hpc. S
abc:hes; liv:hes; ova:hes; spl:hem; sub:hem.


















Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
b N m b6c gav Liv MXB 24.24
c M m b6c gav lun NXB 24.24
289 R f f34 gav TBA MXB 24.25
a R f f34 gav liv MXB 24.25
290 R m f34 gav muL mnl 24.25
a R m f34 gav pta MXA 24.25
b R m f34 gav pta adn 24.25
c R m f34 gav TBA MXB 24.25
d R m f34 gav Liv MXB 24.25
THENYLDIAMINE
291 R f f34 wat tyf mix 19.30
a R f f34 wat Liv mix 19m30
292 R m f34 wat Liv mix 19m30
a R m f34 wat tyf mix 19.30
THIABENDAZOLE
293 R f f3d eat ubL mix 65w65 er
294 R m f3d eat ubL mix 65w65 or
a R m f3d eat ubL tcc 65w65 er
TILIDINE FUNARATE
295 N f cfl eat Lun agc 80w80
a N f cfl eat Liv hpa 80w80
b N f cfi eat tba mix 80w80
c N f cfl eat tba maL 80w80 o
d N f cfi eat tba ben 80w80
296 M m cfl eat Lun agc 80w80
a N m cfl eat Liv hem 80w80
b M m cfl eat Liv hpa 80w80
c M m cfl eat tba mix 80w80 o
d M m cfl eat tba maL 80w80
N m cfl eat tba ben 80w80
297 R f waL eat Liv hpa 24m24 o
a R f waL eat tba maL 24m24
b R f waL eat tba ben 24m24 a
c R f waL eat tba mix 24.24 o
298 R m waL eat Liv hpa 24m24
a R m waL eat tba mix 24m24
b R m waL eat tba ben 24m24 e





23.3mg * P<.7 -
no dre P-1.





















lOOng .:ug.:10. :100.:1.. :10. :100..
















122.mg * P<.02 -
300.mg * P<.2
537.mg * P<.2
TOLUENE*** 1O0ng .:. 1 :10 :. 100.: .. :10. :100.. :. . :10
299 R f sda gav tba mal 24m33 o . + . 578.mg P<.002 +
300 R m sda gav tba maL 24m33 . 940.mg P<.05 +
TOLUENE DIISOCYANATE, COMMERCIAL
301 N f b6c gav MXB MXB 24m25
a N f b6c gav liv MXA 24m25
b N f b6c gav liv hpa 24m25
c M f b6c gav MXA MXA 24.25
d N f b6c gav MXA MXA 24m25
N f b6c gav TBA MXB 24m25
f M f b6c gav liv MXB 24m25
g N f b6c gav lun MXB 24m25
302 M m b6c gav TBA MXB 24.25
a N m b6c gav liv NXB 24m25
b N m b6c gav lun MXB 24m25
303 R f f34 gav MXB MXB 25m25
a R f f34 gav mgL fba 25m25
b R f f34 gav Liv nnd 25m25
c R f f34 gav pni MXA 25m25
d R f f34 gav pni isa 25.25
R f f34 gav adr phe 25m25
f R f f34 gav adr coa 25m25
g R f f34 gav sub fib 25m25
h R f f34 gav pit cra 25m25
i R f f34 gav pit MXA 25m25
j R f f34 gav sub MXA 25.25
k R f f34 gav cLi adn 25m25
I R f f34 gav TBA NXB 25m25
m R f f34 gav liv MXB 25.25
304 R m f34 gav tes MXA 25m25
a R m f34 gav MXB MXB 25m25
b R m f34 gav sub MXA 25m25
c R m f34 gav pan ana 25m25
GRADE (2,4 (80%)- AND 2,6 (20%)) 1mg 100.... : 1.. : 10
+ 181.mg / P<.0005
215.mg / P<.008
250.mg / P<.005 c



























Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
d
R m f34 sub fib 25e25
e
R m f34 gav pit cra 25e25
f
R m f34 gav sub fbs 25.25
g R m f34 gav pit NXA 25.25
h
R a f34 gav sub NXA 25.25
R m f34 gav pni MXA 25.25
R m f34 gav TBA MXB 25e25
k











TRICHLOROETHYLENE*** l1Ong .:. .:ug. :10. :100. g : ..g :10. :100.. : g. :10
305 N f b6c inh lun tue 18.36 a . + 6.329m * P<.002 +
a N f b6c inh liv hpt 18.36 a 13.6gm * P<.06 +
b N f b6c inh thy car 18.36 a 131.gm * P<.2
c Nf b6c inh thy ade l8m36
*
2.23kg P<1.
d Nf b6c inh tba mix 18m36 e 1.32gm * P<.002
a N f b6c inh tba mal 18m36 a 2.08gm * P<.02
306 N m b6c inh liv hpt 18m36 as . + 5.03gm * P<.006 +
a N m b6c inh lun tum 18m36 ms no dre P-1.
b M m b6c inh thy ade 18m36 es no dre P-1.
c N m b6c inh tba mal 18m36 es no dre PnI.
d N m b6c inh tba mix 18m36 as no dre P-1.
307 M m b6c inh Liv hpt 18m31 a .> 4.53gm * P<.3 +
a N m b6c inh Liv ang 18m31 e 77.0gm * P<.8
b N m b6c inh Lun tum 18m31 e no dre P-1.
c M m b6c inh tba mal 18m31 e no dre Pal.
d M m b6c inh tba mix .18m31 e no dre P-1.
308 N f swi inh Lun tur 18m34 a .> 35.4gm * P<.7
a M f swi inh liv hpt 18m34 a 121.gm * P<.2
b
M
f swi inh tba mix l8m34 9.19gm * P<.6
c N f sii inh tba mal 18m34 e 9.84gm * P<.5
309 N mswi inh Liv hpt 18m34 a . + 3.91gm * P<.003 +
a N mswi inh lun tum18m34 a 10.1gm * P<.3 +
b M mswi inh tbamal 18m34
*
6.32gm * P<.08
N mswi inh tba mix 18m34 a 8.07gm * P<.3
310 R fsda gav mgl mix 12m33 a .> no dre P-1.
a R f sda gav kid mix 12m33 a no dro P-1.
b R f sdagav --- leu l2m33e no dre P-1.
c R f sda gav liv mix 12m33 a no dre Pul.
d R fsda gav tba mix12m33 e no dre P-1.
e R fsda gav tba mal 12m33 a no dre P-1.
311 R f sda inhliv ang 24m37 a .> 8.01gm * P<.3
a R fsda inh kid usc 24.37 e 43.2gm * P<.2
b R fsda inh
--- leu 24m37 e no dre P-1.
c R f ada inhliv hpt 24m37 e no dre P-1.
d R f ada inh tba mix 24m37 e 3.89gm * P<.8
a R fsda inh tba mal 24m37 a 6.239m Z P<.6
f R f sda inh tba mal 24m37 a 6.23gm Z P<.6
312 R f sda inh - -tlu 24m37e . * 2.85gm * P<.09
a R f sda inhliv nnd 24m37 a 9.68gm * P<.07
b R fsda inhliv hpt 24m37 e no dre Pal.
c R f ada inh tba mal 24m37 a 1.62gm * P<.2
d R fsda inh tba mix 24m37 e no dre P-1.
313 R msda gav ---lou 12m33 e . 428.mg * P<.08
a R m ada gav kid mix12m33 a no dre Pal.
b R
msda gav liv mix12m33 e no dre P-1.
c R msda gav mgl mix12m33 e no dre P-I.
d R m ada gav tba mal12m33 e 818.mg * P<.4
e Rf sda gav tba mix12m33 a no dre P-1.
314 R msda inh tes ldc 24m37 a . + . 557.mg * P<.0005+
a R m ada inh kid uac 24m37 e 9.499m * P<.03
b Rf sdainh ---Leu 24m37
* 5.93gm * P<.5
c R msda inhliv nnd 24m37 a 30.7gm * P<.2
d Rf sda inhliv ang 24m37 a no dre P-1.
a Rfm da inhliv hpt 24m37 a no dre P-1.
f R a sda inh tba mix 24m37 e 1.88gm * P<.6
g R fm da inh tba mal 24m37 e 10.8gm * P<.9
315 R msda inh mgl tum 24m37 a . + . 120.mg Z P<.0005
a R f sda inh tes ldc 24m37 a 835.mg * P<.02 +
b R sdainh ..- leu 24.37 . 2.81gm * P<.3
c R msda inh kid usc 24m37 e 12.4gm * P<.2
d R msda inhliv hpt 24m37 a no dre P-1. e R msda inh tba mix 24.37 e 428.mg * P<.2
f R msda inh tbamal 24m37 a 1.94gm * P<.4CHRONOLOGICAL SUPPLEMENT
RefNum LoConf UpConf Cntrl IDose lInc 2Dose 2Inc
d c50533 25.2mg 239.mg
a c50533 32.2mg 732.mg
f c50533 36.9mg 421.mg
9 c50533 33.6mg 12.8gm
h c50533 39.2mg n.s.s.
i c50533 57.7mg n.s.s.
I c50533 9.29mg 94.4mg










305 bt3O6m 3.33gm 28.9gm
a bt3O6m 5.28gm n.s.s.
b bt3O6m 21.49m n.s.s.
c bt3O6m 17.39m n.s.s.
d bt3O6m 700.mg 6.89gm
bt3O6m 986.mg n.s.s.
306 bt3O6m 2.229m 59.8gm
a bt3O6m 12.39m n.s.s.
b bt3O6m 2.17gm n.s.s.
c bt3O6a 8.59gm n.s.s.
d bt3O6m 7.939m n.s.s.
307 bt3O6n 1.34gm n.s.s.
a bt3O6n 6.47gm n.s.s.
b bt3O6n 7.94gm n.s.s.
c bt3O6n 3.14gm n.s.s.
d bt3O6n 994.mg n.s.s.
308 bt3O5 4.57gm n.s.s.
a bt3O5 19.8gm n.s.s.
b bt3O5 1.70gm n.s.s.
c bt3O5 2.32gm n. .s.
309 bt3WU 1.989m 22.7gm
a bt3O5 3.02gm n.s.s.
b bt3O5 2.45gm n.s.s.
c bt3O5 2.23gm n.s.s.
310 bt3Ol 98.3mg n.s.s.
a bt3Ol 106.mg n.s.s.
b bt301 109.mg n.s.s.
c bt3Ol 111.mg n.s.s.
d bt3Ol 98.1mg n.s.s.
bt301 297.mg n.s.s.
311 bt3O4m 1.30gm n.s.s.
a bt3O4m 7.03gm n.s.s.
b bt3O4m 3.569m n.s.s.
c bt3O4m 6.539m n.s.s.
d bt3O4m 406.mg n.s.s.
bt3O4m 1.109m n.s.s.
f bt3O4m 1.10gm n.s.s.
312 bt3O4n 1.01gm n.s.s.
a bt3O4n 2.38gm n.s.s.
b bt3O4n 269.mg n.s.s.
c bt3O4n 532.mg n.s.s.
d bt3O4n 312.mg n.s.s.
313 bt3Ol 162.mg n.s.s.
a bt3Ol 87.1mg n.s.s.
b bt3Ol 108.mg n.s.s.
c bt3Ol 363.mg n.s.s.
d bt3Ol 177.mg n.s.s.
bt3Ol 191.mg n.s.s.
314 bt3O4m 336.mg 1.44gm
a bt3O4m 2.87gm n.s.s.
b bt3O4m 1.17gm n.s.s.
c bt3O4m 4.99gm n.s.s.
d bt3O4m 40.5mg n.s.s.
bt3O4m 4.36gm n.sa.s.
f bt3O4m 329.mg n.s.s.
g bt3O4m 789.mg n.s.s.
315 bt3O4n 56.2mg 348.mg
a bt3O4n 375.mg n.s.s.
b bt3O4n 755.mg n.s.s.
c bt3O4n 2.01gm n.s.s.
d bt3O4n 2.59gm n.s.s.
bt3O4n 154.mg n.s.s.



















































































































































































































































































Spe Strain Site Xpo+Xpt
Sex Route Hist No
TRIETHANOLANI NE***
316 R f f3d wat liv nnd 24e26 ev
a R f f3d wat tba mix 24m26 ev
317 R m f3d wat liv nnd 24.26 a
a R m f3d wat liv hpc 24.26 a
b R m f3d wat tba mix 24m26 a
VINYL CHLORIDE***
318 R m wis inh liv ang 52w78 a
a R e wis inh Lun ang 52w78 a
b R m wis inh Lun tum 52w78 o
c R a wis inh bra tum 52w78 a
d R m wis inh ski tur 52w78 a
a R m wis inh nse tur 52w78 o
f R m wis inh tes tur 52w78 a
9 R m wis inh tba mix 52w78 a
4-VINYLCYCLOHEXENE*
319 M f b6c gav ova MXB 24.24
a M f b6c gav ova mtb 24m24
b M f b6c gav ova NXA 24.24
c M f b6c gav ova gct 24m24
d M f b6c gav MXA MXA 24.24
a M f b6c gav arp adn 24.24
f M f b6c gav TBA MXB 24.24
g M f b6c gav Liv MXB 24m24
h M f b6c gav Lun MXB 24.24
320 N m b6c .gav lun MXA 24r24
a M m b6c gav MXA MXA 24.24
b M m b6c gav Lun a/a 24m24
c M m b6c gav TBA MXB 24m24
d M m b6c gav liv MXB 24r24
a N m b6c gav lun MXB 24.24
321 R f f34 gav cli NXA 24.24
a R f f34 gav TBA MXB 24,24
b R f f34 gav liv MXB 24.24
322 R m f34 gav tes ict 24.24
a R m f34 gav ski MXA 24.24
b R m f34 gav ski sqp 24m24
c R m f34 gav adr MXA 24m24
d R m f34 gav TBA MXB 24m24
a R m f34 gav liv MXB 24m24
VINYLIDENE CHLORIDE***
323 M f swi inh rgl mix 12.29 ej
a M f swi inh Lun mix 12.29 ej
b M f swi inh liv hpt 12.29 oj
c N f swi inh Liv ang 12,29 oj
d N f swi inh tba mix 12.29 ej
a M f swi inh tba mal 12.29 eJ
324 M m swi inh kid adc 12.29 oj
a M m swi inh Lun six 12.29 aj
b M m swi inh Liv ang 12.29 eJ
c M m swi inh liv hpt 12.29 eJ
d N m swi inh tba mix 12.29 ej
a M m swi inh tba mal 12r29 eJ
325 R f sda inh Liv mix 24.35 ogN
a R f sda inh tba mix 24.35 ogN
326 R f sda gav Liv ang 12.34 a
a R f sda gav Liv hpt 12r34 a
b R f sda gav tba six 12.34 e
327 R f sda gav liv ang 12m32 a
a R f sda gav tba mix 12.32 a
328 R msda gav liv ang 12r34 e
a R msda gav Liv hpt 12m34 a
b R m sda gav tba mix 12m34 o
329 R msda gav liv mix 12.32 e
a R m sda gav tba mix 12m32 e
330 R f sss inh mgL aff 18m24 e
a R f sss inh mgl adc 18m24 a
b R f sss inh liv cho 18.24 e
331 R m sss inh liv sar 18m24 e
TD50 2TaiLpvL
DR AuOp tes
lOOng . . .lug.:10. :100. g : . 1g :10. :100.. : . :10
.>47.Ogm * P<.3 -
no dre P-1.
&9.59gm * P<.09 -
53.6gm * P<.3 _
no dre P-1.
lOOng..:. .lug. :10. :100. g : .g :10..:100.:Ig. :10
+ . 10.2mg Z P<.0005+
193.mg * P<.0005+
867.mg * P<.2 +
5.82g. * P<.8 +
5.829g * P<.8 +
no dre P-1. +
no dre P-1. +
5.44mg Z P<.0005+
lOOng .. :. .ug.. : 10. :100.. :.1mg.. : 10. : 100.. : g. :10















A * #580.mg \ P<.04
305.mg * P<.2
3.85kg P-1.






lOOng.. : ..lug.:10. :100. . : 1g.:10. :100.:Ig. :10






















.> no dre P-1.
5.32mg P<.8
16.0mg * P<.04 -
49.8mg \ P<.03 -
no dre P-I. -
no dre P-I. -
XYLENE MIXTURE (m-XYLENE, o-XYLENE, p-XYLENE) .... .:10. : 100. 1 : mg.:10. :100.. : g. :10
332 R f sda gav tba maL 24.33 a . + . 524.mg P<.002 +
333 R s ada gav tba maL 24m33 a .> 1.67gm P<.3 +CHRONOLOGICAL SUPPLEMENT
RefNum LoConf UpConf CntrtL Dose lInc 2Dose 2Inc
TRIETHANOLAMINE*** 102*71-6
316 1793 7.669m n.s.s. 0/50
a 1793 1.319m n.s.s. 44/50
317 1793 3.44gm n.s.s. 1/48
a 1793 8.73gm n.s.s. 0/48
b 1793 173.mg n.s.s. 48/48
VINYL CHLORIDE*** 75-01-4
318 1760 4.36mg 32.7mg
a 1760 88.3mg 617.mg
b 1760 208.mg n.s.s.
c 1760 503.mg n.s.s.
d 1760 503.mg n.s.s.
1760 469.mg n.s.s.
f 1760 674.mg n.s.s.


















































Maekawa; J txe, 19,345-357;1986









319 c54999 66.7mg 145.mg 1/50
a c54999 65.9mg 187.mg 0/50
b c54999 181.mg 672.mg 1/50
c c54999 204.mg 888.mg 1/50
d c54999 376.mg 72.6gm 1/50
c54999 450.mg 6.37gm 0/50
f c54999 77.9mg 802.mg 28/50
9 c54999 506.mg n.s.s. 1/50
h c54999 799.mg n.s.s. 6/50
320 c54999 206.mg n.s.s. 4/50
a c54999 245.mg n.s.s. 4/50
b c54999 347.mg n.s.s. 1/50
c c54999 112.mg n.s.s. 26/50
d c54999 216.mg n.s.s. 18/50
c54999 206.mg n.s.s. 4/50
321 c54999 199.mg n.s.s. 1/50
a c54999 98.8mg n.s.s. 38/50
b c54999 766.mg n.s.s. 1/50
322 c54999 34.7mg 166.mg 35/50
a c54999 265.mg 4.36gm 0/50
b c54999 287.mg 12.59m 0/50
c c54999 66.5mg n.s.s. 17/50
d c54999 51.9mg n.s.s. 38/50
a c54999 477.mg n.s.s. 1/50
VINYLIDENE CHLORIDE*** 75-35-4
323 bt4O2n 38.9mg 578.mg 1/89
a bt4O2n 46.6mg n.s.s. 3/89
b bt4O2n 140.mg n.s.s. 0/78
c bt4O2n 178.mg n.s.s. 2/77
d bt4O2n 16.5mg 179.mg 14/89
bt4O2n 38.1mg n.s.s. 3/90
324 bt4O2n 13.6mg 38.7mg 0/66
a bt4O2n 28.3mg n.s.s. 3/87
b bt4O2n 92.2mg n.s.s. 0/60
c bt4O2n 94.4mg n.s.s. 2/62
d bt4O2n 11.1mg 39.7mg 9/87
bt4O2n 25.3mg 350.mg 3/90
325 bt4002 138.mg n.s.s. 0/22
a bt4002 33.9mg n.s.s. 35/60
326 bt403 1.05mg n.s.s. 1/7
a bt403 6.94mg n.s.s. 1/7
b bt403 19.2mg n.s.s. 63/99
327 bt404 80.1ug n.s.s. 0/10
a bt404 .305mg n.s.s. 38/74
328 bt403 .702mg n.s.s. 0/17
a bt403 .702mg n.s.s. 0/17
b bt403 42.7mg n.s.s. 29/100
329 bt404 .303mg n.s.s. 0/6
a bt404 .466mg n.s.s. 13/68
330 1799 6.68mg n.s.s. 64/84
a 1799 19.4mg n.s.s. 1/84
b 1799 214.mg n.s.s. 0/84



















































































































0/4 2.27mg 0/7 4.55mg 0/2
0/4 2.27mg 1/6 4.55mg 0/2
32/50 2.27mg 28/50 4.55mg 25/48
1/4
23/47
0/2 2.27mg 0/6 4.55mg 0/3
0/2 2.27mg 0/6 4.55mg 0/3



























XYLENE MIXTURE (m-XYLENE, o-XYLENE, p-XYLENE) (CAS# 108-38-3, 95-47-6, and 106-42-3) mixture
332 bt904 262.mg 2.26gm 10/49 237.mg 22/40
333 bt904 483.mg n.s.s. 11/45 237.mg 14/38
MaLtoni;aj im,7,415-446;1985/1983
261262 GOLD ETAL.
Spe Strain Site Xpo+Xpt TD50 2TailpvL
Sex Route Hist Notes DR AuOp
XYLENE MIXTURE (60% m-XYLENE, 9% o-XYLENE, 14% p-XYLENE, 17% ETHYLBENZENE) .. 10. 100 .Ig.. 10
334 M f b6c gav thy fca 24m24 #4.799g * P<.04 -
a M f b6c gav TBA MXB 24.24 no dre P-1.
b M f b6c gav Liv MXB 24.24 7.04gm * P<.4
c N f b6c gav Lun MXB 24.24 5.13g. * P<.3
335 N m b6c gav TBA MXB 24.24 > no dre P-1. -
a M e b6c gav Liv MXB 24.24 no dre P-1.
b M m b6c gav Lun MXB 24.24 7.60g. * P<.6
336 R f f34 gav mgL adn 24e24 * #4.11g. * P<.04 -
a R f f34 gav TBA MXB 24.24 1.93gm * P<.8
b R f f34 gav Liv MXB 24.24 51.3g. * P<1.
337 R m f34 gav TBA MXB 24m24 s > 700.mg * P<.5 -
a R m f34 gav Liv MXB 24.24 s no dre P-I.CHRONOLOGICAL SUPPLEMENT
RefNum LoConf UpConf CntrL lDose 1Inc ZDose 2Inc
XYLENE MIXTURE (60% *-XYLENE, 9% o-XYLENE, 14% p-XYLENE, 17% ETHYLBENZENE) 1330-20-7
334 c55232 1.82gm n.s.s. 0/50 350.mg 2/50 707.mg 3/50
a c55232 636.mg n.e.s. 41/50 350.mg 42/50 707.mg 32/50
b c55232 1.63gm n.s.s. 3/50 350.mg 3/50 707.mg 5/50
c c55232 1.409m n.s.s. 4/50 350..g 5/50 707.mg 7/50
335 c55232 847.mg n.s.s. 36/50 352.mg 37/50 707.mg 33/50
a c55232 1.719m n.s.s. 18/50 352.mg 13/50 707.mg 14/50
b c55232 1.50g. n.s.s. 3/50 352.mg 5/50 707.mg 6/50
336 c55232 1.24gm n.s.s. 0/50 175.mg 0/50 354.mg 3/50
a c55232 200.mg n.s.s. 46/50 175.mg 45/50 354.mg 46/50
b c55232 1.40gm n.s.s. 2/50 175.mg 2/50 354.mg 2/50
337 c55232 145.mg n.s.s. 45/50 176.mg 45/50 354.mg 32/50

































25013-16-5 BHA (see BUTYLATED HYDROXYANISOLE)





123-73-9 trans-2-BUTENAL (see CROTONALDEHYDE)
3817-11-6 BUTYL-BUTANOL-NITROSAMINE (see N-BUTYL-N-
(4-HYDROXYBUTYL) NITROSAMINE)









56802-99-4 CHLORINATED TRISODIUM PHOSPHATE
563-47-3 3-CHLORO-2-METHYLPROPENE, TECHNICAL GRADE
(CONTAINING 5% DIMETHYLVINYL CHLORIDE)





7681-52-9 CLOROX (see SODIUM HYPOCHLORITE)
123-73-9 CROTONALDEHYDE






75-27-4 DICHLOROBROMOMETHANE (see BROMODICHLOROMETHANE)
75-09-2 DICHLOROMETHANE (see METHYLENE CHLORIDE)
78-87-5 1,2-DICHLOROPROPANE






106-93-4 EDB (see 1,2-DIBROMOETHANE)
106-89-8 EPICHLOROHYDRIN








106-93-4 ETHYLENE DIBROMIDE (see 1,2-DIBROMOETHANE)
24554-26-5 FANFT (see N-14-(5-NITRO-2-FURYL)-2-THIAZOLYLIFORMAMIDE)
53-96-3 FLUORENYLACETAMIDE (see 2-ACETYLAMINOFLUORENE)







70-25-7 MNNG (see N-METHYL-N'-NITRO-N-NITROSOGUANIDINE)
24554-26-5 N-14-(5-NITRO-2-FURYL)-2-THLAZOLYLJFORMAMIDE
10024-97-2 NITROGEN OXIDE (see NITROUS OXIDE)
--- l-NITROSO-1-HYDROXYETHYL-3-CHLOROETHYLUREA





39884-52-1 NITROSOOXAZOLIDONE (see N-NITROSO-1,3-OXAZOLIDINE)













103-90-2 PARACETAMOL (see ACETAMINOPHEN)
12737-87-0 PCBs (see KANECHLOR 400)




50-06-6 PHENOBARBITONE (see PHENOBARBITAL)
61-76-7 PHENYLEPHRINE.HCI




12737-87-0 POLYCHLORINATED BIPHENYLS (see KANECHLOR 400)
7758-01-2 POTASSIUM BROMATE (see BROMATE, POTASSIUM)
7447-40-7 POTASSIUM CHLORIDE
50-00-0 FORMALDEHYDE




118-74-1 HCB (see HEXACHLOROBENZENE)
7647-01-0 HCI (see HYDROCHLORIC ACID)
118-74-1 HEXACHLOROBENZENE
1415-93-6 HUMIC ACIDS, COMMERCIAL GRADE
302-01-2 HYDRAZINE
7647-01-0 HYDROCHLORIC ACID
7647-01-0 HYDROGEN CHLORIDE (see HYDROCHLORIC ACID)
103-90-2 p-HYDROXYACETANILIDE (see ACETAMINOPHEN)
13743-07-2 1-(2-HYDROXYETHYL)-1-NITROSOUREA
7681-52-9 HYPOCHLOROUS ACID, SODIUM SALT (see SODIUM
HYPOCHLORM)
860-22-0 INDIGO CARMINE (see FD & C BLUE NO. 2)
144-48-9 IODOACETAMIDE
76180-96-6 IQ (see2-AMINO-3-METHYLIMIDAZCJ4,5-flQUINOLINE)




1335-32-6 LEAD ACETATE, BASIC
1335-32-6 LEAD SUBACETATE (see LEAD ACETATE, BASIC)




563-47-3 METHYL ALLYL CHLORIDE (see 3-CHLORO-2-METHYLPROPENE,







79-06-1 2-PROPENAMIDE (see ACRYLAMIDE)
78-87-5 PROPYLENE DICHLORIDE (see 1,2-DICHLOROPROPANE)







68-89-3 SULPYRIN (see DIPYRONE)




35449-36-6 2,2,9,9-TETRAMETHYL-1,10-DECANEDIOL (see GEMCADIOL)
91-79-2 THENYLDIAMINE
148-79-8 THIABENDAZOLE
148-79-8 2-(4-THIAZOLYL)-BENZIMAZOLE (see THIABENDAZOLE)
124-64-1 THPC (see TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM
CHLORIDE)








75104-43-7 TRP-P-1 ACETATE (see 3-AMINO-1,4-DIMETHYL-5H-
PYRIDOI4,3-bIINDOLE ACETATE)
103-90-2 TYLENOL (see ACETAMINOPHEN)




1330-20-7 XYLENE MIXTURE (60% m-XYLENE, 9% o-XYLENE, 14% p-XYLENE,
17% ETHYLBENZENE)
mixture XYLENE MIXTURE (m-XYLENE, o-XYLENE, p-XYLENE)
(CAS NUMBER 108-38-3, 95-47-6, and 106-42-3)
APPENDIX 2: CHEMICAL NAMES IN THIS
PLOT LISTED BY CAS NUMBER
CAS
NUMBER CHEMICAL NAME
mixture ALKYLDIMETHYLAMINE OXIDES, COMMERCIAL GRADE
mixture XYLENE MIXTURE (m-XYLENE, o-XYLENE, p-XYLENE)
















































































































BENZYL CHLORIDE (alpha-chloro toluene)































(CONTAINING 5% DIMETHYLVINYL CHLORIDE)




XYLENE MIXTURE (60% m-XYLENE, 9% o-XYLENE, 14% p-XYLENE,
17% ETHYLBENZENE)
LEAD ACETATE, BASIC








HYDROCHLORIC ACID (hydrogen chloride)
SODIUM CHLORIDE





NITROUS OXIDE (nitrogen oxide)











APPENDIX 4: ROUTE OF ADMINISTRATION
CODES AND DEFINITIONS
23135-22-0 OXAMYL
24554-26-5 N-14-(5-NITRO-2-FURYL)-2-THIAZOLYL]FORMAMIDE (FANFT) Code Route ofAdministration
25013-16-5 BUTYLATED HYDROXYANISOLE (BHA, 2(3)-tert-butyl-4- Code _Route_of______________
hydroxyanisole)
26471-62-5 TOLUENE DIISOCYANATE, COMMERCIAL GRADE (2,4 (80%)- AND eat diet 2,6 (20%)-)
29069-24-7 PREDNIMUSTINE gav gavage
29082-74-4 OCTACHLOROSTYRENE inh inhalation
35449-36-6 GEMCADIOL (2,2,9,9-tetramethyl-1,10-decanediol) wat water
35660-60-7 O,S-DIBENZOYL THLAMINE.HCl
39884-52-1 N-NITROSO-1,3-OXAZOLIDINE (nitrosooxazolidone)
55566-30-8 TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM SULFATE (THPS)
55567-81-2 TILIDINE FUMARATE (Valoron)
56802-99-4 CHLORINATED TRISODIUM PHOSPHATE APPENDIX 5: SITE CODES AND DEFINITIONS
57497-29-7 Z-ETHYL-O,N,N-AZOXYMETHANE
57497-34-4 Z-METHYL-O,N,N-AZOXYETHANE
71277-79-7 GLYCYRRHIZINATE, DISODIUM Code Site
73590-58-6 OMEPRAZOLE
75104-43-7 3-AMINO-1,4-DIMETHYL-5H-PYRIDOJ4,3-bJINDOLE ACETATE
(trp-P-i acetate) --- alltarget sites 76180-96-6 2-AMINO-3-METHYLIMIDAZO[4,5-flQUINOLINE (IQ) abc abdominal cavity 77094-11-2 2-AMINO-3,4-DIMETHYLIMIDAZOq4,5-f1QUINOLINE (MeIQ)ad arelgan
79624-33-2 NITROSO-5-METHYLOXAZOLIDONE adr adrenal gland
--- 2-AMINO-3-METHYLIMIDAZO4,5-flQUINOLINE.HCI (IQ, hydrochloride amd adrenal medulla
salt) arp adrenal capsule
--- BROMOETHANOL auc external auditory canal
--- 1-NITROSO-1-(2-HYDROXYPROPYL)-3-CHLOROETHYLUREA bra brain
--- 1-NITROSO-1-HYDROXYETHYL-3-CHLOROETHYLUREA
cli bram cli clitoral gland




APPENDIX 3: STRAIN CODES AND for forestomach
DEFINITIONS gam gastric mucosa
gum gum
hag Harderian gland
Code Strain ilm ileum
jej jejunum
kid kidney
aap Alpk/Ap ktu kidney tubule
aci ACI lab lung/alveoli/bronchioles
alb albino lar larynx
b6c B6C3F1 lgi large intestine
bal BALB/c liv liver
bcn BALB/c StCrlfC3Hf/Nctr lpp lip
bd9 BD IX lun lung
cb6 C57BL/6 lyd lymph node
cdl Charles River CDI mam mammary tissue (other than or including more than
cdf CDF1 mammary gland)






















mix more than one site; sites specified in published paper
mln mesenteric lymph node
mul multiple organs
MXA more than one site, combined by NTP
MXB more than one site, combined by Berkeley
nac nasal mucosa
nas nasal cavity
ncp nasal cavity, posterior region
ner nervous system











pni pancreatic islets coa
pre preputial gland cra
pro prostate crc
pta pituitary gland, anterior epc
res respiratory system esn
ski skin esp
smi small intestine ess
spd spinal cord fba
spl spleen fbs
stg stomach, glandular fca
sto stomach fcc
sub subcutaneous tissue fib
TBA all tumor bearing animals, NTP fih
tba all tumor bearing animals gcc
tes testis gct
thy thyroid gland ghc
ton tongue grl
trh trachea h/2
tyf thyroid follicle hae
ubl urinary bladder hct
unt urinary tract hem
ute uterus hes
vag vagina hga











a/a alveolar/bronchiolar adenoma Icc
a/c alveolar/bronchiolar carcinoma 1cm
a/t alveolar/bronchiolar tumor ldc
acc acinar-cell carcinoma leu
acn adenocarcinoma, NOS ley
adc adenocarcinoma lle
ade adenoma mal
























































































more than one tumor type; tumor types
specified in published paper
monocytic leukemia
malignant lymphoma, histiocytic type
malignant lymphoma, mixed type
malignant lymphoma, lymphocytic type





more than one tumor type, combined by NTP



























tum tumor or more than one tumor type; tumor types







r Restricted site analysis; the authors either examined or
chose to report data for only a few selected tissues.
s Authors noted that survival was decreased due to toxi-
city, disease, or accidental death.
v Variable or irregular dosing schedules have been used,
e.g., dose level changed during the experiment.
APPENDIX 8: DOSE-RESPONSE CURVE
SYMBOLS AND DEFINITIONS
Code Dose-Response Curve
* consistent with linearity
/ significant departure from linearity, upward curvature
significant departure from linearity, downward curvature
Z significant departure from linearity, more than three dose
groups including controls
APPENDIX 7: NOTECODES AND DEFINITIONS blank
Code Definition
a The exposure time reported on the plot is an average of
the different exposure times of the individual dose
groups in the experiment. For NCI/NTP, both expo-
sure and experiment times have been averaged because
of differential survival among the dose groups. (In the
TD50 calculation for the NCI/NTP bioassays, full lifet-
able data have been used.)
b Diet was specially prepared to be deficient in one or
more vitamins.
e For the general literature we have used an effective
number of animals in a group whenever possible. This
effective number is either: (1) the number of animals
alive at the time of appearance of the first tumor, or if
that is not reported, then (2) the number of animals
examined.
g Some or all of the animals were used as breeders during
the course of the experiment.
j The data for this test have been previously published in
the database. The experimental results have been
revised and re-published by the authors. In the data-
base, we give the same reference number to the test in
both publications.
k For interim and serial sacrifice experiments, we have
reported, as a separate experiment with a k notecode,
each sacrifice time that otherwise met the inclusion
rules of the database. Wherever possible, we have
included unscheduled deaths with the terminal sacrifice
data, and when this has been done, there is no k
notecode for the terminal sacrifice experiment.
either no dose-related effect, or only two dose groups
including controls, so not enough information to determine
a curve shape
APPENDIX 9: REFERENCE CODES
AND DEFINITIONS
Code Reference
acpj Acta Pathologica Japonica
ajim American Journal of Industrial Medicine
anes Anesthesiology
apms Acta Pathologica et Microbiologica Scandinavica Sec-
tion A. Pathology
aric Archives of Research on Industrial Carcinogenesis
bexb Bulletin of Experimental Biology and Medicine




dact Drug and Chemical Toxicology
dgsn Digestion
eaes Ecotoxicology and Environmental Safety
ejca European Journal of Cancer and Clinical Oncology
(formerly European Journal of Cancer, until 1982)
enhp Environmental Health Perspectives
faat Fundamental and Applied Toxicology
fctx Food and Chemical Toxicology (formerly Food and
Cosmetics Toxicology, until 1982)
gann Japanese Journal of Cancer Research (formerly Gann
through Vol 75, 1984)
jnci Journal of the National Cancer Institute (U.S. National
Cancer Institute. Journal)

















jtxe Journal of Toxicology and Environmental Health
onco Oncology
smon Seminars in Oncology
tcam Teratogenesis, Carcinogenesis, and Mutagenesis
tumo Tumori




zkko Journal of Cancer Research and Clinical Oncology
(formerly Zeitschrift fur Krebsforschung und Klinische
Onkologie through Vol 9, 1979)
APPENDIX 10: NCI/NTP BIOASSAYS
EVALUATED AS INADEQUATE IN
TECHNICAL REPORTS
Experiments Evaluated
Chemical Name as Inadequate
4-VINYLCYCLOHEXENE rats, male mice
APPENDIX 11:
AUTHOR'S OPINION CODES AND DEFINITIONS
Code Author's Opinion for Each Site
c NTP evaluation is clear evidence of carcinogenic
activity: studies that are interpreted as showing a
dose-related (i) increase of malignant neoplasms, (ii)
increase of a combination of malignant and benign
neoplasms, or (iii) marked increase of benign neo-
plasms if there is an indication from this or other
studies of the ability of such tumors to progress to
malignancy.
e NTP evaluation is equivocal evidence of carcinogenic
activity: studies that are interpreted as showing a
marginal increase of neoplasms that may be chemi-
cally related.
p NTP evaluation is some evidence of carcinogenic
activity: studies that are interpreted as showing a
chemically related increased incidence of neoplasms
(malignant, benign, or combined) in which the
strength of the response is less than that required for
clear evidence.
+ Author in general literature evaluated site as posi-
tive.
- NTP evaluation is no evidence of carcinogenic
activity: studies that are interpreted as showing no
chemically related increases in malignant or benign
neoplasms; or author in general literature evaluated
site as negative.
blank For NTP and general literature: all other sites.
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APPENDIX 13:
Bibliography: National Cancer Institute/
National Toxicology Program Technical Reports
TECHNICAL PUBLICATION
CHEMICAL NAME REPORT NUMBER DATE
AMPICILLIN TRIHYDRATE 318 1987
BENZYL ACETATE 250 1986
CHLORENDIC ACID 304 1987
CHLORINATED TRISODIUM PHOSPHATE 294 1986
3-CHLORO-2-METHYLPROPENE (TECHNICAL GRADE CONTAINING
5% DIMETHYLVINYL CHLORIDE) 300 1986
CHLORPHENIRAMINE MALEATE 317 1986
1,4-DICHLOROBENZENE 319 1987
1,2-DICHLOROPROPANE 263 1986
DIGLYCIDYL RESORCINOL ETHER (TECHNICAL GRADE) 257 1986
DIMETHYLVINYL CHLORIDE 316 1986
ETHYL ACRYLATE 259 1986
METHYL METHACRYLATE 314 1986
OXYTETRACYCLINE HYDROCHLORIDE 315 1987
PENTACHLORONITROBENZENE 325 1987
PHENYLEPHRINE HYDROCHLORIDE 322 1987
TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM CHLORIDE 296 1987
TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM SULFATE 296 1987
TOLUENE DIISOCYANATE, COMMERCIAL GRADE (2,4 (80%)- AND 2,6 (20%)-) 251 1986
4-VINYLCYCLOHEXENE 303 1986
XYLENES (MIXED) (60% m-, 14% p-, 9% o-, 17% ETHYLBENZENE) 327 1986
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APPENDIX 14: INDEX TO CHEMICAL NAMES IN ALL PLOTS
CAS
PLOT NUMBER CHEMICAL NAME
CAS






















































































C.I. ACID RED 14, DISODIUM SALT














AGERITE 150 (see p-ISOPROPOXYDIPHENYLAMINE)
AGERITE ALBA (see HYDROQUINONE MONOBENZYL
ETHER)
AGERITE DPPD (see DIPHENYL-p-PHENYLENEDIAMINE)
AGERITE POWDER (see PHENYL-beta-NAPHTHYLAMINE)















ALTAX (see BENZOTHIAZYL DISULFIDE)
ALUMINUM POTASSIUM SULFATE

























































































































































































PLOT NUMBER CHEMICAL NAME




4 67-52-7 BARBITURIC ACID
1 543-80-6 BARIUM ACETATE
1 542-88-1 BCME (see BIS-(CHLOROMETHYL)ETHER)
1,3,4 71-43-2 BENZENE
1 319-84-6 alpha-BENZENE HEXACHLORIDE (see alpha-1,2,3,4,5,6-
HEXACHLOROCYCLOHEXANE)
2 369-57-3 BENZENEDIAZONIUM TETRAFLUOROBORATE
1 5351-65-5 BENZENESULPHONOHYDRAZIDE










1 120-78-5 BENZOTHIAZYL DISULFIDE
1 95-14-7 1H-BENZOTRIAZOLE
1 613-94-5 BENZOYL HYDRAZINE
1,2,3 50-32-8 BENZPYRENE (see BENZO(a)PYRENE)
1,2,3 50-32-8 3,4-BENZPYRENE (see BENZO(a)PYRENE)
4 140-11-4 BENZYL ACETATE
4 100-44-7 BENZYL CHLORIDE
1,3 1694-09-3 BENZYL VIOLET 4B (see FD & C
1 20570-96-1 BENZYLHYDRAZINE.2HCl
1 13510-49-1 BERYLLIUM SULFATE
2,3,4 25013-16-5 BHA (see BUTYLATED HYDROXYANISOLE)




















BENZAMIDE ACETATE (see FLECAINIDE ACETATE)
1 21260-46-8 BISMATE (see BISMUTH DIMETHYLDITHIOCARBAMATE)
1 21260-46-8 BISMUTH DIMETHYLDITHIOCARBAMATE
1 7787-59-9 BISMUTH OXYCHLORIDE
2 80-05-7 BISPHENOL A
1 2519-30-4 BLACK PN
1 1937-37-7 C.I. DIRECT BLACK 38
1 2602-46-2 C.I. DIRECT BLUE 6
3 2475-45-8 C.I. DISPERSE BLUE 1
1 3844-45-9 FD & C BLUE NO. 1
1,4 860-22-0 FD & C BLUE NO. 2
3 2784-94-3 HC BLUE NO. 1
3 33229-34-4 HC BLUE NO. 2
1 109-84-2 BOH (see 2-HYDROXYETHYLHYDRAZINE)
1 99-30-9 BOTRAN (see 2,6-DICHLORO-4-NITROANILINE)
1 2519-30-4 BRILLIANT BLACK BN (see
1 3844-45-9 BRILLIANT BLUE FCF (see FD
1,2 5160-02-1 BRILLIANT RED (see D & C RED 9)




PLOT NUMBER CHEMICAL NAME
1 77-65-6 BROMODIETHYLACETYLUREA (see
4 BROMOETHANOL
1 16071-86-6 C.I. DIRECT BROWN 95
1 5351-65-5 BSH (see BENZENESULPHONOHYDRAZIDE)
1 55-98-1 BUSULFAN (see MYLERAN)
1 51-03-6 BUTACIDE (see PIPERONYL BUTOXIDE
3 106-99-0 1,3-BUTADIENE
4 123-73-9 trans-2-BUTENAL (see CROTONALDEHYDE)
2 85-68-7 BUTYL BENZYL PHTHALATE
1,3,4 3817-11-6 BUTYL-BUTANOL-NITROSAMINE (see N-BUTYL-N-
(4-HYDROXYBUTYL)NITROSAMINE)
3 109-69-3 N-BUTYL CHLORIDE
1 88-85-7 2-sec-BUTYL-4,6-DINITROPHENOL
1 N-N-BUTYL-N-FORMYLHYDRAZINE
2,3,4 25013-16-5 2(3)-tert-BUTYL-4-HYDROXYANISOLE (see
HYDROXYANISOLE)





1 136-23-2 BUTYL ZIMATE (see ZINC DIBUTYLDITHIOCARBAMATE)
2,3,4 25013-16-5 BUTYLATED HYDROXYANISOLE






1 75-60-5 CACODYLIC ACID (see DIMETHYLARSINIC
1 543-90-8 CADMIUM ACETATE
1 35658-65-2 CADMIUM CHLORIDE MONOHYDRATE
1 14239-68-0 CADMIUM DIETHYLDITHIOCARBAMATE
1 7790-84-3 CADMIUM SULPHATE
1,2,3 58-08-2 CAFFEINE
1 8003-03-0 CAFFEINE, ASPIRIN, AND PHENACETIN
PHENACETIN, AND CAFFEINE)
4 62-54-4 CALCIUM ACETATE




1 149-30-4 CAPTAX (see 2-MERCAPTOBENZOTHIAZOLE)





1,3 56-23-5 CARBON TETRACHLORIDE
1,3 60391-92-6 CARBOXYMETHYLNITROSOUREA
1 77-65-6 CARBROMAL
1,2 3567-69-9 CARMOISINE (see C..L FOOD
2 9000-40-2 CAROB SEED GUM (see LOCUST
1,2 CARRAGEENAN, ACID-DEGRADED
1 9000-07-1 CARRAGEENAN, NATIVE
4 120-80-9 CATECHOL
1 999-81-5 CCC (see (2-CHLOROETHYL)TRIMETHYLAMMONIUM
CHLORIDE)
1 122-34-9 CDT (see SIMAZINE)
1 9004-32-4 CELLULOSE CARBOXYMETHYL
(see EDIFAS B)
1 474-25-9 CHENODEOXYCHOLIC ACID





1 106-47-8 4-CHLORANILIC (see p-CHLOROANILINE)
1,2 57-74-9 CHLORDANE
1 143-50-0 CHLORDECONE (see KEPONE)
4 115-28-6 CHLORENDIC ACID
1 80-33-1 CHLORFENSON (see p-CHLOROPHENYL-p-
CHLOROBENZENE SULFONATE)
3 63449-39-8 CHLORINATED PARAFFINS (C12,
276GOLD ETAL.
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PLOT NUMBER CHEMICAL NAME
3 63449-39-8 CHLORINATED PARAFFINS (C23, 43% CHLORINE)
4 56802-99-4 CHLORINATED TRISODIUM PHOSPHATE
1 7782-50-5 CHLORINE





4 563-47-3 3-CHLORO-2-METHYLPROPENE, TECHNICAL GRADE





1 61702-44-1 2-CHLORO-p-PHENYLENEDIAMINE SULFATE


















1 999-81-5 (2-CHLOROETHYL)TRIMETHYLAMMONIUM CHLORIDE
3 593-70-4 CHLOROFLUOROMETHANE (see FLUOROCARBON 31)
1,4 67-66-3 CHLOROFORM
1 107-30-2 CHLOROMETHYL METHYL ETHER
1 6959-47-3 2-(CHLOROMETHYL)PYRIDINE.HCI
1 6959-48-4 3-(CHLOROMETHYL)PYRIDINE.HCI
1 56-75-7 CHLOROMYCETIN (see CHLORAMPHENICOL)
1 100-00-5 p-CHLORONITROBENZENE (see 1-CHLORO-4-
NITROBENZENE)









1 107-05-1 CHLOROPROPENE (see ALLYL CHLORIDE)
1 590-21-6 1-CHLOROPROPENE
1 1897-45-6 CHLOROTHALONIL
3 63449-39-8 CHLOROWAX 40 (see CHLORINATED PARAFFINS
(C23, 43% CHLORINE))
3 63449-39-8 CHLOROWAX 500c (see CHLORINATED PARAFFINS
(C12, 60% CHLORINE))
1 54749-90-5 CHLOROZOTOCIN
3,4 113-92-8 CHLORPHENIRAMINE MALEATE
1 94-20-2 CHLORPROPAMIDE
1 101-21-3 CHLORPROPHAM (see ISOPROPYL-N-(3-
CHLOROPHENYL)CARBAMATE)
1 2921-88-2 CHLORPYRIFOS (see O,O-DIETHYL-O-(3,5,6-
TRICHLORO-2-PYRIDYL) PHOSPHOROTHIOATE)
1 12236-46-3 CHOCOLATE BROWN FB
1 4553-89-3 CHOCOLATE BROWN HT
4 67-48-1 CHOLINE CHLORIDE
1 1308-38-9 CHROMIC OXIDE PIGMENT
1 1066-30-4 CHROMIUM (III) ACETATE
4 117-10-2 CHRYSAZIN
2 87-29-6 CINNAMYL ANTHRANILATE









1 43054-45-1 CLOMIPHENE CITRATE
1 1420-04-8 CLONITRALID
3 55600-34-5 CLOPHEN A 30
1,3 11096-82-5 CLOPHEN A 60 (see AROCLOR 1260)
4 7681-52-9 CLOROX (see SODIUM HYPOCHLORITE)
1 107-30-2 CMME (see CHLOROMETHYL METHYL ETHER)
1,3 60391-92-6 CMNU (see CARBOXYMETHYLNITROSOUREA)
1 477-30-5 COLCEMID
3 65765-07-3 COMPOUND 50-892
1 --- CONJUGATED EQUINE ESTROGENS (see PREMARIN)
1 137-29-1 COPPER DIMETHYLDITHIOCARBAMATE
1 10380-28-6 COPPER-8-HYDROXYQUINOLINE
1 56-72-4 COUMAPHOS




1 137-29-1 CUMATE (see COPPER DIMETHYLDITHIOCARBAMATE)
1 135-20-6 CUPFERRON









1 95-33-0 N-CYCLOHEXYL-2-BENZOTHIAZOLE SULFENAMIDE
1 4998-76-9 CYCLOHEXYLAMINE.HCI
1 19834-02-7 CYCLOHEXYLAMINE SULFATE
1,3 50-18-0 CYCLOPHOSPHAMIDE
2 16170-75-5 CYTEMBENA
2 538-41-0 DAAB (see 4,4'-DIAMINOAZOBENZENE)
1 60-11-7 DAB (see N,N-DIMETHYL-4-AMINOAZOBENZENE)
2 785-30-8 DABA (see 4,4'-DIAMINOBENZANILIDE)
1 4342-03-4 DACARBAZINE
1 1897-45-6 DACONIL (see CHLOROTHALONIL)
1 1596-84-5 DAMINOZIDE
4 117-10-2 DANTHRON (see CHRYSAZIN)
1 80-08-0 DAPSONE
1 58-14-0 DARAPRIN (see PYRIMETHAMINE)
1 96-12-8 DBCP (see 1,2-DIBROMO-3-CHLOROPROPANE)
1 488-41-5 DBM (see DIBROMOMANNITOL)
1 91-94-1 DCB (see 3,3'-DICHLOROBENZIDINE)





1 62-73-7 DDVP (see DICHLORVOS)
3 1163-19-5 DECABROMODIPHENYL OXIDE
1 576-68-1 DEGRANOL (see MANNITOL NITROGEN MUSTARD)
1 520-45-6 DEHYDROACETIC ACID (see 3-ACETYL-6-METHYL-2,
4-PYRANDIONE)
1,3 55-18-5 DEN (see N-NITROSODIETHYLAMINE)
1 625-89-8 6-F-DEN (see N-NITROSOBIS(2,2,2-
TRIFLUOROETHYL)AMINE)
1 64039-27-6 beta-2'-DEOXY-6-THIOGUANOSINE MONOHYDRATE
(see beta-THIOGUANINE DEOXYRIBOSIDE)
1 56-53-1 DES (see DIETHYLSTILBESTROL)
1 131-01-1 DESERPIDINE
3 9004-54-0 DEXTRAN
2,3 9011-18-1 DEXTRAN SULFATE SODIUM (DS-M-1)
3 9011-18-1 DEXTRAN SULFATE SODIUM (DST-H)
3 9011-18-1 DEXTRAN SULFATE SODIUM (KMDS-H)
1 --- N-1-DIACETAMIDOFLUORENE
3 3148-73-0 DIACETYL HYDRAZINE
1 2303-16-4 DIALLATE
3 131-17-9 DIALLYL PHTHALATECHRONOLOGICAL SUPPLEMENT
CAS
PLOT NUMBER CHEMICAL NAME
CAS



































































































DICHLOREN (see NITROGEN MUSTARD)




























2,4-DICHLOROPHENOXYACETIC ACID, N-BUTYL ESTER

















































































































































PLOT NUMBER CHEMICAL NAME
1 51-28-5 2,4-DINITROPHENOL







1 123-91-1 p-DIOXANE (see 1,4-DIOXANE)
1 78-34-2 DIOXATHION
1 1746-01-6 DIOXIN (see 2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN)






1 86-30-6 DIPHENYLNITROSAMINE (see N-
NITROSODIPHENYLAMINE)
1 --- N,N-DIPROPYL-4-(4'-1PYRIDYL-l'-OXIDE]AZO)ANILINE
3 621-64-7 DIPROPYLNITROSAMINE (see N-
NITROSODIPROPYLAMINE)
3,4 68-89-3 DIPYRONE
1 142-59-6 DISODIUM ETHYLENEBISDITHIOCARBAMATE (see
ETHYLENEBISDITHIOCARBAMATE, DISODIUM)
1 7757-82-6 DISODIUM SULFATE (see SULFATE, SODIUM)
1 97-77-8 DISULFIRAM (see TETRAETHYLTHIURAM DISULFIDE)




1 330-54-1 DIURON (see 3-(3,4-DICHLOROPHENYL)-
1,1-DIMETHYLUREA)
1 1596-84-5 DMASA (see DAMINOZIDE)
1 57-97-6 DMBA (see 7,12-DIMETHYLBENZ(a)ANTHRACENE)
3 868-85-9 DMHP (see DIMETHYL HYDROGEN PHOSPHITE)
1,2,3 62-75-9 DMN (see N-NITROSODIMETHYLAMINE)
1 120-61-6 DMT (see DIMETHYL TEREPHTHALATE)
1 2439-10-3 N-DODECYLGUANIDINE ACETATE
1 2439-10-3 DODINE (see n-DODECYLGUANIDINE ACETATE)
1,3 90-43-7 DOWICIDE-1 (see o-PHENYLPHENOL)
1 88-06-2 DOWICIDE-2S (see 2,4,6-TRICHLOROPHENOL)
1,3 87-86-5 DOWICIDE-7 (see 2,3,4,5,6-PENTACHLOROPHENOL)
2,3 9011-18-1 DS-M-1 (see DEXTRAN SULFATE SODIUM (DS-M-1))
3 9011-18-1 DST-H (see DEXTRAN SULFATE SODIUM (DST-H))
1 95-33-0 DURAX (see N-CYCLOHEXYL-2-BENZOTHIAZOLE
SULFENAMIDE)
1,4 106-93-4 EDB (see 1,2-DIBROMOETHANE)
1 107-06-2 EDC (see 1,2-DICHLOROETHANE)
1 9004-59-5 EDIFAS A
1 9004-32-4 EDIFAS B
1 150-38-9 EDTA (see EDTA, TRISODIUM SALT TRIHYDRATE)
1 150-38-9 EDTA, TRISODIUM SALT TRIHYDRATE
1 316-42-7 EMETINE.2HCI
1 55965-13-4 EMULSIFIER YN
1 115-29-7 ENDOSULFAN





3 759-73-9 ENU (see 1-ETHYL-1-NITROSOUREA)
3 134-72-5 EPHEDRINE SULPHATE
1,4 106-89-8 EPICHLOROHYDRIN
2,3 75-56-9 1,2-EPOXYPROPANE (see 1,2-PROPYLENE OXIDE)
3 6381-77-7 ERYTHORBATE, SODIUM
1 16423-68-0 ERYTHROSINE (see FD & C RED NO. 3)
1 50-28-2 ESTRADIOL
1 50-28-2 ESTRADIOL-17bets (see ESTRADIOL)
1 22966-79-6 ESTRADIOL MUSTARD
3 140-67-0 ESTRAGOLE









4 140-88-5 ETHYL ACRYLATE
1,2,3,4 64-17-5 ETHYL ALCOHOL
4 16301-26-1 Z-ETHYL-O,N,N-AZOXYETHANE
4 57497-29-7 Z-ETHYL-O,N,N-AZOXYMETHANE
4 100-41-4 ETHYL BENZENE
1 105-36-2 ETHYL BROMOACETATE







2 77-83-8 ETHYL METHYLPHENYLGLYCIDATE
1 63885-23-4 N-ETHYL-N'-NITRO-N-NITROSOGUANIDINE
3 759-73-9 1-ETHYL-1-NITROSOUREA
3 759-73-9 N-ETHYL-N-NITROSOUREA (see 1-ETHYL-1-
NITROSOUREA)
2 614-95-9 1-ETHYL-1-NITROSOURETHAN (see
NITROSOETHYLURETHAN)
1 5456-28-0 ETHYL SELENAC (see SELENIUM
DIETHYLDITHIOCARBAMATE)
1 20941-65-5 ETHYL TELLURAC
1 97-77-8 ETHYL TUADS (see TETRAETHYLTHIURAM
DISULFIDE)
1 14324-55-1 ETHYL ZIMATE (see ZINC
DIETHYLDITHIOCARBAMATE)
1,4 106-93-4 ETHYLENE DEBROMIDE (see 1,2-DIBROMOETHANE)
1 107-06-2 ETHYLENE DICHLORIDE (see 1,2-DICHLOROETHANE)
1 1072-53-3 ETHYLENE GLYCOL
1 151-56-4 ETHYLENE IMINE
2,3 75-21-8 ETHYLENE OXIDE
1 96-45-7 ETHYLENE THIOUREA
1 120-93-4 ETHYLENE UREA






3 759-73-9 ETHYLNITROSOUREA (see 1-ETHYL-1-NITROSOUREA)
1 842-00-2 4-ETHYLSULPHONYLNAPHTHALENE-1-SULFONAMIDE
1 297-76-7 ETHYNODIOL DIACETATE
1 8056-92-6 ETHYNODIOL DIACETATE/ETHINYL ESTRADIOL 110:11
(see OVULEN)
1 96-45-7 ETU (see ETHYLENE THIOUREA)
1 470-82-6 EUCALYPTOL
3 97-53-0 EUGENOL
1,2,3,4 24554-26-5 FANFT (seeN-14-(5-NITRO-2-FURYL)-2-THIAZOLYLI
FORMAMIDE)
1 2353-45-9 FAST GREEN FCF (see FD & C GREEN NO. 3)
1 140-56-7 FENAMINOSULF, FORMULATED
1 55-38-9 FENTHION
3 51630-58-1 FENVALERATE
1 14484-64-1 FERBAM (see FERRIC DIMETHYLDITHIOCARBAMATE)
1 14484-64-1 FERRIC DIMETHYLDITHIOCARBAMATE
1 mixture FERRIC NITROSODIMETHYLDITHIOCARBAMATE AND
TETRAMETHYLTHIURAM
DISULFIDE (see VANGUARD GF)
3 67774-32-7 FIREMASTER FF-1 (see POLYBROMINATEDBIPHENYL
MIXTURE)
3 54143-56-5 FLECAINIDE ACETATE
2 2164-17-2 FLUOMETURON
1 363-17-7 N-(2-FLUORENYL)-2,2,2-TRIFLUOROACETAMIDE
1,2,3,4 53-96-3 FLUORENYLACETAMIDE (see 2-
ACETYLAMINOFLUORENE)
1 28314-03-6 N-1-FLUORENYLACETAMIDE (see 1-
ACETYLAMINOFLUORENE)
1,2,3,4 53-96-3 N-2-FLUORENYLACETAMIDE (see 2-
ACETYLAMINOFLUORENE)CHRONOLOGICAL SUPPLEMENT
CAS
PLOT NUMBER CHEMICAL NAME
1 28322-02-3 N-4-FLUORENYLACETAMIDE (see 4-
ACETYLAMINOFLUORENE)
1 --- N-1-FLUORENYLDIACETAMIDE (see N-1-
DIACETAMIDOFLUORENE)
1,3 7681-49-4 FLUORIDE, SODIUM
1 324-93-6 4'-FLUORO-4-AMINODIPHENYL




3 593-70-4 FLUOROCARBON 31
3 75-88-7 FLUOROCARBON 133a
1 51-21-8 5-FLUOROURACIL
1 3570-75-0 FNT (see FORMIC ACID 2-[4-(5-NITRO-2-FURYL)-2-
THIAZOLYL]HYDRAZIDE)
1 133-07-3 FOLPET (see N-(TRICHLOROMETHYLTHIO)
PHTHALIMIDE)
2,3,4 50-00-0 FORMALDEHYDE
1 31873-81-1 FORMIC ACID 2-[4-(2-FURYL)-2-THIAZOLYL]HYDRAZIDE
1 32852-21-4 FORMIC ACID 2-(4-METHYL-2-THIAZOLYL)HYDRAZIDE
1 3570-75-0 FORMIC ACID 2-[4-(5-NITRO-2-FURYL)-2-
THIAZOLYLJHYDRAZIDE




3,4 75-09-2 FREON 30 (see METHYLENE CHLORIDE)








1 97-16-5 GENITE-R99 (see 2,4-DICHLOROPHENYLBENZENE
SULFONATE)
4 548-62-9 GENTIAN VIOLET
1 --- GERMANATE, SODIUM
1 139-40-2 GESAMIL (see PROPAZINE)
1 77-06-5 GIBBERELLIC ACID
3 67730-11-4 GLU-P-1 (see 2-AMINO-6-METHYLDIPYRIDO[1,2-a:3',
2'-d]IMIDAZOLE)
3 67730-10-3 GLU-P-2 (see 2-AMINODIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE)
3 56-86-0 L-GLUTAMIC ACID
2 2757-90-6 beta-N-1gamma-L(+)-GLUTAMYL]-4-
HYDROXYMETHYLPHENYLHYDRAZINE
1 96-24-2 GLYCEROL alpha-MONOCHLOROHYDRIN
1 765-34-4 GLYCIDALDEHYDE
1 1072-53-3 GLYCOL SULFATE (see ETHYLENE GLYCOL)
1 3741-38-6 GLYCOL SULFITE
4 71277-79-7 GLYCYRRHIZINATE, DISODIUM
1 4680-78-8 FD & C GREEN NO. 1
1 5141-20-8 FD & C GREEN NO. 2
1 2353-45-9 FD & C GREEN NO. 3
1 126-07-8 GRISEOFULVIN
2 9000-30-0 GUAR GUM
1 4680-78-8 GUINEA GREEN B (see FD & C GREEN NO. 1)
2 9000-01-5 GUM ACACIA (see GUM ARABIC)
2 9000-01-5 GUM ARABIC
1 86-50-0 GUSATHION (see AZINPHOSMETHYL)
1,4 118-74-1 HCB (see HEXACHLOROBENZENE)





1 2163-79-3 HERCULES-7531 (see 3-(HEXAHYDRO-4,7-
METHANOINDAN-5-YL)-1,1-DIMETHYLUREA)
















1 26049-68-3 HNT (see 2-HYDRAZINO-4-(5-NITRO-2-FURYL)
THIAZOLE)
4 1415-93-6 HUMIC ACIDS, COMMERCIAL GRADE
1,4 302-01-2 HYDRAZINE





1 619-67-0 p-HYDRAZINOBENZOIC ACID
1 122-66-7 HYDRAZOBENZENE
4 7647-01-0 HYDROCHLORIC ACID
1 50-23-7 HYDROCORTISONE
4 7647-01-0 HYDROGEN CHLORIDE (see HYDROCHLORIC ACID)
1 7722-84-1 HYDROGEN PEROXIDE
1 103-16-2 HYDROQUINONE MONOBENZYL ETHER





2 119-53-9 2-HYDROXY-1,2-DIPHENYLETHANONE (see BENZOIN)
1,3 53-95-2 HYDROXY-N-2-FLUORENYLACETAMIDE (see N-
HYDROXY-2-ACETYLAMINOFLUORENE)








1 --- HYDROXYPROPYL DISTARCH GLYCEROL
1,2,3 148-24-3 8-HYDROXYQUINOLINE
1,3 5208-87-7 1'-HYDROXYSAFROLE
4 7681-52-9 HYPOCHLOROUS ACID, SODIUM SALT (see SODIUM
HYPOCHLORITE)
1 21416-87-5 ICRF-159
1 120-93-4 2-IMIDAZOLIDINONE (see ETHYLENE UREA)
1 3458-22-8 3,3'-IMINOBIS-1-PROPANOL DIMETHANESULFONATE
(ESTER).HCI
1 32607-00-4 IMINODIACETIC ACID, MONOSODIUM
1,4 860-22-0 INDIGO CARMINE (see FD & C BLUE NO.2)
1 87-51-4 INDOLE-3-ACETIC ACID
1,2,3 54-85-3 INH (see ISONIAZID)
4 144-48-9 IODOACETAMIDE
1 75-47-8 IODOFORM
1 122-42-9 IPC (see ISOPROPYL-N-PHENYL CARBAMATE)
1 3458-22-8 IPD (see 3,3'-IMINOBIS-1-PROPANOL
DIMETHANESULFONATE(ESTER).HCI)
3,4 76180-96-6 IQ (see 2-AMINO-3-METHYLIMIDAZC14,5-f1QUINOLINE)
4 --- IQ.HCl (see 2-AMINO-3-METHYLIMIDAZO[4,5-f1
QUINOLINE.HCI)
3 6381-77-7 ISOASCORBATE (see ERYTHORBATE, SODIUM)
1 297-78-9 ISOBENZAN (see TELODRIN)
4 4247-02-3 ISOBUTYL p-HYDROXYBENZOATE
1 5461-85-8 N-ISOBUTYL-N'-NITRO-N-NITROSOGUANIDINE
3 760-60-1 N-ISOBUTYL-N-NITROSOUREA (see N-NITROSO-N-
ISOBUTYLUREA)




1 55-22-1 ISONICOTINIC ACID
1,2,3 54-85-3 ISONICOTINIC ACID HYDRAZIDE (see ISONIAZID)
280GOLD ETAL.
CAS
PLOT NUMBER CHEMICAL NAME











1 122-42-9 ISOPROPYL-N-PHENYL CARBAMATE
2 80-05-7 4,4'-ISOPROPYLIDENEDIPHENOL (see BISPHENOL A)
1 120-58-1 ISOSAFROLE
3 520-18-3 KAEMPFEROL
4 12737-87-0 KANECHLOR 400
1 6119-92-2 KARATHANE (see DINITRO(1-METHYLHEPTYL)
PHENYL CROTONATE)
1 330-54-1 KARMEX (see 3-(3,4-DICHLOROPHENYL)-1,1-
DIMETHYLUREA)
1 115-32-2 KELTHANE (see DICOFOL)
1 143-50-0 KEPONE
3 9011-18-1 KMDS-H (see DEXTRAN SULFATE SODIUM (KMDS-H))
1 303-34-4 LASIOCARPINE
1,4 301-04-2 LEAD ACETATE
1,4 1335-32-6 LEAD ACETATE, BASIC
1 19010-66-3 LEAD DIMETHYLDITHIOCARBAMATE
1,4 1335-32-6 LEAD SUBACETATE (see LEAD ACETATE, BASIC)
1 19010-66-3 LEDATE (see LEAD DIMETHYLDITHIOCARBAMATE)
1 24365-47-7 LEUPEPTIN
1 5141-20-8 LIGHT GREEN SF YELLOWISH (see FD & C GREEN
NO. 2)
1 58-89-9 LINDANE (see gamma-1,2,3,4,5,6-
HEXACHLOROCYCLOHEXANE)
1 434-13-9 LITHOCHOLIC ACID




1,3 67-20-9 MACRODANTIN (see 1-1(5-NITROFURFURYLIDENE)
AMINOIHYDANTOIN)
1,2 632-99-5 MAGENTA I (see ROSANILINE.HC1)
1,2,3 569-61-9 p-MAGENTA (see p-ROSANILINE.HCI)




1 1634-78-2 MALATHION-O-ANALOG (see MALAOXON)
1,2 123-33-1 MALEIC HYDRAZIDE
2 24382-04-5 MALONALDEHYDE, SODIUM
1 mixture MAM ACETATE AND CYCASIN MIXTURE (see
METHYLAZOXYMETHANOL ACETATE AND
CYCASIN MIXTURE)
1 12427-38-2 MANEB (see MANGANESE
ETHYLENEBISTHIOCARBAMATE)
1 12427-38-2 MANGANESE ETHYLENEBISTHIOCARBAMATE
2 69-65-8 D-MANNITOL
1 576-68-1 MANNITOL NITROGEN MUSTARD
3 68006-83-7 MeA-alpha-C (see 2-AMINO-3-METHYL-9H-
PYRIDO-12,3-bl-INDOLE)







1 155-04-4 2-MERCAPTOBENZOTHIAZOLE, ZINC
3 19767-45-4 2-MERCAPTOETHANESULFONATE, SODIUM
1 50-44-2 6-MERCAPTOPURINE
















1 5834-17-3 2-METHOXY-3-DIBENZOFURANAMINE (see 2-
METHOXY-3-AMINODIBENZOFURAN)
1 72-43-5 METHOXYCHLOR
1 1701-77-5 METHOXYPHENYLACETIC ACID
4 563-47-3 METHYL ALLYL CHLORIDE (see 3-CHLORO-2-
METHYLPROPENE, TECHNICAL GRADE
(CONTAINING 5% DIMETHYLVINYL CHLORIDE))
4 57497-34-4 Z-METHYL-O,N,N-AZOXYETHANE
3 25843-45-2 Z-METHYL-O,N,N-AZOXYMETHANE (see
AZOXYMETHANE)
1 6294-89-9 METHYL CARBAZATE
1 71-55-6 METHYL CHLOROFORM (see 1,1,1-
TRICHLOROETHANE)






1 9004-59-5 METHYL ETHYL CELLULOSE (see EDIFAS A)
1,2 758-17-8 N-METHYL-N-FORMYLHYDRAZINE
2 27323-65-5 METHYL LINOLEATE HYDROPEROXIDE
2 --- METHYL LINOLEATE, NATIVE
4 80-62-6 METHYL METHACRYLATE










1 684-93-5 N-METHYL-N-NITROSOUREA (see N-NITROSO-N-
METHYLUREA)
1 140-56-7 METHYL ORANGE B (see FENAMINOSULF,
FORMULATED)
3 21308-79-2 METHYL 12-OXO-trmns-10-OCTADECENOATE
1 298-00-0 METHYL PARATHION
1,3 614-00-6 METHYL-PHENYL-NITROSAMINE (see
NITROSOMETHYLANILINE)
1 144-34-3 METHYL SELENAC (see SELENIUM
DIMETHYLDITHIOCARBAMATE)




1 mixture METHYLAZOXYMETHANOL ACETATE AND
CYCASIN MIXTURE












1 302-15-8 METHYLHYDRAZINE SULFATE
1 115-09-3 METHYLMERCURIC ACETATE (see
MERCURYMETHYLCHLORIDE)CHRONOLOGICAL SUPPLEMENT
CAS
PLOT NUMBER CHEMICAL NAME











1 90-94-8 MICHLER'S KETONE
1,3 137-30-4 MILBAM (see ZINC DIMETHYLDITHIOCARBAMATE)
1 2385-85-5 MIREX
1 39801-14-4 MIREX, PHOTO-
1 126-85-2 MITOMEN (see NITROGEN MUSTARD N-OXIDE)
1 50-07-7 MITOMYCIN-C
1 66-27-3 MMS (see METHYL METHANESULFONATE)
1,2,3,4 70-25-7 MNNG (see N-METHYL-N'-NITRO-N-
NITROSOGUANIDINE)
1 684-93-5 MNU (see N-NITROSO-N-METHYLUREA)
1 101-14-4 MOCA (see 4,4'-METHYLENE-BIS(2-CHLOROANILINE))
3 1068-57-1 MONOACETYL HYDRAZINE
1 79-11-8 MONOCHLOROACETIC ACID
3 108-90-7 MONOCHLOROBENZENE (see CHLOROBENZENE)
3 315-22-0 MONOCROTALINE
3 32221-81-1 DL-MONOSODIUM GLUTAMATE
3 142-47-2 L-MONOSODIUM GLUTAMATE
1 32607-00-4 MONOSODIUM IMINODIACETIC ACID (see
IMINODIACETIC ACID, MONOSODIUM)






1 87-56-9 MUCOCHLORIC ACID (see alpha,beta-DICHLORO-beta-
FORMYLACRYLIC ACID)
1 55-98-1 MYLERAN
1 142-59-6 NABAM (see ETHYLENEBISDITHIOCARBAMATE,
DISODIUM)
1 86-86-2 1-NAPHTHALENE ACETAMIDE






1,2 91-59-8 beta-NAPHTHYLAMINE (see 2-NAPHTHYLAMINE)
2 81-16-3 2-NAPHTHYLAMINO,1-SULFONIC ACID
2 81-16-3 NAS (see 2-NAPHTHYLAMINO,1-SULFONIC ACID)
1 2611-82-7 NEW COCCINE (see SX PURPLE)
1 531-82-8 NFTA (see N-14-(5-NITRO-2-FURYL)-2-THIAZOLYLI
ACETAMIDE)
1 7440-02-0 NICKEL
1 373-02-4 NICKEL (II) ACETATE
1 13927-77-0 NICKEL DIBUTYLDITHIOCARBAMATE




2 59-67-6 NICOTINIC ACID
1 553-53-7 NICOTINIC ACID HYDRAZIDE
1 --- NIGROSINE
1 12034-09-2 NIOBATE, SODIUM
1 139-94-6 NITHIAZIDE
1,2 7631-99-4 NITRATE, SODIUM
1 10102-43-9 NITRIC OXIDE
1 139-13-9 NITRILOTRIACETIC ACID
1 18662-53-8 NITRILOTRIACETIC ACID, TRISODIUM SALT,
MONOHYDRATE
































































126-85-2 NITROGEN MUSTARD N-OXIDE



















































































1 25081-31-6 NITROSOIMINODIACETIC ACID
3 86451-37-8 N-NITROSOMETHYL-2,3-DIHYDROXYPROPYLAMINE









1 684-93-5 NITROSOMETHYLUREA (see N-NITROSO-N-
METHYLUREA)




3,4 39884-52-1 NITROSOOXAZOLIDONE (see N-NITROSO-1,3-
OXAZOLIDINE)
1 4515-18-8 NITROSOPIPECOLIC ACID
1 5632-47-3 NITROSOPIPERAZINE (see N-NITROSOPIPERAZINE)








1 mixture beta-NITROSTYRENE AND STYRENE MIXTURE (see
STYRENE AND beta-NITROSTYRENE MIXTURE)
4 10024-97-2 NITROUS OXIDE
4 115-28-6 5-NORBENE-2,3-DIMETHANOL (see CHLORENDIC ACID)
1 68-23-5 NORETHYNODREL
1 --- NORETHYNODREL/MESTRANOL 125:11 (see ENOVID-E)














































































































































PCBs (see AROCLOR 1254)
PCBs (see AROCLOR 1260)
















































PLOT NUMBER CHEMICAL NAME
CAS
















































































PHOTODIELDRIN (see DIELDRIN, PHOTO-)
PHOTOMIREX (see MIREX, PHOTO-)
PHTHALAMIDE
PHTHALIC ANHYDRIDE










PIPERONYL BUTOXIDE IN SOLVENT
PIPERONYL SULFOXIDE
PIVALOLACTONE
PLANOFIX (see 1-NAPHTHALENE ACETIC ACID)
POLYBROMINATED BIPHENYL MIXTURE
POLYBROMINATED BIPHENYLS
POLYCHLORINATED BIPHENYLS (see AROCLOR 1254)
POLYCHLORINATED BIPHENYLS (see AROCLOR 1260)
POLYCHLORINATED BIPHENYLS (see KANECHLOR 400)
POLYVINYLPYRIDINE-N-OXIDE
PONCEAU 3R (see FD & C RED NO. 1)
PONCEAU 4R (see SX PURPLE)
PONCEAU MX (see D & C RED NO. 5)
PONCEAU SX (see FD & C RED NO. 4)
POTASSIUM BROMATE (see BROMATE, POTASSIUM)
POTASSIUM CHLORIDE





















































































































C.I. BASIC RED 9.HCI (see p-ROSANILINE.HCI)
C.I. FOOD RED 3
D & C RED NO. 5
D & C RED NO. 9
D & C RED NO. 10
FD & C RED NO. 1
FD & C RED NO. 2
FD & C RED NO. 3
FD & C RED NO. 4


















SANAMYCIN (see ACTINOMYCIN C)
L-SARCOLYSIN (see MELPHALAN)









SODIUM ARSENITE (see ARSENITE, SODIUM)
SODIUM AZIDE (see AZIDE, SODIUM)




SODIUM CYCLAMATE (see CYCLAMATE, SODIUM)
SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE
SODIUM FLUORIDE (see FLUORIDE, SODIUM)
SODIUM HYPOCHLORITE
SODIUM NIOBATE (see NIOBATE, SODIUM)
SODIUM NITRATE (see NITRATE, SODIUM)
SODIUM SULFATE (see SULFATE, SODIUM)
SODIUM TETRAFLUOROBORATE (see
TETRAFLUOROBORATE, SODIUM)




SQ 18506 (see trans-5-AMINO-312-(5-NITRO-2-
FURYL)VINYL-1,2,4-OXADIAZOLE)





PLOT NUMBER CHEMICAL NAME





1 mixture STYRENE AND beta-NITROSTYRENE MIXTURE
3,4 96-09-3 STYRENE OXIDE
1 1596-84-5 SUCCINIC ACID 2,2-DIMETHYLHYDRAZIDE (see
DAMINOZIDE)
1 57-50-1 SUCROSE
1 971-15-3 SULFADS (see DIPENTAMETHYLENETHIURAM
HEXASULFIDE)
1 95-06-7 SULFALLATE
1 7757-82-6 SULFATE, SODIUM
1 127-69-5 SULFISOXAZOLE
1 --- SULFITE, POTASSIUM METABI-
1 77-79-2 3-SULFOLENE
1 77-46-3 4,4'-SULFONYLBISACETANILIDE
3,4 68-89-3 SULPYRIN (see DIPYRONE)
1,2 2783-94-0 SUNSET YELLOW FCF (see FD & C YELLOW NO. 6)
1 22571-95-5 SYMPHYTINE
1 569-57-3 TACE
2 39300-88-4 TARA GUM
1 1934-21-0 TARTRAZINE (see FD & C YELLOW NO. 5)
1 97-18-7 TBP (see 2,2-THIOBIS(4,6-DICHLOROPHENOL))
1 1746-01-6 TCDD (sae 2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN)
1,3,4 79-01-6 TCE (see TRICHLOROETHYLENE)
1 72-54-8 TDE (see p,p'-DDD)
1 297-78-9 TELODRIN
3 542-75-6 TELONE II
1 150-68-5 TELVAR (see 3-(p-CHLOROPHENYL)-1,1-
DIMETHYLUREA)
1 116-06-3 TEMIK (see ALDICARB)
3 23031-25-6 TERBUTALINE
1 7411-49-6 3,3',4,4'-TETRAAMINOBIPHENYL.4HCI









1 97-77-8 TETRAETHYLTHIURAM DISULFIDE
1 116-29-0 TETRAFIDON (see 2,4,5,4'-TETRACHLORODIPHENYL
SULFONE)
1 63886-77-1 TETRAFLUORO-m-PHENYLENEDIAMINE.2HCI






4 35449-36-6 2,2,9,9-TETRAMETHYL-1,10-DECANEDIOL (see
GEMCADIOL)
1,3 137-26-8 TETRAMETHYLTHIURAM DISULFIDE
1 mixture TETRAMETHYLTHIURAM DISULFIDE AND FERRIC
NITROSODIMETHYLDITHIOCARBAMATE
(see VANGUARD GF)
1 97-74-5 TETRAMETHYLTHIURAM MONOSULFIDE
1 2227-13-6 TETRASUL (see p-CHLOROPHENYL-2,4,5-
TRICHLOROPHENYL SULFIDE)
1 64039-27-6 beta-TGdR (see beta-THIOGUANINE DEOXYRIBOSIDE)
4 91-79-2 THENYLDIAMINE
4 148-79-8 THIABENDAZOLE





1 :3 79-19-6 THIOCARBAMYLHYDRAZINE (see
THIOSEMICARBAZIDE)
1. 115-29-7 THIODAN (see ENDOSULFAN)
285
CAS
PLOT NUMBER CHEMICAL NAME
1 139-65-1 4,4'-THIODIANILINE




1,3 137-26-8 THIRAM (see TETRAMETHYLTHIURAM DISULFIDE)
4 124-64-1 THPC (see TETRAKIS(HYDROXYMETHYL)
PHOSPHONIUM CHLORIDE)
4 55566-30-8 THPS (see TETRAKIS(HYDROXYMETHYL)
PHOSPHONIUM SULFATE)
1 37087-94-8 TIBRIC ACID (see 2-CHLORO-5-(3,5-
DIMETHYLPIPERIDINOSULPHONYL)BENZOIC ACID)
4 55567-81-2 TILIDINE FUMARATE
1 1114-71-2 TILLAM-6-E (see PROPYL N-ETHYL-N-
BUTYLTHIOCARBAMATE)
1,2 7772-99-8 TIN (II) CHLORIDE
1 13463-67-7 TITANIUM DIOXIDE
1 --- TITANIUM OXALATE, POTASSIUM
1,3 137-26-8 TMTD (see TETRAMETHYLTHIURAMDISULFIDE)




4 26471-62-5 TOLUENE DIISOCYANATE, COMMERCIAL GRADE (2,4
(80%)- AND 2,6 (20%)-)
1 636-23-7 2,4-TOLUENEDIAMINE.2HCI (see 2,4-
DIAMINOTOLUENE.2HCI)
2 15481-70-6 2,6-TOLUENEDIAMINE.2HC1 (see 2,6-
DIAMINOTOLUENE.2HCI)

















1 93-72-1 2-(2,4,5-TRICHLOROPHENOXY)PROPIONIC ACID
1 93-76-5 2,4,5-TRICHLOROPHENOXYACETIC ACID
1,4 102-71-6 TRIETHANOLAMINE










1 900-95-8 TRIPHENYLTIN ACETATE
1 76-87-9 TRIPHENYLTIN HYDROXIDE




1 150-38-9 TRISODIUM ETHYLENEDIAMINETETRAACETATE
TRIHYDRATE (see EDTA, TRISODIUM SALT
TRIHYDRATE)
1,4 75104-43-7 TRP-P-1 ACETATE (see 3-AMINO-1,4-DIMETHYL-5H-
PYRIDO14,3-bANDOLE ACETATE)
1 72254-58-1 TRP-P-2 ACETATE (see 3-AMINO-1-METHYL-5H-
PYRIDO14,3-bJINDOLE ACETATE)
3 54-12-6 DL-TRYPTOPHAN
1,2,3 73-22-3 L-TRYPTOPHAN286 CHRONOLOGICAL SUPPLEMENT
CAS
PLOT NUMBER CHEMICAL NAME
CAS




UNADS (see TETRAMETHYLTHIURAM MONOSULFIDE)
UREA
URETHANE
VALORON (see TILIDINE FUMARATE)
VANADYL SULFATE
VANCIDE BL (see 2,2-THIOBIS(4,6-DICHLOROPHENOL))
VANCIDE BN (see SODIUM BITHIONOLATE)
VANCIDE PB (see 1,2,3-TRICHLORO-4,6-
DINITROBENZENE)
VANGUARD GF









FD & C VIOLET NO. 1
VITAMIN A ACID
VITAMIN C (see L-ASCORBIC ACID)
VITAMIN D2
VITAMIN E (see DL-alpha-TOCOPHERYL ACETATE)
XYLENE MIXTURE (m-XYLENE, o-XYLENE, p-XYLENE)
XYLENE MIXTURE (60% m-XYLENE, 9% o-XYLENE,
14% p-XYLENE, 17% ETHYLBENZENE)
2,4-XYLIDINE.HCl
2,5-XYLIDINE.HCl
C.I. DISPERSE YELLOW 3
C.I. PIGMENT YELLOW 12

















C.I. PIGMENT YELLOW 83
C.I. SOLVENT YELLOW 14 (see 1-PHENYLAZO-2-
NAPHTHOL)
C.I. VAT YELLOW 4
DIARYLANILIDE YELLOW (see C.I. PIGMENT
YELLOW 12)
FD & C YELLOW NO. 5
FD & C YELLOW NO. 6
ZEARALENONE
ZECTRAN (see MEXACARBATE)





ZINEB (see ZINC ETHYLENEBISTHIOCARBAMATE)
ZIRAM (see ZINC DIMETHYLDITHIOCARBAMATE)
ZIRCONIUM (IV) SULFATE
CAS NUMBER = Chemical Abstracts Service registry number
PLOT 1 Gold, L.S., Sawyer, C.B., Magaw, R., Backman, G.M., de Veciana, M.,
Levinson, R., Hooper, N.K., Havender, W.R., Bernstein, L., Peto,, R., Pike, M., and Ames,
B.N. A carcinogenic potency database of the standardized results of animal bioassays.
Environ. Health Perspect. 58: 9-319 (1984).
PLOT 2- Gold, L.S., de Veciana, M., Backman, G.M., Magaw, R., Lopipero, P.,
Smith, M., Blumenthal, M., Levinson, R., Bernstein, L., and Ames, B.N. Chronological
supplement to the carcinogenic potency database: standardized results of animal bioassays
published through December 1982. Environ. Health Perspect. 67: 161-200 (1986).
PLOT 3 Gold, L.S., Slone, T.H., Backman, G.M., Magaw, R., Da Costa, M.,
Lopipero, P., Blumenthal, M. and Ames, B.N. Second Chronological Supplement to the
Carcinogenic Potency Database: Standardized Results of Animal Bioassays Published
through December 1984 and by the National Toxicology Program through May 1986.
Environ. Health Perspect. 74: 237-329 (1987).
PLOT 4 = This publication.
1,3,4
1 1
3
1
1,2,3,4
4
1,2,3,4
1,3
1
3
1
3
4
4
2
1
1
83-79-4
13472-45-2
103-90-2
97-74-5
57-13-6
51-79-6
55567-81-2
27774-13-6
97-18-7
6385-58-6
6379-46-0
mixture
13927-77-0
62-73-7
865-21-4
108-05-4
593-60-2
75-01-4
100-40-3
75-35-4
1694-09-3
302-79-4
50-81-7
50-14-6
59-02-9
mixture
1330-20-7
21436-96-4
51786-53-9
2832-40-8
6358-85-6
5979-28-2